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1 Aim 
This project aimed to analyze the cellular pattern of human skin resident immune 
cells with regard to their number, distribution and function. The specific focus of this 
project was on various subsets of dendritic cells, which were characterized through 
phenotypical and functional comparisons. The resulting data were compared to the 
pattern of DCs found in patients undergoing allogeneic hematopoietic cell 
transplantation – a therapy whose outcome is believed to be closely associated with 
the turnover mechanisms of the DC subset. 
2 Abstract 
Dendritic cells (DCs), a hematopoietic cell type belonging to the sub-group of 
cells called antigen presenting cells (APCs), inhabit a central role in innate and 
adaptive immunity. Although the DC family is very heterogeneous, all members share 
unique features. Most importantly, DCs can stimulate an immune response. This is 
due to the cells’ ability to capture and process antigens and to maturate in the 
presence of danger signals presented by pathogens. Maturation in turn results in the 
migration of DCs from the tissue they reside in to the draining lymph nodes, as well 
as in the subsequent presentation of the acquired antigens to T cells. 
In the skin, which is one of the most immunogeneic organs, DCs are present in 
sizable numbers in both the epidermis and the dermis. This study focused on two 
types of DCs: epidermal Langerhans cells (LCs) and dermal DCs (DDCs). While 
much is understood about LCs, far less is known about the role that DDCs play in 
skin immunity. Therefore one purpose of this study was to characterize DDCs and to 
compare their phenotype and functions to that of LCs. 
This study used two different methods to characterize human skin resident 
immune cells with regard to their number and distribution. First, a stable analytical 
immunohistochemistry-based method was developed and applied to a substantial 
number of healthy skin donors. This enabled a quantitative analysis of skin DC types 
and skin resident T cells at different anatomical locations in situ. A novel method to 
count dermal cell populations in situ was developed that resulted in the first published 
quantification of APCs, DDCs, as well as T cells in human dermis. Second, the 
traditional form of the emigration assay, which selectively enriches vital cells capable 
of ex vivo emigration from the skin, was upgraded toward a stable analytical method 
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to separate epidermal LCs from DDCs. In this way, both skin DC types became 
accessible in sufficient numbers to allow for a comparison of phenotypes and 
functions in vitro.  
The resulting phenotypic observations clearly showed that both, LCs and DDCs 
are not fully mature after their emigration ex vivo and that both can be transformed 
into a phenotypically more mature state by treating them with inflammatory cytokines. 
What’s more, LCs are also functionally in an immature state after their emigration. 
They efficiently took up antigen, showed a low capacity to trans-migrate in response 
to chemokines, and demonstrated a low capacity to stimulate allogeneic T cells in a 
mixed leukocyte reaction (MLR). For the first time this study observed all these main 
APC functions not only for LCs but additionally for DDCs. As these observations were 
made in relation to LCs of the same donor, it could be concluded that DDCs are 
functionally more mature than LCs after emigration. DDCs showed a lower antigen 
uptake capacity than LCs but were superior in terms of their migratory and 
stimulatory capacity. However, treatment with cytokines could skew LC functions 
toward functional capacities observed for DDCs, i.e., it decreased LCs’ Ag uptake 
and increased their migratory and stimulatory capacity, whereas the cytokine 
treatment did not alter DDCs’ functional capacities. 
After improving immuno-histochemistry and the emigration assay using healthy 
skin samples, these newly developed techniques were implemented in clinical trials 
to observe the number, distribution and migratory capacity of skin DCs and T cells in 
patients undergoing allogeneic hematopoietic cell transplantation (aHSCT). Such a 
study is of importance because the turnover of DCs and T cells is closely associated 
with the occurrence of acute graft-versus-host disease (aGvHD), the major cause of 
morbidity and mortality after aHSCT. Due to the study design used, this study 
concisely demonstrate that at the onset of aGvHD, different DC types accumulate 
along with effector T cells in skin lesions of aGvHD but not in uninvolved skin of the 
same patient. These results suggest that in addition to donor T cells LCs and DDCs 
play a role during the early phase of cutaneous aGvHD directly within the site of 
inflammation. The view of many authors that DC depletion in the transplant recipient, 
especially in target organs, is a promising approach for aGvHD prophylaxis and 
therapy is further underscored by these results.  
One targeting strategy to inhibit GvHD by eliminating recipient DCs may be the 
use of DC specific monoclonal antibodies. Alemtuzumab (anti-CD52) is a monoclonal 
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antibody and has proven effective in preventing aGvHD after aHSCT. It may, despite 
depleting donor T cells, also work by targeting recipient DCs. To determine whether 
the last mechanism of action is significant, a second clinical study investigated the 
effects of intravenous alemtuzumab on DCs by comparing the number of these cells 
in skin and blood of patients before and after a 4-week course of alemtuzumab 
treatment. The result was that although skin DCs weakly express the target antigen 
CD52 the number of these cells was not consistently reduced by alemtuzumab. In 
contrast, circulating blood DCs have a stronger CD52 expression and were 
significantly reduced by the treatment. 
In conclusion, this work provides new insights into the phenotypical and 
functional characteristics of human skin DCs, as well as into the fate of these cell 
types during aHSCT. The investigation of the APC system during aGvHD as carried 
out here will help to understand the process of aGvHD in more detail. All these efforts 
may hopefully support the development of new approaches for therapy and 
prevention of this major limitation of aHSCT and may help to improve this only 
curative therapy for several life-threatening diseases. 
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3 Introduction 
3.1 Organization of the Skin 
The skin (also known as the cutis or integument) is the largest organ of the 
human body. It covers a total surface area of about 2.2 m2 in adults and makes up 
approximately 16% of the total body weight. The skin consists of several different 
layers. The outermost of these layers, the epidermis, varies from 75-100 µm in 
thickness over most surfaces of the body.1 At the top, the epidermis contains a 
stratified squamous epithelium with a layer of keratin referred to as the 
stratum corneum. This topmost layer is followed by a very thin granular layer (stratum 
granulosum) consisting of a single or double row of cells, a spiny layer 
(stratum spinosum) and a basal layer (stratum basalis). The epithelial cells of the 
basal layer are closest to the basal lamina (basement membrane) and to the 
underlying connective tissue, the dermis. Four major cell types can be distinguished 
in the epidermis, namely keratinocytes, melanocytes, Merkel cells and Langerhans 
cells (LCs). A distinct border consisting of a series of ridges (epidermal ridges) and 
papillae (dermal papillae) divides the epidermis from the dermis [Figure 3-1].  
 
 
 
 
 
 
 
 
 
 
 
Figure 3-1: Organization of the skin: Haematoxilin/eosin staining of a 5 µm cryosection of a split 
skin sample. 1 Stratum corneum; 2 Stratum granulosum; 3 Stratum spinosum; 4 Stratum basale; 5 
epidermal ridge; 6 papillary dermis; 7 reticular dermis. The scale bar indicates a length of 100µm.
  
The dermis is primarily composed of extra-cellular matrix, and contains 
fibroblasts, DCs, macrophages (Mφ), mast cells, and infiltrating T lymphocytes. The 
dermal thickness is difficult to measure because the border with the underlying 
hypodermis is indistinct. However, it is believed that at most sites of the body the 
dermis is approximately 1-2 mm thick. Two distinct regions are present in the dermis, 
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the papillary layer and the reticular layer. The papillary layer includes the area of the 
dermal papillae and consists of lose connective tissue. Blood vessels that supply the 
epidermis are located in these papillae. The reticular layer, on the other hand, is 
thicker than the papillary layer and consists of more dense, irregularly structured 
connective tissue composed mainly of collagen bundles. The term “reticular” refers to 
the netlike arrangement of these bundles.  
The skin fulfills many different functions, including mechanical protection against 
external abrasion or injury, thermoregulation, and sensory reception. In addition, it is 
involved in the regulation of body fluids, ions and possesses metabolic functions. As 
the first barrier against the surrounding environment, the skin is equipped to sense 
dangers presented by pathogens. Considered one of the most immunogeneic 
organs, the skin reacts to pathogens by triggering inflammation and potent T cell 
responses.2 Cells of the immune system are present in sizable numbers in both the 
epidermis and the dermis. The concepts of the ‘skin immune system’ by Jan Bos3 
and the ‘skin-associate lymphoid tissue’ by Wayne Streilein4 emphasize that these 
immuno-competent cells of hematopoietic origin did not just accidentally reside in or 
pass through epithelia tissues, but rather play a systematic role in the immunologic 
surveillance of tissues. 
 
3.2 Immune Cells of the Skin  
Immune cells of the skin include DCs, Mφ, mast cells, T lymphocytes as well as 
some B lymphocytes, NK cells and neutrophils.5;6 A central role in innate and 
adaptive immunity to infections and antigens in vivo is inhabited by DCs, and a 
relatively dense network of these cells line the skin.7 Although the DC family is very 
heterogeneous in terms of phenotype and distribution within the body, all members 
share unique features.  
Hallmarks of DCs are their ability to capture antigens (Ags), to process and 
present Ag peptides, and to migrate out of their tissues to secondary lymphoid 
organs, where the stimulation of resting T cells takes place.8-10 DCs originate from 
bone marrow precursors that enter the blood and migrate to peripheral tissues like 
the skin were they reside in an immature state.10 Immature DCs behave as sentinels, 
with a strong ability of Ag uptake and processing, but a low ability of T cell 
stimulation. A DC-type specific repertoire of endocytotic receptors, for example 
CD207/Langerin, dectin-2, Fc-, complement-, mannose- and scavenger receptors, 
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promote the internalization of microbial products, which are then directed to antigen-
processing compartments.11-13 This uptake of foreign antigen and the subsequent 
exposure to immune and inflammatory agonists activate the maturation process of 
immature DCs.10;14  
DC maturation is associated with several coordinated events, including changes 
in cell morphology, a switch from an Ag processing to an Ag presenting stage, and 
the enhanced expression of co-stimulatory molecules. As a consequence, DCs have 
the ability to stimulate and bias T cell responses in secondary lymphoid organs.15;16 
Moreover, while a wide variety of cell types can present antigens to activated T cells, 
mature DCs also have the unique ability to stimulate nave T cells.10  
Maturation induces the migration of DCs from tissues to the afferent lymphatics 
and their homing to secondary lymphoid organs. The recruitment of DCs into the 
secondary lymphoid organs is chemokine dependent. Chemokines are a super-family 
of small proteins that play a crucial role in immune and inflammatory reactions and in 
viral infection.17-20 Chemokines act by binding to specific receptors on the cells’ 
surface. The main regulatory element is the receptor expression on DCs and their 
subsequent responsiveness to the respective chemokine. Specifically, the chemokine 
receptor CCR7 is responsible for the migration of DCs to the secondary lymphatics.21 
Ligands for CCR7 are CCL19 (MIP-3β), constitutively expressed by stromal cells and 
mature DCs in T cell areas, and CCL21 (6Ckine), constitutively expressed by 
lymphatic endothelial cells. The expression of CCR7 gradually increases during DC 
maturation and governs the efflux of DCs into the lymphatic vessels and the 
secondary lymphatic organs.22 
Maturation constitutes an important checkpoint in mounting an immune 
response, because immature DCs not only fail to prime T cells efficiently,23 but also 
serve to promote tolerance induction.24-27 The functional stage of maturation is 
irreversible and is followed by apoptosis after a brief period of time.28 In healthy 
human skin there are two subsets of DCs, epidermal LCs and dermal dendritic cells 
(DDCs). Both participate in immuno-surveillance of the skin. 
 
3.2.1 Langerhans Cells  
The dendritic cell type which resides in the epidermis is the LC.29 They are 
located in a mostly suprabasal position and form a regular network. Morphologically, 
LCs possess conspicuous rod- and tennis racket-shaped organelles referred to as 
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Birbeck granules.30 These structures are sub-domains of the endosomal recycling 
compartment and are involved in Ag processing.31 A variety of endocytic receptors, 
for example, Fc- and complement receptors,11 dectin-2,12 and CD207/Langerin,13 as 
well as the expression of surface molecules for the presentation of internalized Ags, 
namely, CD1 and major histo-compatibility complex (MHC) class I and class II, 
facilitate the outstanding Ag processing function of LCs.11;32-36 Because LCs are 
leukocytes, they express the “leukocyte common antigen” CD45, but they lack 
specific lineage markers like CD3, CD14, CD16, CD19, CD20, and CD56 that specify 
other leukocyte subsets.29 Although the hematopoietic origin of LCs has been known 
for a long time,37;38 the nature of the circulating precursor remains controversial. It is 
clear that during ontogeny, LC precursors populate the epidermis and start to 
express specific molecules such as ATPase, MHC class II and CD207/Langerin, as 
well as Birbeck granules.29;39-41 It was found that during the steady state, a base rate 
of LCs leave the skin in journey to the secondary lymphatics,42 which suggests that 
resting LCs are replenished by the entry of a blood-born precursor.43;44 However, 
recent studies in mice revealed that during the steady state, hardly any LC 
precursors home to the skin, whereas resting LCs are capable of local clonal 
expansion.45 This suggests that, at least in mice, LCs may renew in healthy skin 
rather than being substituted by a circulating precursor.46 
Under microbial stimulation or during inflammation, LCs maturate and the 
number of these cells migrating to the lymph nodes increases considerably.42 This 
emigration from the skin is quite fast - several millimetres within 30 minutes - and is 
directed to the lymph nodes and into secondary lymphoid organs.47 Whether LCs 
themselves present the acquired Ag directly to T cells, or whether they have a 
regulatory function, or even whether they pass the Ag to a lymph node-resistant DC 
for final presentation is currently under investigation.47-49 However, it is known that 
during inflammation, the LC population is replenished by the recruitment of 
precursors from the periphery. Under inflammatory conditions, monocytes have been 
shown to be effective LC precursors in vivo in mice,50 as well as in a human in vitro 
skin-reconstitution model.51 
LCs are the most extensively studied DC type. The dramatic changes during the 
maturation process, including reorganization of cell surface phenotype,52-54 increase 
of T cell stimulatory capacity,52 down regulation of Ag processing properties,55 down 
regulation of phagocytosis,56 and the translocation of MHC class II molecules to the 
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cell surface57 were all first observed on LCs. However, today, LCs are no longer 
regarded as being representative of DCs in general. This is because recent studies 
suggest that several features of LCs distinguish them from other types of DCs. LCs 
may possess regulatory functions under certain circumstances and may not be 
necessary for the induction of certain immunologic skin reactions, like contact 
hypersensitivity.48;49;58-60 What’s more, the initiation of a protective T cell response to 
certain viral antigens was shown to be provided from dermally derived DCs rather 
than from epidermal LCs.61-65 The role of those dermally derived DCs in skin 
immunity has been mostly overlooked in studies of the past. However, recent 
observations have revived the interest in the DC variant of the dermis. 
 
3.2.2 Dermal Dendritic Cells 
 Dendritic cells of the dermis were identified more than 120 years after LCs.66;67 
They reside between extra-cellular matrix components at the capillary level and in the 
higher part of the reticular dermis.7 Compared to LCs, DDCs have rarely been 
investigated so far. This might be due to the fact that interstitial DDCs lack a specific 
marker. While they can be distinguished from LCs by the absence of CD207 
expression,68;69 their differentiation from Mφs is very difficult. Both, DDCs and Mφs 
are bone marrow-derived mononuclear phagocytes that express CD45. It is known 
that together they constitute about 60% of all murine dermal cells,6 whereas a 
confidential quantitative in situ analysis of these cells in humans has not been 
published so far. Some authors suggest that the expression of MHC class II, CD11c, 
CD36, CD205, CD206, CD209 and/or Factor XIIIa clearly distinguishes human DDCs 
from Mφs. However, all of these markers could also be expressed by Mφs under 
certain circumstances.66;68;70-72 To date, all published approaches for identifying a 
DDC phenotype have only examined a heterogeneous DDC population that partly 
expressed markers thought to be specific for Mφs, leading to the conclusion that 
phenotypically DDCs can not be definiteley separated form Mφs to date.66;68 
The turnover of DDCs in the dermis appears to be quite similar to the processes 
found for LC homeostasis in the epidermis. In the steady state, a low in situ 
proliferation of DDCs has been recently described in mice and humans.70 
Nevertheless, the existence of a still undefined hematopoietic DDC precursor has 
also been proven in parabiotic mice.70 Especially under inflammatory conditions, this 
precursor population reconstitutes the pool of DDCs. There is more and more 
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evidence that monocytes and/or Mφs could give rise to DDCs under certain 
(inflammatory) circumstances.73 If this is true, it would account for the recent 
problems regarding a phenotypic separation of DDCs and Mφs. 
Like LCs, DDCs are able to take up Ags, emigrate from the dermis, maturate on 
their way to the draining lymph node, and to stimulate resting T cells upon their 
arrival.66;74 DDCs are equipped with a specific pattern of receptors that facilitate the 
uptake of exogenous Ag. Beside Fc-, complement-, and heat shock protein 
receptors, they also express the macrophage mannose receptor (MMR/CD206), 
which is a type I lectin that mediates the endocytosis of mannosylated glycoproteins 
or mannose-coated particles and facilitates Ag presentation.75;76 CD206 is expressed 
on DDCs and Mφs but never on LCs75 and thus was used to identify the population of 
dermal mononuclear phagocytes, referred to as DDCs in this work.  
Other than various analogies, few studies can offer evidence of functional 
differences between DDCs and LCs. However, it has been shown that the migration 
of DDCs to the lymph node clearly precedes that of LCs in the context of a skin 
inflammation model.48 Moreover, DDCs colonize different areas in the lymph node 
compared to LCs and they are able to stimulate the antibody secretion of naïve 
B cells, a function that is not provided by LCs.48;77 In sum, despite some evidence of 
functional differences, the relative importance of DDCs compared to epidermal LCs in 
the skin immune responses is still unclear. The capacity of both cell populations to 
stimulate, bias, or inhibit T cell responses remains controversial and only limited 
information has been derived from a functional side-by-side comparison of these 
cells. 
 
3.2.3 T Lymphocytes 
The prevailing understanding of skin immunity today is that DCs represent the 
afferent limb (surveillance and initiator cells) of the immune response, whereas 
T lymphocytes represent the major efferent limb (effector cells) of the immune 
response. The T cell lineage is defined by the expression of CD3, a protein complex 
associated with the T cell receptor (TCR), and the -chain. Together CD3, TCR and 
-chain form the TCR complex whose role is Ag recognition. Two different forms of 
TCRs occur in humans, the αβ TCR and the γδ TCR. 
The vast majority of skin resident T lymphocytes are αβ TCR+ memory or 
effector T cells responding to specific peptid Ag.78;79 In order for αβ TCR+ T cells to 
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be activated, peptide Ags have to be displayed on antigen presenting cells (APCs) in 
the context of MHC molecules in conjunction with sufficient co-stimulation. This 
process is believed to take place in the secondary lymphatics after the migration of 
T cells and APCs to these structures. There are two major types of αβ TCR+ 
T lymphocytes that differ in their expression of the co-receptors CD4 and CD8 with 
specificity for MHC II or MHC I, respectively. T cells with CD4 surface expression are 
referred to as THelper cells (TH cells), and T cells with CD8 surface expression are 
referred to as cytotoxic T cells (CTLs).  
TH cells can only recognize peptide Ag in the context of MHC class II and are 
mainly involved in immuno-modulatory processes, but they can also acquire cytotoxic 
functions. CD4+ T cells can further be subdivided in a functional manner because 
they drive a different quality of immune response of the TH1 or TH2 type depending 
on the cytokines they produce.80 CD8+ T cells, on the other hand, recognize peptide 
Ag in the context of MHC class I and are specialized to kill cells that are infected by 
viruses, intracellular bacteria, or that are malignantly degenerated.81 For sufficient 
activation leading to cell proliferation and the acquisition of effector functions, both 
T cell subtypes require two independent signals. The first signal is the binding of the 
TCR to the MHC-Ag complex. The second is provided by co-stimulatory molecules 
displayed by professional APCs. These co-stimulatory molecules, among them CD80 
and CD86, bind to specific ligands on T cells. Only if both signals are provided a 
complete T cell activation, including IL-2 production, clonal expansion and acquisition 
of effector functions, take place. 
A separate lineage of CD3+ T lymphocytes, referred to as γδ T cells, expresses 
a TCR of γδ type.82  In the peripheral blood, only 1-3% of T cells are γδ T cells, but 
within the epidermis they represent up to 40%.83 In contrast to αβ T cells, γδ T cells 
do not recognize Ag in the context of classical MHC molecules. This is in line with the 
absence of CD4 and CD8 co-receptors on most of these cells.84 However, γδ T cells 
have been found to recognize viral glycoproteins displayed on CD185 even in the 
absence of APCs.86 
Effector functions of activated γδ T cells resemble those of conventional αβ 
T cells in many aspects. Thus, γδ T cells are able to exert potent cytotoxic effector 
functions via direct (release of granzymes or perforines) or indirect (expression of 
INFγ) lysis or by induction of apoptosis (via Fas/Fas ligand-dependent pathways).87-90 
Furthermore, they produce cytokines of TH1-type, but also have the intrinsic capacity 
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to make TH2 cytokines if activated under appropriate conditions.91;92 However, 
γδ T cells are more than effector cells. Contrary to conventional αβ T cells, γδ T cells 
are also able to produce connective tissue growth factor, fibroblast growth factor, as 
well as keratinocyte growth factor, and they play an important role in epithelial repair 
and wound healing.93;94 Moreover, they contribute to local immune surveillance.95-97 
Some authors suggest that γδ T cells play a role in the regulation of local skin 
inflammatory reactions by controlling migration of inflammatory αβ T cells into the 
skin.98;99 
 
3.3 Allogeneic Hematopoietic Stem Cell Transplantation (aHSCT) 
In an allogeneic hematopoietic stem cell transplantation (aHSCT), the recipient 
receives a graft from a compatible, healthy donor. Patients with hematopoietic 
malignancies and inherited or acquired non-malignant blood cell disorders can be 
cured by an aHSCT. During an aHSCT, patients first receive a conditioning treatment 
consisting of chemotherapy with or without total body irradiation (TBI). This treatment 
aims to immuno-suppress the host in order to decrease graft rejection, and also to 
reduce the number of malignant cells. Thereafter the host receives an infusion of 
donor bone marrow or donor peripheral-blood stem cells. The therapy aims to correct 
the underlying deficiency which caused the defective immunity or hematopoesis by 
the establishment of a healthy immune and hematopoietic system. For that reason, 
the key result of an aHSCT is the conversion of both the hematopoietic and the 
immune system from recipient to donor type.  
Cure rates of aHSCTs exceed 80% for some otherwise fatal diseases, such as 
chronic myeloid leukaemia, in the case of full histo-compatibility leukocyte antigen 
(HLA) matched transplants.100 However, the success of aHSCTs relies on the ability 
to reduce transplant-related morbidity and mortality while preserving the graft-versus-
leukemia (GVL) effect that is essential for low relapse rates. 
 
3.4 Graft-versus-Host Disease 
 Graft versus host disease (GvHD) is the major cause of morbidity and mortality 
after an aHSCT. Of patients transplanted with a related, HLA-matched allograft, 30-
60% develop acute GvHD (aGvHD), of those, 10-20% with a severe clinical course. 
Overall, aGvHD results directly or indirect in a mortality rate of 50%.101 
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A GvHD response can occur when three factors are present:  (1) The 
transplanted graft contains immunologically competent cells, (2) the recipient is 
incapable of rejecting the transplanted cells, and (3) the recipient tissue expresses 
Ags that are not present in the transplant donor and are thus recognized as 
foreign.102 GvHD is traditionally divided into an acute (aGvHD) and a chronic 
(cGvHD) form based on the time point of onset and certain clinical and histo-
pathological findings.103 Historically it has been thought that aGvHD occurs within the 
first 100 days after an aHSCT, whereas cGvHD can occur at any time thereafter. 
However, in light of the recent understanding of the patho-physiology of GvHD, this 
classification is no longer satisfactory. It is now known that dependent on the intensity 
of pre-conditioning and immuno-suppression, typical signs of aGvHD can also appear 
after day 100 post–transplant, while chronic manifestations could also be observed 
from day 31 onwards.104 Furthermore, the development of cGvHD out of aGvHD is 
frequently observed. 
 
3.4.1 The Model of GvHD Pathogenesis 
The patho-physiology of aGvHD can be considered as a three-step process in 
which innate and adaptive immune systems interact: (1) The recipients’ tissue is 
damaged during the pre-transplant conditioning regimen including chemotherapy 
and/or radiation. This causes (2) donor T cell activation and clonal expansion and 
leads to (3) the attack of host tissues by cellular and inflammatory factors. It is 
striking that aGVHD, as a manifestation of an allo-reactivity against histo-
compatibility differences present in the entire host, mostly involves just three major 
target organs, namely the skin, the gut and the liver.105;106 These three organs share 
the presence of a highly dense network of DC populations that possess a heightened 
immunogenic potential.107 In all phases of GvHD, DCs have been demonstrated to 
play a critical role that considerably influences quality and quantity of the evolving 
immune reaction against the host.108-110 However, DCs are also required to induce 
and maintain a graft versus leukemia (GvL) response.111-113 
 
3.4.1.1 Phase 1: Tissue Damage Caused by the Conditioning Regimen 
Chemotherapy and/or irradiation causes direct tissue damage and loss of 
epithelial integrity, which can lead to the systemic exposure to microbial products like 
lipopolysaccharide (LPS), which in turn can activate the innate immue system.114-118 
The resulting activation of the innate immune system in general and of DCs in 
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particular is an important initiating event in the induction of GVHD. Beside the 
conditioning regimen itself, inflammatory cytokines like TNFα or IFNγ which were 
released by activated Mφ or direct cellular interactions trigger the activation of DCs.119  
 
3.4.1.2 Phase 2: Donor T Cell Activation 
Donor T cells have been demonstrated to be the primary immuno-competent 
cells that induce GvHD120 but that also mediate beneficial graft-versus-leukemia 
(GVL) responses.121 The incidence of GvHD correlates with the number of donor 
T cells transfused.122 Following their infusion to irradiated hosts, naïve donor T cells 
are initially retained within secondary lymphoid tissues.123 Subsequently, activated, 
host Ag-carrying DCs from peripheral tissues arrive in these draining lymph nodes. 
Whether they present the tissue Ag directly to donor T cells at these sites or whether 
they deliver Ags to specialized resident APC populations is currently not clear.48;124 
However, it is known that within the secondary lymphatics a rapid burst of donor 
T cell proliferation occurs during a developing GvHD response. Later on, large 
numbers of lymphoblasts enter the blood circulation and recruitment of effector 
T cells to peripheral tissues such as the skin and gut takes place.48;123;125;126 DCs 
from skin and gut are able to foster the expression of tissue-specific homing 
receptors on activated T cells and thus influence the recirculation of these effector T 
cells back to the tissue from which the DCs originated. For example, DCs derived 
from skin-draining lymph nodes prime functional E/P-selectin ligand expression on 
activated T cells and the selective trafficking of these cells to the skin.48;127 
Furthermore, DCs that had remained or were recruited to GvHD target organs may 
theoretically contribute to the effector phase of the graft-versus-host response in that 
they may actively recruit T cells to target organs via the secretion of inflammatory 
chemokines and may thus support the inflammatory response in situ. 
 
3.4.1.3 Phase 3: Attack of Host Tissues - Exemplified in Human Skin 
Skin involvement is observed in about 90% of aGvHD cases. It is characterized 
by efflorescent erythematous macules of varying extent and distribution.128;129 Skin 
lesions are the earliest presentation of aGvHD and generally appear 2 to 6 weeks 
after an aHSCT with a median rate of 3 weeks.130 Histological hallmarks of acute skin 
GvHD are keratinocyte apoptosis, inflammatory infiltrates, as well as endothelial cell 
damage.131 GvHD is often difficult to diagnose, because clinical signs and symptoms 
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may mimic drug- or virus-induced skin rashes,132 and certain histo-pathological 
features of aGvHD are non-specific and may also be a consequence of chemo-
radiotherapy.129;133;134 
Mainly infiltrating donor effector T cells,135;136 in combination with inflammatory 
cytokines,137;138 provoke the profound tissue injury that characterizes aGVHD. Both 
CD8+ and CD4+ T cells are found to infiltrate the skin during aGvHD. CD8+ CTL target 
epidermal keratinocytes expressing the recipients’ peptides in the context of MHC 
class I. CD4+ T helper cells, together with Mφs and other mononuclear cells, may be 
responsible for the production of inflammatory cytokines, such as IFNγ and TNFα. 
Probably due to these cytokines, the expression of MHC II and of several adhesion 
molecules is induced on epithelial cells of the skin136;137;139-142 and on other target 
organs.143-145 Therefore, it is feasible that cytotoxic CD4+ T cells also recognize 
recipients’ peptides presented by MHC class II molecules in target organs.146;147 
However, the expression of MHC II in target organs is not necessary for the induction 
or prolongation of aGvHD, as shown in a mouse model.143 
T cell effector mechanisms include Fas/FasL,148 perforine/granzyme, as well as 
granule exocytosis.149;150 The former two may be most important, considering that the 
capacity to induce lethally aGvHD in mice is impaired by a double but not by a single 
knockout of these pathways.151 In addition to effector T cells recently, a role of other 
cell populations such as NK cells,152 γδ T cells153;154 and regulatory T cells155-159 has 
been incorporated into the model of pathogenesis and modulation of GvHD 
responses. 
 
3.4.2 The APC System During aHSCT and GvHD 
If an aHSCT recipient receives a full matched donor graft, donor T cells can only 
recognize MHC-bound peptides derived from protein products of polymorphic genes 
that are present in the recipient but not in the donor. GvHD is therefore not a reaction 
against a specific pathogen but instead is a reaction against ubiquitously expressed 
and virtually limitlessly available minor histocompatibility antigens (miHAs). 
Consequently, potentially every APC, stimulated to mature by any mechanism, could 
be licensed to prime alloreactive T cells. Nevertheless, the type of APCs that are 
most probably required for the induction of GvHD are DCs, because only these cells 
are capable of priming naïve T cells, a cell type that is required to induce 
GvHD.125;160;161  LCs and also splenic DCs alone have been shown to be sufficient to 
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drive a GvHD response in a mouse model in which other APC types were unable to 
prime T cells.162;163 Consequently, the fate of different DC types during GvHD 
induction and prolongation is of special interest for the understanding of these 
processes.  
It is a known fact that chemotherapy and irradiation deplete the majority of 
differentiated DCs and their circulating precursor populations in the host. After an 
aHSCT, these cells are replaced by either differentiated DCs contained in the graft or 
by differentiation from donor progenitor cells. The kinetics of this process vary at 
different body sites and also dependending upon the mode of conditioning,164;165 as 
well as the presence or absence of donor T cells in the graft.162;166 Within human 
blood, the recovery and full conversion of DCs to donor type is very rapid and 
precedes that of B cells.164;167;168 However, the situation for tissue resident DC 
subsets is more complex. Even a myeloablative conditioning is unable to eradicate all 
recipient derived DCs in the skin and therefore skin DCs, as well as Mφs, appear 
fairly resistant to conversion to a full donor chimerism in situ. This might largely be 
due to the capacity of these populations to be maintained by a radiation resistant 
precursor cell.70;162;164-167 In summary, in the skin a mix of recipient derived and donor 
derived skin DCs coexists during a considerable time post-transplantation. 
Interestingly, recipient and donor DCs have unique roles in the pathogenesis of 
GvHD.70;166 
 
3.4.2.1 Host DCs 
DCs of host origin that survive the conditioning regimen are not only required 
but are alone sufficient to initiate aGvHD.109;163 This fact has been shown in both 
CD4+ and CD8+ T cell dependent aGvHD models.163 The type of host DC that is 
required for the induction of aGvHD is not known to date, but a model in mice seems 
to indicate that epidermal host LCs are sufficient for the development of a skin 
response.162 In this model, the conversion of skin DC chimerism to complete donor 
origin prior to an aHSCT completely prevents the development of aGvHD. This fact 
combined with the fact that during the GvHD response, donor T cells expand 
simultaneously in liver, lung and spleen suggests that donor T cells interact with host 
DCs not only in secondary lymph tissues, but also directly within the target organs 
where they possibly amplify the inflammatory reaction.143;169 Such a conclusion is 
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further supported by the observation that the depletion of DCs and Mφs in the liver 
and spleen limits the donor T cell infiltration into these organs during aGvHD.170 
 
3.4.2.2 Donor DCs 
Besides uptake and presentation of Ags on MHC class II molecules, DCs are 
able to display ingested Ags on MHC class I molecules. In this process, termed 
cross-presentation, Ags leave the endogenous pathway for MHC I presentation.171 
Due to this ability, donor DCs contained in the graft or those arising from transplanted 
hematopoietic precursors can acquire miHAs from apoptotic cells of the recipient for 
MHC I presentation. One would conclude from this fact that donor DCs might also 
play a role in GvHD induction. However, several studies using different models in 
mice have shown that this is not the case.109;163 Such failure of donor DCs to support 
GvHD induction may be due to the lack of large donor DC numbers available at early 
time points after transplantation. What’s more, one study in mice also suggests that 
the process of cross-priming itself may be too inefficient to induce GvHD.109 Taken 
together, donor DCs do not initiate a GvHD response. 
However, a role of donor DCs in GvHD cannot be excluded totally. For example, 
it has been shown that, after initial induction through recipient DCs, maximal GvHD 
depends on engraftment of donor DCs.172 Furthermore, donor DCs may also be 
required for the perpetuation of tissue injury in target organs. 
Otherwise certain donor DC populations appear to impede the induction of 
GvHD by their contribution to peripheral tolerance.173;174 Consistent with this 
understanding, it has been demonstrated that an infusion of cultured DCs with 
suppressive properties can inhibit GvHD.175;176 In summary, it is very likely that also 
donor DCs play a critical role in the pathogenesis of GvHD. 
 
3.4.3 State-of-the-Art Therapy and Prevention of GvHD  
To date, the most effective means of treating aGvHD is the use of 
immunosuppressive glucosteroids, such as prednisone, methylprednisolone or 
dexamethasone.177 Such treatment typically consists of topical application to the 
involved skin areas and/or systemic administration via oral intake.178 The mechanism 
of action of glucosteroids includes lympholysis and suppression of pro-inflammatory 
cytokines. 
  Introduction 
17 
To diminish the risk of GvHD, all patients undergoing an aHSCT receive 
immunosuppressive agents that partially impair the immunity of the graft, while 
maintaining the GvL effect.178 The combination of cyclosporin A with or without 
methotrexate is generally used as prophylaxis for matched sibling transplants. 
Depending on the respective transplant setting, non-methothrexate-containing 
regimes, such as everolimus, FK 506, mycophenolate mofetil, are also often applied. 
Furthermore, promising new strategies have been developed to treat and/or prevent 
the development of GvHD. These include treatment with nucleoside analogues 
(pentostatin)179 and cyclophosphamide, or with monoclonal antibodies180  such as 
daclizumab181, etanercept182, infliximab183, as well as novel approaches such as 
psoralen-enhanced UVA irradiation and extracorporeal photophoresis.184;185  
Despite the development of novel therapies, some transplants are inherently 
likely to cause the development of lethal GvHD. This is most often the case in 
mismatched, or matched but unrelated, donor-recipient settings. Under these 
unfavourable transplant conditions, the depletion of donor T cells from the graft is 
used to prevent GvHD. This is achieved by positive (CD2,3,4,5,6,8) and/or negative 
(CD34) selection,178 and significantly reduces the incidence and severity of clinical 
GvHD.186 Furthermore in vivo T cell depletion strategies using Alemtuzumab or anti-
thymocyte globuline (ATG) are frequently applied in the treatment of such high-risk 
patients.178 However, the depletion of donor T cells from the grafts also has major 
draw-backs, including an increased incidence of hazardous infectious complications, 
less tumor control by T cell mediated GvL effects, and a higher rate of graft failure. 
Due to these adverse effects, T cell depletion does not improve the overall mortality 
after an aHSCT in humans.187 
 
3.4.4 The Concept of Recipient DC Depletion 
The role of DCs in the pathogenesis of GvHD as understood today provides a 
rationale for targeting recipient DCs resistant to the conditioning regimen in order to 
prevent GvHD.162 This idea is not new as the prospect that depletion of recipient DCs 
may attenuate or even prevent GvHD was first suggested more than 20 years ago.188 
Depletion of recipient DCs may not impair pathogen specific immune responses, as 
these can also be initiated by donor DCs, but may abolish the GvL effect.112 To 
preserve the beneficial GvL effect a regional DC depletion, only in GvHD target 
organs such as the skin, may be a promising aproach.  
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Novel conditioning therapies, such as UV light or monoclonal antibodies against 
DCs, are recently under way to accelerate or enhance skin resident DC 
depletion.162;189 Moreover, existing drugs approved for prevention or treatment of 
GvHD may partially act by DC depletion. For instance, Alemtuzumab (Campath-1H), 
a humanized antibody directed against CD52, was found to eradicate DCs in the 
peripheral blood.190 Alemtuzumab is approved for the treatment of patients with 
advanced chronic lymphocytic leukaemia (CLL)191;192 and is effective in vivo and in 
vitro in preventing GvHD.193;194 Its mode of action is via binding to CD52, a marker 
expressed on the surface of lymphocytes, monocytes, Mφs, eosinophils and certain 
subtypes of DCs,190;195-197 and it mediates cell death by antibody-dependent 
cytotoxicity and apoptosis.198;199 Alemtuzumabs’ GvHD preventive effect was 
generally believed to be due to the depletion of donor T cells before or during stem 
cell infusion.194 But, considering that anti-CD52 antibodies eradicate blood DCs,190 
the depletion of DCs in the transplantation recipient could be an alternative 
mechanism of its GvHD-preventive effect. Whether Alemtuzumab also depletes other 
types of DCs, especially those which reside in GvHD target organs, has not been 
studied so far. 
 
The special focus of this work lies upon different subsets of skin resident DCs in 
healthy donors and in patients suffering from aGvHD after receiving an aHSCT. 
Despite the fact that the development of interventional studies in humans are 
burdened with limitations and difficulties, such studies are of eminent interest for the 
scientific community. This work provides new insights into the phenotypical and 
functional characteristics of human LCs and DDCs, as well as the into the fate of both 
cell types during aHSCT. The quantitative and qualitative investigation of the DC 
system during an episode of GvHD as carried out by this research will help to 
understand the process of GvHD in more detail. Furthermore, the methodology to 
investigate skin DCs developed here was used to explore the DC depleting potential 
of a drug approved for the prevention of GvHD. All these efforts may hopefully 
support the development of new approaches for therapy and prevention of this major 
limitation of aHSCT and may help to improve the only curative therapy for several 
life-threatening diseases.  
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4 Patients, Materials und Methods 
4.1 Patients 
All studies performed met the Declaration of Helsinki and were approved by the 
local ethics committee. All patients agreed by written informed consent to their 
participation. 
 
4.1.1 Patients of the aGvHD Study 
Table 4-1 Characteristics of patients: Patients’ and donors’ characteristics including study number; 
age, gender, disease, donor type, HLA compatibility, aGvHD onset (day post transplant), degree of 
cutaneous GvHD, location of biopsies, Abbreviations: ALL, acute lymphoid leukemia; AML, acute 
myeloid leukemia; F, female; M, male; MDS, myelodysplastic syndrome; pat.No., patient number. 
aGvHD Location of biopsy (body site) Pat. 
No. 
Age/ 
Sex Disease 
HLA-match, 
donor day degree lesional skin uninvolved skin 
1 53/M Mantle Cell Lymphoma 
matched, 
unrelated 65 1 right thigh left lower leg 
2 45/M AML matched, 
unrelated 32 3 right thigh left thigh 
3 54/F AML 9 of 10, sibling 15 2 right upper arm left shoulder 
4 45/F AML matched, sibling 16 3 left upper arm left forearm 
5 42/F AML matched, sibling 12 2 right upper arm left forearm 
6 62/M Multiple Myeloma matched, sibling 12 3 left thigh right thigh 
7 63/F Follicular Lymphoma 9 of 10, unrelated 34 1 right shoulder right loin 
8 59/M AML 9 of 10, unrelated 17 3 upper back (middle) lower back (right) 
9 66/M MDS matched, 
unrelated 34 3 upper back (right) right shoulder 
10 35/M CLL matched, sibling 56 3 right shoulder upper back (right) 
11 56/M AML matched, sibling 22 1 upper back (left) upper back (right) 
12 62/M MDS matched, 
unrelated 76 2 right shoulder lower back (middle) 
13 57/M AML matched, sibling 5 1 lower back (middle) upper back (right) 
14 50/M AML 5 of 10, sibling 11 2 upper back (middle) left shoulder 
15 40/M T-ALL matched, 
unrelated 19 3 right upper arm right thigh 
16 34/M B-ALL matched, 
unrelated 16 3 left shoulder lower back (left) 
17 61/F AML 9 of 10, unrelated 14 3 left shoulder lower back (left) 
18 21/M pre B-ALL matched, 
unrelated 16 1 left shoulder right shoulder 
19 50/M Plasmocytoma 9 of 10, unrelated 20 3 right shoulder right thigh (back) 
20 32/F cortical T-ALL 9 of 10, unrelated 20 1 right thigh right thigh 
21 66/M CML matched, 
unrelated 8 1 right thigh right shoulder 
Median 
53 
6 F 
15 M 
9 AML  
4 ALL 
 2 lymphoma 
2 MDS 
4 other 
matched (n=14) 
9 of 10 (n=6) 
5 of 10 (n=1) 
unrelated (n=13) 
sibling (n=8) 
17 2 
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Immuno-histochemistry and/or the emigration assay was performed to 
determinate LC, DDC and T cell numbers in lesional and uninvolved skin samples of 
21 patients with acute graft versus host disease (6 female, 15 male). All patients 
received mobilized peripheral blood stem cells from unrelated (n=13) or sibling (n=8) 
donors. 14 out of 21 patients received a full HLA matched graft, 6 patients received 
grafts with a mismatch in one out of 10 allels and one patient was transplanted with a 
haplo-identical graft. Median age was 53 years (range 21-66). GvHD prophylaxis 
(n=16) consisted of cyclosporin A (n=14), methotrexat (n=11), tacrolimus (n=4) 
or/and mycophenolate mofetil (n=2). Lesions of aGvHD were diagnosed and graded 
according to standard clinical criteria.200 Median day of aGvHD onset was day 17 
(range 5-76). The median grade of aGvHD was °II with 7 patients developing skin °I, 
4 patients °II and 10 patients °III. 
 
4.1.2 Patients of the Alemtuzumab Study 
Table 4-2: Patients’ Characteristics and Alemtuzumab Treatment:  
Shown are patients’ 
characteristics and 
Alemtuzumab treatment. 
Serum concentrations of 
Alemtuzumab at the time of 
aHSCT were determined by 
BioAnaLab Limited, Oxford, 
UK using ELISA. 
 
Abbreviations: aHSCT, 
allogeneic hematopoietic 
stem cell transplantation; 
n.a., not available. 
 
*relative lymphocyte count 
after Alemtuzumab 
treatment in relation to 
respective cell count before 
Alemtuzumab treatment; 
lymphocyte counts before 
were set at 100% 
 
 
In order to determinate the effect of Alemtuzumab on emigrating LCs, DDCs 
and on peripheral blood DC numbers, skin and peripheral blood was obtained from 
10 patients (2 female, 8 male) with CLL before and after an Alemtuzumab therapy. All 
patients received mobilized peripheral blood stem cells from related (n=4) or 
unrelated (n=6) donors. Median age was 54,5 years (range 44 to 66). 
 
Pat. 
Nr. 
Age 
[years] 
Binet 
stage 
before 
therapy 
Cumulative 
Alemtuzum
ab dose 
[mg] 
serum 
concentration 
of 
Alemtuzumab 
at time of 
aHSCT 
[ng/ml] 
Lymphocytes 
[x106/ml] 
before/after 
Alemtuzumab 
(relative cell 
numbers*) 
1 54 C 62 <31 8.4 / 2.3 (28%) 
2 52 C 315 490 0.3 / 0.0 (4%) 
3 51 B 463 168 1.4 / 0.3 (20%) 
4 57 C 436 48 63.1 / 0.3 (1%) 
5 55 C 203 54 0.5 / 0.0 (8%) 
6 52 C 403 <31 17.9 / 0.2 (1%) 
7 44 B 133 256 0.6 / 0.5 (95%) 
8 64 C 353 116 1.7 / 0.1 (5%) 
9 66 C 343 n.a. 0.9 / 0.0 (5%) 
10 65 C 163 n.a. 31.1 / 0.2 (1%) 
  
 
 
  
Median 
(range) 
54,5 
(44-66) 
 
329 
(62-463) 
85 
(< 31-490) 
 
1.57 / 0.16 (5%) 
(0.3-63.1 / 0.0-2.3) 
(1% - 95%) 
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4.2 Skin Samples of Patients and of Healthy Control Donors 
4.2.1 Shave Biopsies 
After informed consent of patients epidermal shave biopsies were obtained by a 
dermatologist. A minimal platelet count of 50x109/L peripheral blood was required to 
ensure prompt healing of the skin area.  Briefly, under local anesthesia with Xylonest 
1% (AstraZeneca GmbH; Wedel, Germany). The upper skin layers were removed 
with a scalpel. A biopsy extension of approximately 1 cm2 was aspired. The biopsy 
was immediately transferred into RPMI 1640 medium (Biochrom AG, Berlin, 
Germany) stored at 4 °C and processed within the next 2 h. 
 
4.2.2 Femoral Skin 
Split skin samples obtained from the femur during skin transplantation served as 
one source of control skin. After obtainment using a dermatome femoral skin samples 
were immediately transferred into RPMI medium and processed within the next 2 h. 
Samples were briefly washed in RPMI medium to remove blood contaminations. 
Although consisting of epidermis and only a small dermal fraction, split skin samples 
bear a major analogy to shave biopsies compared to other control skin. Split skin 
samples were cut in pieces of approximately 1 cm2 using a scalpel. 
 
4.2.3 Foreskin 
Foreskin samples obtained by circumcision served as a second source of 
control skin. After excision foreskin was immediately transferred into RPMI medium 
and processed within the next 3 h. Samples were briefly washed in RPMI medium to 
remove blood contaminations. Connective and fatty tissue was removed and the 
sample was cut in pieces of approximately 1 cm2 using a scalpel.  
 
4.2.4 Breast Skin 
Skin obtained during mama reduction plastic served as a third source of control 
skin. After obtaining the skin, it was immediately transferred into RPMI medium and 
processed within the next 2 h. Samples were briefly washed in RPMI medium to 
remove blood contaminations. Connective and fatty tissue was removed and the 
sample was cut in pieces of approximately 1 cm2 using a scalpel. 
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4.3 Immunohistochemistry 
4.3.1 Material 
4.3.1.1 Buffer and Supplements 
HSA human serum albumin - Immuno, Baxter GmbH,  
Unterschleißheim, Germany 
PBS  Dulbecco’s Phosphate Buffered Saline-0,0095 M - BioWhittaker, 
Belgium or PAA Laboratories GmbH, Pasching, Austria 
TBS 0,1M Tris buffered saline produced from a 0,5M stock solution 
including 60,55 g/l Tris ultrapur, 85,20 g/l NaCl, 26 ml/l 8M HCl. 
Manufactured by the Klinik-Apotheke Universitätsklinikum 
Dresden, Germany. 
washing buffer I PBS +5% HSA 
washing buffer II TBS +5% HSA 
washing buffer III PBS +10%Tween20 (Dako) 
 
4.3.1.2 Reagents 
acetone Merck, Darmstadt, Germany 
alkaline          Levamisol solution (0,005 M) - Vector Laboratories, Burlingame, 
phosphatase         CA, USA 
inhibitor 
BCIP/NBT 5-Bromo-4-Chloro-3-Indoxylosphat and Nitroblue- 
Tetrazoliumchlorid in Tris-Buffer including stabilizers and N,N-
Dimethylformamide - DakoCytomation, Glostrup, Denmark 
barrier marker Roti® liquid barrier marker – Carl Roth GmbH, Karlsruhe, Germany 
DMF N,N-Dimethylformamide – Sigma Aldrich, Steinheim, Germany 
Fast Blue BB-salt Sigma Aldrich 
Naphtol-AS-MX- Sigma Aldrich 
phosphate 
Jung tissue  Leica Microsystems GmbH, Nussloch, Germany 
freezing medium 
Mayer´s  4,4 g/L C.I. 75290, 28 g/L AL2(SO4)3 x 18 H2O, 1 g/L C6H8O7 x  
hemalum sulution H2O - Merck, Darmstadt, Germany 
MountFluor Biocyc, Luckenwalde, Germany 
SuperPicTureTM    including broad spectrum poly horseradish peroxidase conjugate 
Kit           and AEC (3-amino-9-ethylcarbazole) single solution chromogen –  
        Zymed® Laboratories, San Francisco, CA, USA 
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peroxidase block DakoCytomation, Glostrup, Denmark 
protein block serum free - DakoCytomation, Glostrup, Denmark 
Tris- Hydro-          C4H11NO3 · HCL, 157,6 g/mol - Applichem, Darmstadt, Germany  
chloride 
Table 4-3: Antibodies for Immunohistochemistry 
Source 
* Dako Cytomation, Glostrup, Denmark     † BD Biosciences Pharmingen, San Jose, USA 
 Sigma Saint Louis, Missouri, USA     £ eBioscience, San Diego, CA, USA 
 Zymed Laboratories, San Francisco, CA, USA   ¢ Lab Vision, Westinghouse, CA 
‡ Beckman Coulter, Immunotech, Marseille,  
 
 
4.3.1.3 Equipment 
Cryotome  CM 1900 - Leica, Wetzlar, Germany 
Eclipsenet Eclipse Inc. Rockford, IL, USA 
Software 
Incubator  Heraeus / Kendro Laboratory Products, Gera, Germany 
microscope Optiphot-2 light microscop - Nikon, Düsseldorf, Germany attached 
to KY-F55B camera - JVC, Friedberg, Germany 
pipettes  Falcon, Becton Dickinson Labware Franklin Lakes, NJ, USA 
 
4.3.1.4 Consumable Material 
Specimen Molds Cryomold® Intermediate 15 mm x 15mm x 5mm – Sakura Finetek, 
Zoeterwoude, NL 
Pasteur pipette Falcon, Becton Dickinson Labware Franklin Lakes, NJ, USA 
scalpel Asculap AG & Co. KG, Tuttlingen, Germany 
slides HistoGripTM coated slides. Zymed, San Francisco, CA, USA 
antibody specificity host conjugate clone isotype 
Anit-FITC * - rabbit HRP polyclonal F(ab’) 
Anti-mouse IgG  mouse goat AP polyclonal not specified 
SuperPicTureTM Kit  mouse, rabbit, rat not specified poly HRP not specified not specified 
CD1a * human mouse FITC NA1/34 IgG2 
CD3 ‡ human mouse FITC UCHT1 IgG1 
CD3  human rabbit non polyclonal not specified 
CD206 † human mouse PE 19.2 IgG1κ 
CD207 ‡ human mouse PE DCGM4 IgG1 
HLA-DR † human mouse Pc5 G46-6 IgG2 
IgG1 ‡ irrelevant mouse FITC 679.1Mc7 IgG1 
IgG2 ‡ irrelevant mouse FITC 679.1Mc7 IgG2 
IgG1κ £ irrelevant mouse PE P3 IgG1κ 
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4.3.2 Methods 
4.3.2.1 Generation of Cryo-Sections from Skin Biopsies 
 Skin samples were transferred to specimen molds, embedded in tissue freezing 
medium and incubated at -20 °C for at least 24 h. This procedure did not negatively 
affect the quality of the following staining, as staining results of liquid nitrogen frozen 
samples were indistinguishable from -20 °C frozen samples. Four to seven cryo-
sections of 5 µm thickness were manufactured using a cryotome and were applied to 
slides. Consecutive sections were placed on different slides to ensure that sections 
on one slide did not represent the same cells. For experiments aiming to compare 
staining results between biopsies of different origin (lesional vs. unaffected skin from 
GvHD patients) or between biopsies treated in different ways (untreated vs. dispase I 
digested skin) the respective specimens were arranged on the same slide. This 
procedure assured that the compared biopsies were stained under the same 
conditions and excluded differences due to varying staining intensities. Slides were 
stored at –20 °C until staining was performed. 
 
4.3.2.2 Single-Color-Staining of Cryo-Sections Using Horseradish Peroxidase (HRP) 
Sections were fixed in acetone for 10 minutes at –20 °C and framed with a 
hydrophobic barrier marker to avoid the leakage of antibody or washing buffer from 
the slide. Slides were placed in a moist chamber during the staining procedure. 
Sections were rehydrated with 500 µl washing buffer I for 10 minutes at room 
temperature (RT). After removing the washing buffer sections were stained with 
300 ml of a 1:50 dilution of the primary monoclonal antibody (shown in Table 4-3) for 
70 minutes at RT or at 4 °C overnight. For CD1a a 1:100 dilution was used. Slides 
were washed three times with 1 ml washing buffer I for 10 minutes at RT followed by 
a peroxidase block (5 drops per slide) and a protein block (5 drops per slide) each for 
10 minutes at RT to quench endogenous peroxidase activity and block unspecific 
protein binding sites. For detection the SuperPicTureTM Kit was used according to the 
manufacturer’s instructions. Briefly the sections were incubated for 60 minutes at RT 
with the poly-conjugated horseradish peroxidase solution (5 drops per slide) and 
washed 3 times for 10 minutes at RT with 500 µl washing buffer I thereafter. After 
removing the washing buffer, four drops of the AEC (3-amino-9-ethylcarbazole) single 
solution chromogen were added to each slide. In order to achieve an optimal 
visualization, the staining procedure was microscopically monitored and the skin 
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sections were rinsed gently with distilled water to stop the reaction when the staining 
was intensive enough for specific epitope detection. Background staining of keratin in 
the stratum corneum was observed with some antibodies; however, no unspecific 
binding occurred within the cellular epidermal or dermal layers. 
After staining, skin sections were counterstained with Mayer’s hemalaun for 
15 sec and rinsed in distilled water for 2 minutes. Finally, the skin sections were 
mounted in MountFlow and analysed by conventional light microscopy. 
 
4.3.2.3 Analysis of Single-Color-Staining 
Three investigators independently evaluated the number of stained cells in 
sections from patients and in control skin in a blind folded manner. Cells were 
counted using a microscope (200x magnification) attached to a camera and a 
computer running Eclipsenet. As LC were found virtually exclusive in the epidermis, 
they showed a linear distribution in vertical skin sections. The LC number per 
microscopic field as well as the length of the respective epidermis [µm] were 
determined using the Eclipsenet software. 
Figure 4-1: Analysis of Single-Color-Staining: Microscopic fields of cryo-sections from a 
healthy control donor stained with anti-CD207 (a) or with anti-CD206 (b) (magnification 
200x). Counterstaining was performed with Mayer’s hemalum. The length (L) of the 
epidermis and the area (A) of the upper dermis was calculated using Eclipsenet software. 
Cells stained positive for CD207 within the epidermis or for CD206 within the upper dermis 
were counted. Scale bars represent a lenth of 100µm. 
  
 To compare distinguished LC numbers per epidermal length to recently 
published LC numbers per epidermal area LCs/mm2, results were calculated using 
the following formula. 
                     2                  2               
cell number on L        for the         15 
LC/mm2 =           shown example:           = 298 LC/mm2 
           L [mm]            869x10-3 [mm] 
L = 869µm 
cell number = 15 
A   = 70383 µm² 
cell number = 23 
100µm 
a b 
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 DDCs were two-dimensional distributed within the sections. In order to 
standardize the measurements, the number of cells was determined within a sector 
ranging 100 µm deep from the epidermis inwards (upper dermis). The sector area 
was defined using the Eclipsenet software and the cell number within the area was 
counted. Counting was performed for 6 representative microscopic fields (200x 
magnification) from each of the three investigators and averaged. 
 T cells were located in both, epidermis and dermis. As T cells were very 
unevenly distributed epidermal T cell numbers in 15 different microscopic fields were 
counted by three investigators and normalized to the full epidermal length or upper 
dermal area within these 15 microscopic fields. Investigators determined a whole of 5 
microscopic fields different from each other. 
 In addition, T cell clusters, consisting of more than 3 interrelated T cells, were 
found in the dermis and the number of these clusters as well as T cells within a given 
cluster was determined. If the number of T cells could not be resolved within a cluster 
because single T cells were not definable among each other, their number was 
calculated. Thereto the cluster area was measured and divided by an approximated 
single T cell area, with a given diameter of 10m. 
 
4.3.2.4 Immunoenzymatic Doublestaining of Vertical Skin Sections  
Sample-slides were prepared as described in section single-color-staining. After 
rehydration with wash buffer III (300 µl per slide; 5 min at RT), Dual Endogenous 
Enzyme Block was added (200 µl per slide; 5 min at RT) to inhibit endogenous 
alkaline phosphatase, peroxidase, and pseudoperoxidase activity. 
After three washing steps with wash buffer III (300 µl per slide; 2 min at RT) 
unspecific protein binding sites were blocked with serum free protein blocking 
reagent (3 drops per slide; 5 min at RT). After removing the protein block the first 
primary antibody (300 µl of a 1:100 dilution of CD3) was added and slides were 
incubated over night at 4 °C. After three washing steps with wash buffer II (300 µl per 
slide; 2 min at RT) sections were incubated with the first detection antibody (300 µl 
HRP/Polymer reagent for 1 h at RT). The HRP/Polymer conjugate was removed by a 
brief washing step and 200 µl of DAB+ Chromogen working solution was added to 
the slide for approximately 10 min at RT. DAB+ working solution was prepared by 
thoroughly mixing one drop DAB+ Chromogen with 1 ml of DAB+ Substrate Buffer. 
The slides were then rinsed gently with distilled water and placed in a fresh wash 
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buffer bath for 5 min. Excess wash buffer was taped off and skin sections were 
incubated with Double-stain Block (200 µl per slide; 3 min at RT). After brief wash the 
second primary antibody was added (300 µl of a 1:100 dilution of CD206; for 1 h at 
RT). After washing to remove unbound antibody the second detection antibody was 
added to the slide (300 µl of Mouse/Rabbit LINK for 1 h at RT). Sections were 
washed and the second detection antibody, the Polymer/AP reagent was added 
(300 µl per slide; 1 h at RT). After a new wash step, Permanent Red Chromogen was 
added for visualization (200 µl per slide, for approximately 10 min). Permanent Red 
working solution was prepared by thoroughly mixing 1 ml of Permanent Red 
Substrate Buffer with 10 µl Permanent Red Chromogen. Samples were gently rinsed 
with distilled water and counterstained with Mayer’s hemalaun (15 sec at RT) 
followed by a thorough rinse with distilled water for 2 min.  
In order to achieve an optimal visualization, the staining procedure of both 
HRP/DAB+ and AP/Permanent Red reaction were microscopically monitored and the 
skin sections were rinsed gently with distilled water to stop the reaction when the 
staining was intensive enough for specific epitope detection. First and second 
primary antibody were substituted by isotype matched antibodies with irrelevant 
specificity as negative controls. If unspecific staining reactions were observed the 
appropriate samples were excluded from the analysis. Finally, skin sections were air 
dried, mounted in MountFlow™ and analysed with conventional light microscopy. 
 
4.3.2.5 Multi-Step Immuno-Fluorescence Double-Staining of Vertical Skin Sections  
Sample-slides were prepared as described in section single-color-staining. After 
rehydration with wash buffer I for 5 min, unspecific protein binding sites were blocked 
with three drops of serum free protein blocking reagent to each slide for 5 min. 
Excess protein blocking reagent was taped off followed by incubation with 300 µl of a 
1:100 dilution of the first primary antibody or negative control (CD207 or mouse IgG1) 
per slide over night at 4 °C. To wash the skin sections, the slides were covered with 
500 l of wash buffer I for 2 min. The wash buffer was taped off and the washing step 
was repeated twice. 
Skin sections were incubated with 300 µl of first secondary antibody (anti mouse 
Cy3) per slide for 1 h at RT. Excess antibody was removed by washing, followed by 
incubation with 300 µl of mouse IgG antibody per slide for 20 min at RT to block the 
anti-mouse binding sites at first secondary antibody. After the block, the skin sections 
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were washed again to remove remaining antibody. 300 µl of second primary FITC 
conjugated antibody (CD1a or IgG2) was added to each slide for 1 h at RT. Unbound 
antibody was washed off and the skin sections were incubated with 300 µl of second 
secondary antibody (anti FITC rabbit) per slide for 1 h at RT. After washing, 300 µl of 
antibody (anti rabbit Cy2) was applied for 1 h at RT. Counterstaining was performed 
with DAPI 1:1000 for 10 min at RT. After brief wash, the tissue sections were 
immediately mounted in anti fading mounting medium (MountFlow™). 
Finally, skin sections were viewed by fluorescence microscopy or stored at 4 °C 
in the dark. In addition, a double staining of CD3 versus CD206 was performed. In 
contrast to CD1a versus CD207 staining, an IgG blocking step was not necessary 
after the first secondary antibody, as the two primary antibodies were derived from 
different species. 
 
4.4 Isolation, Detection and Functional Characterization of Skin DCs 
4.4.1 Material 
4.4.1.1 Buffer, Media, Sera and Non-Cytokine Supplements 
AIM-V  Serum Free Lymphocyte Medium contains L-Glutamin, 
Streptomycin-sulfat (50 µg/ml), Gentamycinsulfat (10 µg/ml): 
Gibco™, Auckland/Paisley, Schottland/Grand Island N.Y., USA 
Cryomedium    contained 130 ml (% v/v) heat inactivated human single donor 
plasma und 40 ml (% v/v) DMSO 
HSA human serum albumine: Immuno, Baxter GmbH, Unterschleiß-
heim, Germany 
IMDM  BIOWhittaker, Cambrex, Verviers, Belgium 
PBS  Dulbecco’s Phosphate Buffered Saline-0,0095 M: BioWhittaker, 
Belgien 
Pen/Strep penicillin/streptomycin: Cambrex BioSciences Verviers, Verviers, 
Belgium 
RPMI 1640  contains 2,0 g/l NaHCO3 and 0,532 g/l N-Acetyl-L-Alanyl-L-
Glutamin: Biochrom AG, Berlin, Germany  
X-VIVO 15   BioWhittaker, Verviers, Belgium 
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All media and reagents were sterile and endotoxin-free. If indicated, media were 
supplemented with 100 U/ml Pen/Strep and/or with heat-inactivated, autologous 
serum or with HSA (1, 5 or 10% v/v as specified for a particular experiment). 
 
4.4.1.2 Cytokines and Chemokines 
The followig sterile recombinant, endotoxin-, pyrogen-, mycoplasma- and 
carrier-free human cytokines were used. All R&D Systems cytokines were 
reconstituted in PBS with HSA; other cytokines were reconstituted and stored 
according to manufacturer’s directions. 
IL-1β,   R&D Systems, Wiesbaden, Germany 
IL-6   R&D Systems, Wiesbaden, Germany 
MIP-3β   Sigma-Aldrich Chemie GmbH, Steinheim, Germany 
PGE2   Pharmacia / Upjohn, Erlangen, Germany 
TNFα   R&D Systems, Wiesbaden, Germany 
4.4.1.3 Reagents 
BSA-FITC Sigma Aldrich, Steinheim, Germany 
dispase I  Roche, Penzberg Germany 
DMSO  Dimethyl-Sulfoxid -  
Ficoll  Biocoll, density 1,077 - Biochrom AG Berlin, Germany 
Flow-countTM  Beckman Coulter, Inc. Mervue, Ireland 
fluorospheres   
methyl-  [3H]TdR, 1 µCi/µl - Amersham, Little Chalfont, UK 
[3H]thymidine   
 
Table 4-4: Antibodies for FACS: 
Source: 
§ R&D Systems, Minneapolis, MN, USA  ¥ Caltag Laboratories, Burlingame, CA, USA 
*  DakoCytomation, Glostrup, Denmark   ¢ Lab Vision, Westinghouse, CA, USA 
† BD Biosciences Pharmingen, San Jose, USA  ¶ Serotec, Oxford, UK 
‡ Beckman Coulter, Immunotech, Marseille,France 
 
antibody label clone isotype  antibody label clone isotype 
         
CCR7 § FITC 150503 IgG2  CD52 ¶ FITC MCA1642F IgG1 
CD1a * FITC NA1/34 IgG2  CD52 ¶ PE MCA1642F IgG1 
CD1a † PE HI149 IgG2  CD56 † PE NCAM16.2 IgG1 
CD1b † FITC M-T101 IgG1κ  CD80 † PE L307.4 IgG1 
CD3 † FITC SK7 IgG1  CD71 ¶ PE DF1513  IgG2 
CD3 † PE SK7 IgG1  CD83 ‡ FITC HB15a IgG2 
CD3 ¥ Pc5 S4.1 IgG2  CD86 † FITC 2331 IgG1 
CD4 * FITC MT310 IgG1  CD123 † PE 9F5 IgG1κ 
CD4 ‡ PE 13B8.2 IgG1  CD206 † PE 19.2 IgG1 
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antibody label clone isotype  antibody label clone isotype 
         
CD8 * FITC C8/144B IgG1  CD207 ‡ PE DCGM4 IgG1 
CD8,CD4, 
CD3* FITC,PE,PC5 CatNo: TC65401  
E-cadherin 
† FITC 36 IgG2 
CD11a † FITC G43-25b IgG1  FactorXIIIa ¢ non AC-1A1 IgG1κ 
CD11c † PE Leu-M5 IgG1  goat-anti-
mouse  
FITC polyclonal IgG 
CD14 ‡ PE RMO52 IgG2  HLA-DR † Pc5 G46-6 IgG2 
CD14 ‡ FITC RMO52 IgG2  Lin 1 † FITC CatNo: 340546 
CD19 * FITC HD37 IgG1  γδ TCR † FITC B1 IgG1 
CD20 * FITC B-Ly1 IgG1  IgG1 ‡ FITC 679.1Mc7 IgG1 
CD40 † FITC 5C3 IgG1κ  IgG1 ‡ PE 679.1MC7 IgG1 
CD45 ‡ Pc5 J33 IgG1  IgG1 ‡ Pc5 679.1MC7 IgG1 
 
4.4.1.4 Equipment 
Beta-counter  Liquid Scintillatin and Luminescence Counter, 1450 Micro Beta-
Trilux -  Wallac Distribution GmbH, Freiburg, Deutschland 
CellQuest Pro  Version 4.0.2. -  Becton Dickinson and Co., San Jose, CA, USA 
Software  
 
Clean bench  Heraeus Safe Hera, Gera, Germany 
centrifuges   palletizing of cells in suspension was done by 1500 U/min, at 
room temperature for 20 minutes. Multifuge 3 S-R, Kendro 
Labatory Products and Hettich, Rotixa 50 RS, Tuttlingen, 
Germany  
drying chamber  Memmert GmbH, Schwabach, Germany 
FACSCalibur™  four-color, dual-laser, benchtop system (488 nm argon-laser and 
635 nm red diode-laser) for flow-cytometry. Becton Dickinson 
and Co., San Jose, CA, USA connected to a peripheral PC 
(Power PC G3 3000 MHz 1MB Cache 64MB/6GB HD/48x 
CD/Zip; Mac OS) 
FACSVantageTM SE High Speed  
488 nm argon-laser Becton Dickinson, and Co., San Jose, CA, 
USA connected to a peripheral PC (Power PC G3 3000 MHz 
1MB Cache 64MB/6GB HD/24x CD/Zip; Mac OS) 
Incubator  Heraeus / Kendro Laboratory Products, Gera, Germany 
Multipette plus eppendorf, Hamburg, Germany 
pipettes  Falcon, Becton Dickinson Labware, BD and Co., Franklin 
Lakes, NY, USA 
shaker   MS 1 Minishaker, IKA – Works, INCA, Wilmington, USA 
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Sysmex   The automated counting device Sysmex XE-2100 is adapted for 
XE-2100   measurement of rare cell numbers and routinely used in our lab. 
 It requires a sample volume of 170µl and detects cell numbers 
above 5.000 cells per ml. 
water bath WB 6 – MS Laborgeräte, Wiesloch, Germany 
 
4.4.1.5 Consumable Material 
filtermap disks printed filtermaps A, Walac Oy, Finnland 
filter mesh 40 µm pore size, Miltenyi Biotec, Bergisch Gladbach, Germany 
Monovetten  Sarstedt Monovetten Li-Heparin LH/9ml, Sarstedt AG & Co., 
Nürnbrecht, Germany 
Pasteur-  Falcon, Becton Dickinson Labware, BD and Co., Franklin  
pipette   Lakes, NY, USA 
 
petri-dishes  Ø3,5cm Greiner bio-one, Solingen-Wald, Germany 
tubes   Falcon, Becton Dickinson Labware, BD and Co., Franklin  
(5,15, 50 ml)  Lakes, NY, USA 
scalpel  Asculap AG & Co. KG, Tuttlingen, Germany 
szintillator  Meltilex™A, Wallac Oy, Finland 
disks  
transwell insert 8 µm pore size transwell insert, BD Labware Europe, Le Pont, De 
Claix, France 
6,12,24 well flat  Nunclon Surface, Nunc A/S, Roskilde, Dänemark 
bottom plate 
96-well round  BD, Lincoln Park, USA 
bottom plate  
 
4.4.2 Methods 
4.4.2.1 Separation of Epidermal and Dermal Layers by Dispase I Digestion 
For separating the epidermis from the dermis femoral skin, foreskin, breast skin 
or shave biopsies from patients respectively, were treated with 1 U of the bacterial 
enzyme dispase I in 1 ml PBS for 1 h at 37 °C. After incubation the epidermal layer 
was peeled of201 and both layers were washed in PBS supplemented with HSA (5 % 
v/v). In case of shave biopsies and femoral skin the separation was possible 
immediately after 1 h of incubation. Thicker skin specimens like foreskin and breast 
skin were not always separable after 1 h incubation. The respective samples were 
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washed with PBS and incubated floating on medium at 37 °C or in PBS at 4 °C 
respectively. After 12 to 14 h the epidermis could be peeled off. 
 
4.4.2.2 Emigration Assay 
Whole shave biopsies or their epidermal and dermal parts separated by dispase 
I digestion were rinsed with PBS and mounted (dermal site down) into 12 well plates 
floating on 3 ml X-vivo 15 supplemented with 100 U/ml Pen/Strep. Shave biopsies 
were cultured at 37 °C in a humidified atmosphere with 5% CO2. 72 h later medium 
containing the emigrated cells was harvested. Cells were passed through a filter 
mesh (40 µm pore size) washed with washing buffer I and obtained for immuno- 
fluorescence staining. Absolute numbers of migrated DC were counted using a 
FACSCalibur™ and Flow-countTM fluorospheres, after which they were sorted or 
used for functional analyses. 
 
4.4.2.3 Determination of Cell Vitality by Trypan-Blue Incorporation 
10 µl of the respective cell suspension were added to 90 µl of trypan blue 
solution and immediately analyzed using conventional light microscopy (200x 
magnification). As several filamentous fragments were observed within the 
emigration culture, only objects that could definitely assign to cells of hematopoietic 
origin were included in the analysis. Vital cells were evaluated by the lack of a blue 
staining. 
 
4.4.2.4 Maturation of ex vivo Emigrated Dendritic Cells from the Skin 
Maturation of emigrating LCs and DDCs could be achieved during days 2–3 of 
the emigration assay by adding a combination of inflammatory cytokines, consisting 
of (IL-1β (2 ng/ml), IL-6 (1000 IU/ml), TNFα (10 ng/ml)) and PGE2 (5 mM/ml) to the 
emigration culture. 
 
4.4.2.5 Immuno-Fluorescence Staining, FACS and Cell Sorting  
Direct Fluorescein isothiocyanate (FITC), R Phycoerythrin (PE) or R 
Phycoerythrin-Cyanin 5.1 (PC5) conjugated mouse anti-human mAbs listed in Table 
4-4 were used. 
Immunofluorescence staining was performed according to the manufacturers’ 
instructions immediately after harvesting cells from the emigration assay. Briefly, cells 
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were harvested, washed with buffer I, centrifuged and re-suspended in 100 µl of 
washing buffer I (4 °C). All further staining steps were performed on ice. 10 µl of each 
moAb was added per 1x106 emigrated cells. After 20 minutes cells were double 
washed with buffer I, re-suspended in 500 µl washing buffer and immediately 
analysed.  
Flow cytometry studies used a FACSCaliburTM running BD CellQuest Pro 
Software, Version 4.0.2. Instrument setup including system start, compensation, 
compiling of measurement protocols and data analysis was performed as described 
previously.202 Instrument settings are shown in Figure 4-2. 
Cell sorting was performed using FacsVantage running CellQuest software and was 
technical assisted by laboratory staff of the Medizinische Klinik I. 
Figure 4-2: Instrument Settings for FACS and Sorting: Instrument settings of FACSCalibur and 
FACS Vantage used for analysis and/or sorting of emigrated cell populations. 
 
 
4.4.2.6 Single Platform Enumeration of Cells in Emigration Culture 
To each prepared sample a defined volume/number of Flow-countTM 
fluorospheres was added directly before running flow-cytometry (normally 50µl = 
49300-49500 beads depending on the assayed concentration). Flow-count 
fluorospheres appeared in the highest FITC and PE channels and did not interfere 
with the labeled sample. A life-gate was set around the Flow-count fluorospheres in a 
FITC/PE Dot-Plot and a defined number of fluorospheres (normally 5000) was 
measured in parallel with the sample. The absolute number of a cell population within 
the sample (defined by a gate) could be calculated by the formula:  
Instrum ents Settings 
for FACSC alibur
Instrum ents Settings 
for FACSVantage
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total number of cells =  (added fluorospheres) x (measured cell number) 
               measured florospheres 
4.4.2.7 Antigen Uptake 
 Emigrated cells were suspended in PBS and incubated with FITC conjugated 
BSA (final concentration 50 µg/ml) for 10 and 60 minutes at 37 °C or on ice as a 
negative control. Cells were washed 3 times with ice cold PBS to stop Ag uptake and 
were analyzed immediately by FACSCaliburTM. Flowcytometric analysis was 
performed with gate on large FSC, SSC, MHC II and the DC-type specific markers. 
4.4.2.8 Transmigration Assay 
Because endotoxin and other bacterial products are able to cause a very fast 
(15 minutes) inhibition (80%) of chemotaxis to most chemokines,203 only endotoxin-
free reagents were applied. Chemotaxis experiments were performed by using 
polycarbonate filters of 8 m pore size in 24-transwell chambers. A given number of 
LCs or DDCs (cell input) was placed into culture medium onto the upper chamber of 
a transwell. The lower chamber contained 700 µl of culture medium supplemented 
with 100 ng/ml MIP-3β or of medium not supplemented for control (spontaneous 
trans-migration). Transmigrated cells were FACS counted after 4 h using a 
FACSCalibur™ and Flow-countTM fluorospheres. The percentage of migrated cells 
out of the cell input was determined. Scores for chemotactic transmigratory capacity 
(∆Mi) were calculated subtracting the spontaneous transmigration from the Mip-3β 
induced transmigration. 
 
4.4.2.9 Mixed Leukocyte Reaction 
DCs were co-cultured with 105 allogeneic PBMC in triplicate round-bottom micro 
wells of a 96-well-plate at variable ratios from 10:1 to 1000:1 (PBMC:DC) in AIM-V 
media supplemented with HSA (1 % v/v) and Pen/ Strep (100 U/ml). The viability of 
thawed cryopreserved PBMC responders that were derived from a single whole 
blood donation always exceeded 90 % as determined by trypan blue exclusion. 50 % 
of PBMC were CD3+ T cells (41 % were CD4+ and 7 % were CD8+). 
Prior to the assay DC had been washed to remove cytokines and they had been 
irradiated with 60 Gy (137Cs) before mixing with responder cells. Co-culture was 
allowed for 72 h. Triplicates of every ratio were incubated for 72 h.  
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4.4.2.10 Incorporation of Methyl-[3H] Thymidine 
The resulting proliferation of responder T cells was based on the incorporation 
of methyl-[3H]thymidine during the last 18 h of the 3 days culture, as measured in a 
beta scintillation counter. PBMCs stimulated with phytohemagglutinin (PHA) served 
as positive controls and a [3H]Thymidine incorporation of ≥ 40 000 counts per 
minute (cpm) was always detected in these settings. Stimulator cells alone as well as 
pure PBMC cultures served as negative controls and never reached values above 
200 cpm. 
 
4.4.2.11 Assessment of Donor Chimerism 
Donor chimerism of skin DCs was determined with a multiplex- polymerase 
chain reaction (PCR) for informative short-tandem-repeat (STR) markers. DNA 
extraction and PCR were performed by Prof. Dr. Thiede and his laboratory of 
molecular biology as previously described.204 A minimum of 200 sorted cells was 
required to achieve reliable quantitative results. The sensitivity of the applied method 
is 5%; donor chimerisms >95% were defined as complete whereas those below 95% 
as incomplete. 
 
4.4.2.12 Statisticial Analysis 
Statistical analysis was performed using GraphPadPrism software. As sample 
sizes did not allow testing of a Gaussian distribution, medians and ranges were used 
for descriptive statistics and non-parametric tests were used to calculate statistical 
differences. Intra-individual differences (unaffected and lesional skin) were analyzed 
for their significance using Wilcoxon matched pairs test (two sided). Differences 
between patients and healthy controls were analyzed by Mann and Whitney test 
(two-sided). Statistical significance is indicated by asterisks in all figures. *P value 
<0.05, ** P value <0.005, *** P value <0.0005. 
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5 RESULTS 
5.1 Results Part I – Development of Techniques 
5.1.1 In Situ Analysis of APCs and T Cells in Human Skin  
The surface expression of MHC class II (MHC II) is a fundamental characteristic 
of APCs. To investigate the location and distribution of APCs in healthy human skin 
vertical cryo-sections were labelled against HLA-DR, a human MHC II antigen. The 
detection was performed using a single-color-staining AEC/HRP system. To visualize 
the dermo-epidermal border, specimens were counterstained with Mayer’s hemalaun 
solution. As shown in Figure 5-1 the nuclei rich epidermal compartment could easily be 
distinguished from the dermal layer with only few scattered nuclei.  
Immuno-histochemistry was performed with skin specimens derived from 
different anatomical sites, i.e., femoral skin, female breast skin and male foreskin. 
Epidermal thickness as well as incidence and appearance of epidermal ridges varied 
between skin sources. In sections of all donors and skin types MHC II+ cells could be 
detected in both, epidermis and dermis [Figure 5-1]. 
 
      femoral skin   breast skin   foreskin 
   
 
 
 
 
 
 
 
 
Median Range N Median Range N Median Range N 
E 2.5/mm 0-8.5 9 23.0/mm 6.4-31.9 5 15.3/mm 8.4-30.5 10 
D 329/mm2 254-620 9 444/mm2 359-486 5 518/mm2 379-719 10 
Figure 5-1: MHC class II+ cells numbers vary at different anatomical locations: Labelling against 
HLA-DR to visualize MHC II+ APCs in representative sections of healthy human skin from different 
anatomical sites. Original magnification 600x. Bars indicate a length of 50µm. Median number of 
epidermal (E) and dermal (D) MHC II+ cells, range and number of donors investigated are summarized 
below for the respective anatomical site. 
 
Epidermal MHC II+ cells were mainly located in the stratum basale and stratum 
spinosum and partly showed dendritic processes. Within the epidermis no cluster 
formation of APCs was observed. In healthy femoral skin a median number of 2.5 (0-
8.5 n=9) MHC II+ cells was found per millimeter of epidermis. Epidermal APC 
numbers in breast and foreskin were significantly higher compared to femoral skin 
(P<0.05). 
E 
D 
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MHC II+ cells were also detected within the papillary and reticular dermis. They 
appeared as single cells with pronounced dendrites as well as in clusters of several 
interrelated cells. In the upper dermis extending to 100 µm deep from the epidermis 
329/mm2 (254-620 n=9) MHC II+ cells were found. Their number considerably 
decreased within deeper dermal areas. 284/mm2 (164-315 n=5) MHC II+ cells were 
found in the area reaching from 100 – 200 µm and 188/mm2 (104-240 n=5) cells in 
the area reaching from 200 – 300 µm [Figure 5-2]. The observed scarcity in deeper 
dermal areas was significant in both cases (P=0.01). 
Figure 5-2: MHC class II+ cell numbers decrease in deeper dermal areas: Staining of MHC class II 
(HLA-DR) in representative sections of healthy femoral skin. Consecutive dermal areas of 100 µm 
starting from the dermo-epidermal junction were defined using ECLIPSE software. Original 
magnification 200x. Bar indicate a length of 100µm. The number of MHC II+ cells within each dermal 
area is indicated for 5 different donors. P values (* <0.05) 
 
To establish a standardized method for the quantitative determination of dermal 
cells, positive stained cells were counted in the dermal area extending to 100 µm 
deep from the epidermis. This area will be referred to as upper dermis in the rest of 
the work. Foreskin and breast skin were inhabited by equal numbers of MHC II+ cells,  
whereas their number was significantly lower in the upper dermis of femoral skin. By 
using a panel of phenotypic markers the entirety of MHC II+ APC was differentiated 
into distinct APC subtypes. 
 
5.1.1.1 Langerhans cells 
LCs visualized by labelling against CD207 appeared round occasionally with 
short dendritic processes. They were located in the suprabasal layer of the epidermis 
in a “bead like” arrangement whereas almost no CD207+ cells were detected within 
the dermis [Figure 5-3]. 
0-100 µm 
100-200 µm 
200-300 µm 
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A median number of 22.3/mm (11.0-34.7 n=19) CD207+ LCs was found within 
femoral skin samples of healthy donors. Breast skin as well as foreskin was inhabited 
by equal numbers of CD207+ LC. 
       femoral skin   breast skin    foreskin 
   
 
 
 
 
 
 
 
Median Range N Median Range N Median Range N 
E 22.3/mm 11.0-34.7 19 22.7/mm 12.6-29.7 5 17.4/mm 10.1-44.3 10 
Figure 5-3: Equal LC numbers at different anatomical sites: LC were visualized by CD207 
staining,  representative sections of healthy human skin from different anatomical sites are 
shown. Bars indicate a length of 50µm. Median number of epidermal (E) CD207+ cells, range and 
number of donors investigated are summarized in the table below for each anatomical site. 
 
Another well established marker for the detection of LCs in situ is CD1a. 
Although an equal epidermal distribution of CD1a+ and CD207+ cells was found 
at all investigated anatomical sites, cell outlines differed considerably according 
to the used detection antibody.  
Figure 5-4: CD207 and CD1a staining resulted in different LC outlines and numbers: 
Representative HRP single-staining of LCs by either CD207 (first column) or CD1a (second 
column) are shown. Labelling was performed in vertical skin sections counter-stained with Mayers 
hemalaun (first row) and in epidermal sheets (second row). Bars indicate a length of 50µm. 
Shown in the graph are CD207+ and CD1a+ LC numbers per mm epidermis in sectioned femoral, 
fore- and breast skin of healthy control donors as paired samples. *P>0.05 
 
 
CD207 CD1a 
CD207 CD1a 
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Staining against CD1a showed a more irregular cell shape with pronounced 
dendritic processes compared to CD207 staining [Figure 5-4]. A median number of 
29.4/mm (18.3-36.6 n=14) CD1a+ cells/mm was found in healthy femoral skin. LC 
numbers in female breast skin and foreskin did not differ from this value. Although 
both, CD1a and CD207, are referred to as specific markers for LCs numbers of 
CD1a+ cells significantly exceeded that of CD207+ cells by around 20% at any 
anatomical site investigated [Figure 5-4]. 
On the basis of these findings, the distribution of CD1a and CD207 on LCs was 
characterized in detail. CD207 expression appeared particularly on the cell body and 
weaker on peripheral dendrites, whereas CD1a labeled preferably dendrites.  
To investigate whether CD1a and CD207 were co-expressed, multi-step 
enzymatic and fluorescence double staining were employed in skin sections to detect 
both LC markers simultaneously. Every CD207+ cell also co-expressed CD1a in both 
staining approaches. However, there was evidence for a small cell population 
expressing CD1a but not CD207 [Figure 5-5]. 
Figure 5-5: Detection of a small LC subset expressing CD1a but lacking CD207 using 
vertical sections: Multi-step enzymatic (left) and fluorescence (right) double staining of LCs in 
sectioned femoral skin using CD1a and CD207. CD1a was detected by HRP (brown) or FITC 
(green), CD207 was detected by AP (black) or Cy3 (red) respectively. Counterstaining (blue) was 
performed with Mayers hemalaun (left) or DAPI (right). Pictures of separated fluorescence 
channels are provided in the Appendix Figure 7-1. Arrows indicate CD1a+ cells that appear to 
lack CD207. Bars indicate a length of 20µm. 
 
CD1a / CD207 / M. hemalaun CD1a / CD207 / DAPI 
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Contrary to these observations performed in skin sections, multi-color-
immunofluorescence staining of epidermal sheets in combination with confocal 
microscopy revealed that all LCs co-expressed CD207 and CD1a [Figure 5-6]. 
Although some CD1a+ cells showed only a very little and weak CD207 expression, all 
of them were clearly positive for the marker. Confirmatory to single-color-staining 
CD1a expression was found all over the cell body including peripher dendrites, 
whereas CD207 was located close to the cell body. 
Figure 5-6: LC show full co-expression of CD1a and CD207 in epidermal sheets: Shown is multi-
step fluorescence double staining of CD1a+ (green) and CD207+ (red) in epidermal sheets detected by 
confocal microscopy. Bars indicate a length of 20µm. 
 
5.1.1.2 Dermal Dendritic Cells 
In this study anti-CD206 was used to detect dermal phagocytes referred to as 
DDCs. Staining against CD206 was located close to the cell body, but also dendritic 
processes were occasionally observed. CD206+ cells seemed to be distributed by 
random within the papillary and reticular layer of the dermis [Figure 5-7]. Partly clusters 
of CD206+ cells predominantly at hair follicles and vascular glands were detected. A 
median number of 353/mm2 (176-617 n=16) CD206+ cells was found in the upper 
dermis of healthy femoral skin. DDC numbers in healthy breast skin and foreskin 
were not significantly different [Figure 5-7]. A continuous decrease in cell density with 
increasing dermal depth as shown for MHC II+ cells was confirmed by CD206. 
CD1a / CD207 CD1a / CD207 
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     femoral skin        breast skin   foreskin 
  
 
 
 
 
 
 
 
 
Median Range N Median Range N Median Range N 
D 353/mm2 176-617 16 365/mm2 268-381 5 301/mm2 260-491 10 
Figure 5-7: CD206+ DDCs at different anatomical sites: A representative labelling of CD206 in 
sections of healthy human skin from different anatomical sites is shown. Original magnification 600x. 
Bars indicate a length of 50µm. Median number of CD206+ cells in the upper dermis (D), range and 
number of donors investigated are summarized in the table below for each anatomical site. 
 
5.1.1.3 T Cells 
In healthy epidermis CD3+ T cells were very infrequent. They were located 
within the stratum basale and stratum spinosum, had an approximate diameter of 
10 µm and appeared solitary and round. A median of 0.3/mm (0.0-1.8 n=8) CD3+ 
cells was found in the epidermis of femoral skin. CD3 cell numbers in healthy breast 
skin did not differ from this value but the larger epidermis of foreskin was inhabited by 
significantly more T cells (P<0.0001). No T cell clusters were detected within healthy 
epidermis. 
     femoral skin         breast skin   foreskin 
  
  
 
 
 
 
 
 
 
Median Range N Median Range N Median Range N 
E 0.3/mm 0.0-1.8 8 1.8/mm 0.0-8.5 5 8.9/mm 1.4-25.9 10 
D 111/mm2 46-211 8 158/mm2 56-270 5 195/mm2 84-411 10 
Cl 3.7/mm2 0.0-12.1 8 3.8/mm2 0.0-5.6 5 1.25/mm2 0-10.1 10 
Figure 5-8: CD3+ T cells at different anatomical sites: A representative labelling of CD3+ in 
sections of healthy human skin from different anatomical sites is shown. Original magnification 600x. 
Bars indicate a length of 50µm. Median numbers of epidermal (E) and upper dermal (D) CD3+ cells, 
range and number of donors investigated are summarized in the table below for each body site. 
Furthermore the median number, range and donors investigated of clusters (CL) consisting of >3 
interrelated CD3+ cells in the upper dermis are shown. 
 
Within the upper papillary dermis T cells were unevenly distributed. Some areas 
completely lacked CD3+ cells, whereas others were inhabited by considerable T cell 
numbers. They occurred as solitary, round cells as well as in focal clusters of various 
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interrelated cells [Figure 5-8]. A median number of 111/mm2 (46-211 n=8) CD3+ cells 
was detected in the upper dermis of femoral skin. In analogy to epidermal T cells 
equal numbers were observed in breast skin, whereas significant more CD3+ cells 
were found in the upper dermis of foreskin (P=0.034). In addition the number of 
clusters consisting of >3 interrelated CD3+ cells was investigated. A median of 3.7 
clusters/mm2 (0.0-12.1 n=8) was determined in healthy femoral skin. An equal 
number of clusters was found in breast and foreskin skin of healthy donors. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5-9: Clusters of CD206+ DDC and CD3+ T cells in the dermis: Multi-step enzymatic (left 
and middle) and fluorescence double staining of CD206 and CD3 in sectioned femoral skin. CD3 was 
detected by HRP (brown) or FITC (green) whereas CD206 was detected by AP or Cy3 (both red) 
respectively. Counterstaining (blue) was performed with Mayers hemalaun (left and middle). Original 
magnification 1000x. Bars indicate a length of 50 µm. 
 
The composition of the clusters was assessed by double-colour-staining and 
multi-colour-immunofluorescence. In these experiments CD3+ T cells could be 
observed in close apposition to CD206+ DDC [Figure 5-9]. 
 
CD206 / CD3    CD206 / CD3    CD206 / CD3  
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5.1.2 Isolation and Quantification of Emigrated Cells via Emigration-Assay 
5.1.2.1 The Emigration Assay – Migratory Cell Populations 
During the incubation of skin sheets floating dermal site down on medium, part 
of skin resident leukocytes spontaneously emigrate from the tissue into the culture 
medium. After 2 to 3 days they can be harvested as a single cell suspension from the 
supernatant. This method referred to as “emigration assay” was initially described by 
Richters et al.205 and was applied in the present study to investigate the nature of the 
emigrating cell types. 
Femoral skin biopsies of 1 cm2 size were incubated dermal site down on 
medium for three days at 37 °C. Thereafter emigrated cells were harvested. The 
vitality of emigrated cells was always above 90 % (91-96 % n=5) as tested by trypan 
blue exclusion. Applying immunofluorescence staining and flow cytometry 
(fluorescence associated cell sorting -FACS) emigrated cells were characterized in 
detail. All of the following FACS-analyses are representative results out of at least 
three experiments with different skin donors. 
To identify emigrated cells of hematopoietic origin, the surface expression of the 
pan-leukocyte marker CD45+ was applied [Figure 5-10]. 
Figure 5-10: The Emigration Assay 
 
A.) Simplified scheme of the emigration 
assay. During incubation skin 
resident APCs (LCs and DDCs) as 
well as T cells emigrate out of the 
skin into the medium. 
 
 
 
 
B.) FACS analysis of the emigration 
assay supernatant. Two populations 
of CD45+ cells with different 
granularity (SSC) were observed. 
Virtually all CD45+/SSChigh cells 
express MHC class II and resemble 
APCs. The majority of CD45+/SSClow 
cells express CD3. 
 
 
 
 
C.) In the emigration assay large cells 
with dendritic processes and smaller 
lymphocytes could be observed 
using cytospins and conventional 
light microscopy. 
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The population of emigrated CD45+ cells could be differentiated into two 
subpopulations regarding their granularity (side-scatter pattern). As indicated in Figure 
5-10 one subpopulation showed a high granularity (brown) whereas a second 
population (green) showed a low, lymphocyte like granularity. Virtually all of the cells 
with the high side scatter pattern (86% (71-95% n=3)) were MHC II+ and therefore 
resemble APCs. Contrary, only a few cells with low granularity (9% (5-14% n=3)) 
expressed MHC II. The majority of these cells expressed the T cell marker CD3 (65% 
(49-74% n=3)), a marker that is not expressed on APCs (4% (<1-6% n=3)).  
The process of emigration was strictly temperature depended, as no CD45+ 
cells were detected if the assay was performed at 4 °C. This clearly indicates that 
cells did not simply falling out of the tissue but rather actively leave it.  
Taken together emigrated CD45+ mainly cells belonged to two cell families: 
1.) APCs; characterized by high granularity and the expression of MHC II and 
2.) “lymphocytic like” cells; characterized by a typical low granularity – most of them 
are CD3+ T cells.  
This observation could be confirmed by light microscopy using cytospins of the 
emigration assay supernatant. APCs and lymphocytes could clearly be distinguished 
by their morphology. Large (Ø 15-25 µm) mononuclear APCs (LCs and DDCs) with a 
granular cytoplasm and dendritic processes could be distinguished from smaller 
sized (Ø 10 µm), round “lymphocyic like” cell bodies that exhibited a clear cytoplasm 
without granula [Figure 5-10].  
To prove the phagocytic function of MHC II+ cells FITC labelled bovine serum 
albumine (BSA-FITC) was applied to the epidermal site of the biopsy before 
performing the emigration assay. Only MHC II+ cells were found to incorporate BSA-
FITC whereas MHC II negative cells did not inhabit the capacity to take up BSA-FITC 
during the emigration assay [see Appendix Figure 7-2]. 
MHC II+ cells were analyzed using different surface markers in order to identify 
diverse APC subtypes [Figure 5-11]. The surface expression of a marker was 
demonstrated by FACS applying specific fluorescence labelled antibodies in 
comparison to an isotype matched antibody of irrelevant specificity. 
The LC marker CD207 was expressed by a minor population of emigrated 
MHC II+ cells (12 % (3-62 % n=12)), whereas a major proportion (65 % (8-81% 
n=12)) expressed the DDC marker CD206. Also a population of CD14+ cells was 
detected 35% (34-42% n=3) within MHC II+ cells, part of them were also positive for 
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CD206. CD207+ LC strongly co-expressed CD1a whereas CD206+ DDC only dimly 
expressed this marker [Table 5-1 and Figure 5-11]. 
 
Table 5-1: Proportion of emigrated 
LCs, DDCs and T cells: Median 
portion, range and donors investigated 
of CD207+ LCs, CD206+ DDCs and 
CD14+ Mφs within emigrated MHC 
class ΙΙ+ APCs are indicated. 
 
 
 
 
 
 
 
 
Figure 5-11: Phenotype of Emigrated MHC II+ APCs: 
Shown is the analysis of emigrated MHC II+ APCs. CD207+ 
LCs, CD206+ DDCs and CD14+ Mφs were detected. 
CD207+ LCs strongly co-expressed CD1a. CD206+ DDCs 
also dimly expressed CD1a and part of them co-
expressed CD14. 
 
Emigrated CD3+ cells were found to consist of a major fraction of CD4+/CD8- 
THelper cells (TH) 41% (28-78% n=7) and two minor populations of CD4-/CD8+ 
cytotoxic T cells (CTL) 17% (7-37% n=8) and  CD4-/CD8- T cells expressing the 
γδ T cell receptor type 21% (18-25% n=3) [Figure 5-12 and Table 5-2]. 
Table 5-2: Proportion of T cell subsets: Median 
portion, range and number of donors investigated of 
CD3+/CD4+ TH cells, CD3+/CD8+ CTL and of 
CD3+/γδ TCR+ cells that emigrated from femoral skin 
samples are summarized. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5-12: Emigrated T cell subsets: 
Shown is the phenotypical analysis of 
emigrated CD3+ lymphocytes. Three T cell 
subsets including CD4+ TH cells, CD8+ CTL 
and CD3+/CD45+ γδ TCR+ T cells were found. 
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LC 
MHC II+/ 
CD207+ 
12 % 3 -62 % 12 
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45 % 8-81 % 12 
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35 % 34-42 % 3 
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No CD19 or CD20 positive B cells were found within the emigrated lymphocyte 
like population. A minor population of CD56+ NK cells was observed in some 
experiments but this population was not further investigated in detail. 
Taken together all cell populations detected in situ by immuno-histochemestry 
were found to emigrate during the emigration assay. On one hand this includes 
MHC II+ APC consisting of CD207+ LC and CD206+ DDC. On the other hand also 
CD3+ T cells leave the tissue during the assay. The T cell population consisted of a 
majority of TH cells as well as of smaller but distinct populations of CTL and 
γδ T cells. 
 
5.1.2.2 Development of the Emigration Assay Towards a Diagnostic Tool  
The kinetic of APC emigration was determined during a period of 4 days. After 
each 24 h of incubation emigrated MHC II+ cells were harvested from the supernatant 
and enumerated [Figure 5-13]. Afterwards the biopsy was further incubated in fresh 
medium. Experiments were done in triplicates with femoral skin biopsies of three 
different healthy donors. Already after 24 h MHC II+ APC were detectable in the 
supernatant. Their total number peaked between day 2 and 3 and decreased 
thereafter. Regarding to these observations the incubation period was fixed to 3 days 
in order to maximize the yield of emigrating APCs. Relative and absolute numbers of 
MHC II+ cells in the emigration culture did not correlate (r=0,14; R2=0,02; n=16). Thus 
it was decided to use absolute cell numbers rather than the relative proportion of 
emigrated cells to analyze the emigration assay.  
To test the reproducibility of the emigration assay up to four skin samples per 
donor were cultured in parallel. Donations of femoral skin (n=3) and female breast 
skin (n=3) were used [Figure 5-13]. Total numbers of emigrated MHC II+ cells showed 
variances within a single donor. The number of emigrated APC also varied between 
skin donations from different anatomical sites. In analogy to immuno-histochemistry 
femoral skin, female breast skin and foreskin were compared regarding the number 
of emigrated APC [Table 5-3]. 
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Figure 5-13: Kinetic and Reproducibility of the Emigration Assay: A.) Shown are numbers of 
MHC II+ cells emigrated out of femoral skin over a period of four days. The supernatant of the 
emigration assay was harvested daily. Mean and SEM of duplicates are indicated. One representative 
experiment out of three is shown. B.) Shown are numbers of MHC II+ cells emigrated from femoral 
skin and female breast skin of different donors. For every donor the emigration assay was performed 
with a minimum of 4 samples in parallel. Numbers of emigrated MHC II+ cells are indicated as single 
values for every sample of each donor to demonstrate the reproducibility of the assay. Medians are 
indicated as bars. 
Of note, the dermal thickness of skin samples from different sources differed 
due to sample acquisition. Femoral split skin samples were constituted of a thin 
dermal layer. Contrary skin from breast reduction plastic or foreskin were obtained as 
full skin samples and consisted of a thicker, intact dermal layer.  
Table 5-3: Number of cells emigrated from skin samples of different anatomical sites: Median 
numbers, range and number of investigated donors of MHC II+ APCs, MHC II+/CD207+ LCs and 
MHC II+/CD206+ DDCs emigrated from femoral skin, breast skin or foreskin are summarized. 
** P>0.005 in comparison to femoral skin. 
skin source MHC II+ APC  
[x103/cm2] 
MHC II+/CD207+ LC 
[x103/cm2] 
MHC II+/CD206+ DDC 
[x103/cm2] 
    
femoral skin (n=10) 30.3 (11.1-105.9) 6.5 (1.1-19.1) 11.5 (2.7-78.7) 
breast skin (n=6) 8.0 (3.4-60.9)** 1.1 (0.5-2.6)** 4.5 (1.4-23.0)** 
foreskin (n=5) 10.1 (0.6-15.1)** 0.8 (0.2-2.2)** 1.4 (0.2-9.8)** 
 
Contrary to results from immuno-histochemistry most MHC II+ cells could be 
harvested from cultures of femoral skin. Out of breast skin (P=0.005) as well as out of 
foreskin (P=0.005) significantly less APCs emigrated despite their constitution of a 
thicker dermal compartment. Also more MHC II+/CD207+ LCs and MHC II+/CD206+ 
DDCs could be harvested from femoral skin compared to skin from the two other 
anatomical sites [Table 5-3].  
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The mixture of dermal and epidermal cell types as well as the low cell number 
that could be harvested from the emigration assay complicated a detailed analysis of 
emigrated cells’ phenotype and made a functional comparison of LCs and DDCs very 
difficult. To circumvent these issues a bacterial enzyme derived from Bacillus 
polymyxa named dispase I was used to separate the epidermis from the dermis. 
Thereby the emigration assays could be performed for each layer separately [Figure 
5-16]. 
 
5.1.2.3 Adaptation of the Emigration Assay by Prior Dispase Digestion 
As shown in Figure 5-14 dispase I detached the epidermis from the underlying 
basement membrane which remains on the dermis. The basement membrane was 
visualized by staining against collagen type IV a main component of this structure. As 
shown the detachment leads to a stringent separation of LCs from DDCs.  
  Collagen Type IV     CD1a        CD207         CD206 
 
Figure 5-14: Dispase detachment of epidermal and dermal skin layer: Shown are sections from 
healthy breast skin digested with dispase I prior to immunohistochemistry. Labelling against collagen 
type IV (basement membrane), CD1a (LCs); CD207 (LCs), and CD206 (DDCs) indicated a stringent 
separation of epidermal and dermal cell subsets by dispase I digestion. Original magnification 200x, 
bars indicate a length of 200µm. 
 
Enzymatic treatment could potentially alter the pattern of surface markers by 
digesting them from the surface or by activating cells to reorganize their expression. 
For that reason, the influence of dispase I treatment on the expression of several 
markers was investigated. Cells emigrated from whole skin were treated with 
dispase I and their expression of CD1a, CD3, CD206, CD207 and MHC II was 
compared to untreated cells of the same donor. Cells were treated with two different 
concentrations (1U/ml and 2U/ml) of dispase I for one hour at 37 °C. In both cases no 
differences in the number of positive cells or in the extent of marker expression (MFI) 
was observed for CD1a, CD3, CD206, CD207 and MHC II. A direct digestion of these 
markers by dispase I could therefore be excluded. Contrary to this, CD4 was 
completely digested from the surface of cells. Also the expression of CD8 was 
markedly decreased but remained detectable after dispase I treatment. However, 
CD3+ lymphocytes co-expressing CD4 or CD8 were detectable in the emigration 
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assay of dispase I treated skin samples. This was due to a reconstitution of these 
markers during the culture period and was proven using peripheral blood T cells. 
CD4 completely disappeared from the surface of peripheral blood T cells after 
dispase I treatment, whereas CD8 expression was considerably decreased. After 3 
days of culture both markers reconstituted to nearly the expression level found on 
untreated T cells [see Appendix Figure 7-3]. As during the emigration assay skin 
T cells were also cultured for a period of 3 days, they could reconstitute the 
expression of both markers. 
 Besides the stringent separation of epidermal and dermal derived cell subsets 
the yield of emigrated LCs could significantly (P<0.05) be increased by dispase I 
treatment. A prior treatment of the biopsy with dispase I, also if dermis and epidermis 
were not separated from each other, resulted in a higher number of emigrated LCs. 
[Figure 5-15A]. However, dispase I treatment did not significantly influence the yield of 
DDCs isolated by a dermal emigration assay. Contrary to LCs their number appeared 
slightly lower compared to untreated samples. Interestingly, the total number of 
MHC II+ APCs emigrated from separated epidermis and dermis outnumbered that of 
untreated or dispase I treated whole skin samples. 
Also after the separation of skin layers, emigration still remained an active 
process. As Figure 5-15B shows, MHC II+ APCs did not simply fall out of their epithelial 
layer but needed to emigrate out of it in an active, temperature dependent manner. At 
an incubation temperature of 4 °C MHC II+ cells were unable to leave whole skin 
biopsies as well as the epidermis and dermis separated by dispase I treatment. This 
experiment shows impressively that only active migrating cells will be isolated by the 
emigration assay. 
Furthermore the reproducibility of the emigration assay was increased by prior 
detachment of epidermis and dermis [Figure 5-15C]. Compared to whole skin 
incubations [Figure 5-13] only a slight interindividual fluctuation in the number of 
emigrated MHC II+ cells within epidermal or dermal samples of the same donor was 
observed. 
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Figure 5-15 A,B,C: The emigration assay after dispase I treatment: A.) Numbers of emigrated 
APCs (brown), LCs (blue) and DDCs (orange) were compared between untreated (plain) whole skin 
biopsies, dispase I treated (checkered) whole skin biopsies and separated epidermal and dermal parts 
of 10 different donors. Compared to whole skin, significantly more LCs emigrated from dispase I 
treated whole skin samples and also from separated epidermis. The number of emigrated DDCs was 
not altered significantly by dispase I treatment. *P>0.05 B.) Femoral skin samples of 3 different donors 
were separated into epidermis and dermis or incubated as whole skin. The emigration assay was 
performed at 37 °C and at 4 °C. Emigration of MHC II+ cells (HLA-DR) was found to be an active, 
temperature depended process that did not occur at 4 °C, neither from whole skin incubations, nor 
from epidermis or dermis alone. C.) Shown are numbers of MHC II+ cells (HLA-DR) emigrated from 
epidermis and dermis of femoral skin from three different donors. For every donor the emigration 
assay was performed with a minimum of 3 samples in parallel. Emigrated MHC II+ cell numbers are 
indicated as single values for every sample of each donor to indicate the reproducibility of the assay. 
 
 In summary the separation of skin layers by dispase I digestion prior to the 
emigration assay resulted in a higher yield of LCs as well as their complete 
separation from DDCs. These improvements facilitated a detailed phenotypic 
investigation of LCs and DDCs and enabled their functional comparison in vitro. 
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5.2 Results Part II- Comparing Characteristics of Emigrated Cell Subsets 
5.2.1 Phenotypical Comparison of Emigrated LCs and DDCs 
Virtually all MHC II+ APCs that emigrated from an epidermal culture co-
expressed CD207 and therefore were LCs. Contrary, dermal MHC II+ APCs were not 
homogeneous but consisted of a major subset of CD206+ DDCs [Figure 5-16]. A 
detailed phenotypic comparison of separately isolated LCs and DDCs is shown in 
Figure 5-17. 
 
 
Figure 5-16: Scheme of the improved emigration assay: After detachment of epidermis from 
dermis the emigration assay was performed for each layer separately. The approach is schematically 
depicted. MHC II+ APCs were found within the emigrated cell population of both, epidermis and dermis 
by FACS analysis. Almost all epidermal APCs coexpressed CD207, whereas CD206 was expressed 
by a majority of dermal APCs. 
 
Compared to DDCs, LCs exhibited a higher granularity and expressed a 
significant (P<0.05) higher density of surface MHC II (HLA-DR). LCs did not express 
CD206 whereas DDCs lacked CD207 expression. Both, LCs and DDCs expressed 
CD1a but to different extents. LCs are strongly positive for CD1a, whereas DDCs 
show a significant (P<0.05) weaker expression of this marker. CD1b was weakly 
expressed on both cell types. A weak expression of the T cell co-receptor CD4 was 
detected on LCs as well as on DDCs, whereas the CD8 T cell co-receptor was 
completely absent on both. The lipopolysaccharide (LPS) receptor, a typical Mφ 
marker, was absent on LCs but also stained a subpopulation of CD206+ DDCs. 
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Figure 5-17: Phenotypic comparison of LCs and DDCs: Shown is the phenotypic comparison of 
separately isolated MHC II+/CD207+ LCs (blue) and MHC II+/CD206+ DDCs (orange). Cells were 
compared regarding their surface expression of CD1a, CD1b, CD4, CD8, CD14, E-cadherin and a 
Lineage cocktail (CD3, CD14, CD16, CD19, CD20 and CD56). An isotype matched antibody with 
irrelevant specificity served as control (grey). 
 
The adhesion molecule E-cadherin that is involved in cell trafficking of 
leukocytes was dimly detected on LCs and DDCs. Factor XIIIa, a plasma beta-
globulin referred to as dermal dendrocyte marker 66 was only expressed by DDCs but 
not by LCs. Due to the lack of a specific DC marker in various organs for example in 
the peripheral blood, antibody cocktails were designed consisting of markers for all 
non-DC cell types expected. The antibody Lin1 (lineage cocktail 1) from BD 
bioscience includes CD3, CD14, CD16, CD19, CD20 and CD56 and is used to 
identify DC in the peripheral blood. Also LCs did not stain positive for Lin1, indicating 
that none of the marker is expressed by these cells. Contrary, DDC were stained by 
Lin 1. 
 
5.2.2 Comparison of Emigrated Epidermal and Dermal T Cell Subsets 
Also the distribution of different T cell subsets within each skin layer was 
investigated. As shown in Table 5-4 the incidence of different T cell subsets varied 
considerably between epidermis and dermis. The epidermis was populated by a 
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majority of γδ T cells as 48% (9-73% n=7) of emigrated epidermal CD3+ cells were 
found to belong to this cell type. Epidermal CD4+/CD8- T helper cells (TH) [20% (5-
40% n=13)] and CD4-/CD8+ cytotoxic T cells (CTL) [21% (5-43% n=13)] were equally 
frequent. 
Table 5-4: Proportion of different T cell subsets emigrated from epidermis and dermis: Median 
portion, range and number of donors investigated of CD3+/CD4+ TH cells, CD3+/CD8+ CTL and of 
CD3+/γδ TCR+ cells that emigrated from either epidermis or dermis of femoral skin samples are 
summarized. 
    T cell subsets from Epidermis            T cell subsets from Dermis 
 
 
 
 
 
 
 
 
 
 
 
 
From the dermis a major fraction of TH cells (33 % (20-68 % n=11)) and two 
minor fractions of CTL 18 % (12-57 % n=11) and γδ T cells (20 % (3-44 % n=5)) were 
found to emigrate. Thus, the incidence of T cell subsets emigrating from dermis was 
similar to the T cell pattern initially observed to emigrate from whole skin samples. 
Compared to epidermis approximately six times more CD3+ T cells emigrated from 
dermis. 
 
5.2.3 Functional Aspects of Emigrated Skin DC Subsets 
DCs inhabit unique features to fulfil their role as immunologic sentinels. To show 
that the observed cell populations inhabit all relevant DC functions and therefore 
resemble professional APCs, these functions were tested in several assays in vitro. 
 
5.2.3.1 Antigen Uptake 
A first and crucial step to fulfil the role of an APC is the uptake of exogenous 
Ags. Every DC type has a specific repertoire of endocytotic receptors that support the 
internalization of microbial products and their direction to Ag-processing 
compartments.11-13 Per definition LCs express CD207, a marker that was not 
expressed from DDCs which instead express CD206. Furthermore DDCs were found 
to express the complement receptors CD11a and CD11c, whereas LCs did not. The 
Cell Type Median Range N 
TH cell 
CD3+/ 
CD4+ 
20 % 25-40 % 11 
CTL 
CD3+/ 
CD8+ 
21 % 5-43 % 8 
γδ T cell 
CD3+/ 
γδ TCR+ 
48 % 9-73 % 7 
Cell Type Median Range N 
TH cell 
CD3+/ 
CD4+ 
33 % 20-68 % 11 
CTL 
CD3+/ 
CD8+ 
18 % 12-57 % 11 
γδ T cell 
CD3+/ 
γδ TCR+ 
20 % 3-44 % 5 
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transferrin receptor, involved in the uptake of iron was expressed by LCs, whereas 
only part of DDCs was positive for this marker [Figure 5-18]. 
 
Figure 5-18: Expression of markers involved in Ag uptake and BSA-FITC uptake capacity of 
LCs and DDCs: A.) MHC II+/CD207+ LCs (blue) and MHC II+/CD206+ DDCs (orange) isolated by the 
emigration assay were tested on their surface expression of CD11a, CD11c and CD71. An isotype 
matched antibody with irrelevant specificity served as control (grey). B.) Comparison of LCs, DDCs 
and skin derived lymphocytes (grey) capacity to take up BSA-FITC during a 10 or 60 min incubation 
time. Results represent the mean of at least 5 experiments ± standard deviation (SD) of the BSA-
Uptake-Ratio. * P<0.05, ** P<0.005 
 
The capacity of protein Ag (pAg) uptake was measured by the ingestion of FITC 
labelled bovine serum albumin (BSA-FITC). The assay provides the possibility to 
quantify the amount of ingested pAg.  
Emigrated LCs, DDCs and dermal lymphocytes as a control population were 
tested in vitro for their ability to take up BSA-FITC. A BSA-Uptake-Ratio was 
determined dividing the geometric mean fluorescence intensity (proportional to the 
amount of ingested BSA-FITC) by that of a negative control (see section 4.4.2.7). 
The uptake of BSA-FITC was evaluated for two incubation times, i.e., 10 and 60 min.  
A clear detectable pAg uptake (BSA-Uptake-Ratio >1) could be observed for 
both, LCs and DDCs. In contrast, lymphocytes as control population did never took 
up BSA-FITC to levels that were observed for LCs or DDCs [Figure 5-18]. After 10 min 
LCs showed a slightly enhanced pAg uptake capacity compared to DDCs, but the 
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CCR7 
difference was not significant. After 60 min significant (P<0.005) more BSA-FITC was 
taken up from LCs compared to DDCs.  
 
5.2.3.2 Chemotactic Transmigration Toward MIP-3β 
 The emigration of DCs out of their tissue to the lymph as well as the homing to 
the T cell areas of the draining lymph nodes are necessary steps to induce an 
immune response.7 The emigration assay itself focused on cells that are able to 
make the first step out of the tissue. The homing to the lymph node is regulated by a 
chemotactic migration toward low-molecular-weight chemokins or cytokines like 
MIP-3β (ELC) which is expressed especially in lymphoid tissues.206 MIP-3β is a 
chemoattractant for DCs207 and Mφ progenitor cells208 and acts through 
CC chemokine receptor 7 (CCR7).206 The surface expression of CCR7 on DCs is a 
requirement to respond to MIP3β and was therefore investigated on LCs and DDCs. 
 
   
 
 
  
 
Figure 5-19: Expression of the chemokine receptor CCR7 on 
LC and DDC: MHC II+/CD207+ LCs (blue) and MHC II+/ 
CD206+ DDCs (orange) isolated by the emigration assay were 
gated and tested on their expression of the chemokine receptor 
CCR7 by FACS. An isotype matched antibody with irrelevant 
specificity served as control (grey). 
 
 
 As shown in Figure 5-19 CCR7 was clearly detectable on the surfaces of both, 
LCs and DDCs. Both cell types are therefore potentially able to respond to MIP-
3β after their isolation by the emigration assay. Their capacity to migrate towards a 
MIP-3β gradient was tested in an in vitro trans-well assay. The quantity of trans-
migrated LCs or DDCs was determined as percentage of the respective cell number 
added to the assay. For every experiment the spontaneous trans-migration of cells 
was measured in control samples that did not contain the chemoattractant MIP-3β. 
This spontaneous trans-migration was subtracted from the observed trans-migration 
in response to MIP-3β in order to obtain the MIP-3β induced trans-migratory capacity 
(∆ Mi). 
Shown in Table 5-5 is the trans-migration of LCs and DDCs for three different 
donors. Experiments for every donor were performed in triplicates. In the absence of 
Mip-3β only very few (<2%) LCs and DDCs respectively were detected in the lower 
emigrated LC  
emigrated dermal DC 
Isotype control 
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trans-well chamber. The diameter of the pores in the membrane (Ø 8 µm) was well 
below the diameter of the trans-migrating cells (Ø 20-26 µm, determined by 
microscopy of cyto-spins (see section 5.1.2.1). Therefore a passive dropping of LCs 
or DDCs through the membrane can be excluded. 
Table 5-5: MIP-3β induced trans-migratory capacity of LCs and DDCs: Results are expressed as 
percentage of transmigrated cells from cell input. The spontaneous trans-migration [(-)MIP-3β], the 
trans-migration in response to MIP-3β [(+)MIP-3β] and the trans-migratory capacity (∆Mi) calculated 
from both values for LCs and DDCs of three different donors are indicated. In the last row mean, 
standard deviation and number of donors of a group are indicated. ∆Mi of LCs and DDCs differed 
significantly (P=0.004) as calculated by paired T test. 
 
 Langerhans cells Dermal dendritic cells 
 (-) MIP-
3β  
[%] 
(+) MIP-
3β  
[%] 
∆ Mi   
[%] 
(-) MIP-
3β  
[%] 
(+) MIP-
3β  
[%] 
∆ Mi   
[%] 
Donor 1 0.8 19.1 18.3 1.2 42.8 41.6 
Donor 2 0.5 21.7 21.2 0.2 29.0 28.8 
Donor 3 1.0 20.8 19.8 1.5 38.9 37.4 
       
∆M Mean 
±SD 
19,8 ± 1.5 (n=3) 35.9 ± 6.6 (n=3) [P=0.04] 
 
 In response to the chemo-attractant a considerable proportion of LCs or DDCs 
initially added to the upper chamber trans-migrated and could be detected in the 
lower chamber. MIP-3β induced the trans-migration of 19,8 % ± 1.5 % (n=3) LCs and 
of 35.9 % ± 6.6 % (n=3) DDCs. The proportion of trans-migrated DDC was higher 
than that of the respective LC in all tested donors. This difference in the 
responsiveness toward MIP-3β was statistically significant (P=0.04). 
 
5.2.3.3 Stimulation of Resting T cells 
A further major function of DCs is the stimulatory capacity of resting T cells. This 
function was tested in vitro by an allogeneic mixed leukocyte reaction (allo-MLR). The 
allo-MLR was performed with three increasing DC numbers resulting in 
stimulator:responder ratios (S:R ratio) from 1:10 to 1:1000.  
Side by side comparison of emigrated LCs and dermal APCs regarding their 
capacity to stimulate the MLR was performed with skin of 5 different skin donors. For 
practical reasons the whole population of emigrated dermal APCs was used for the 
MLR. As previously shown CD206+ DDCs constituted only part of the MHC II+ cells 
that are potentially able to stimulate the MLR. Therefore the dermal emigrated cells 
were referred to as dermal APCs rather than DDCs in this section. 
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Table 5-6: Stimulatory capacity: Shown is the stimulatory 
capacity of LCs and DDCs isolated from 5 different skin 
donors toward allogeneic PBMC from one single donor. 
Results are indicated as averaged counts/min from 
triplicates in a stimmulator:responder (S:R) ratio of 1:10. A 
factor DDC/LC was calculated and is also indicated. 
 
 
 
 
 
 
 
 
 
 
Figure 5-20: Stimulatory capacity: 
Comparison of the stimulatory capacity of 
emigrated LCs and DDCs. One out of three 
representative experiment is shown. 
 
A representative experiment is shown in  
Figure 5-20. Both, emigrated LCs and dermal APCs stimulated the proliferation of 
resting allogeneic lymphocytes. The stimulatory capacity of emigrated dermal APCs 
exceeded that of LC in all experiments. At the S:R ratio of 1:10 the stimulatory 
capacity of dermal APCs was in median 2.8 (1.3-65.6 n=5) [Figure 5-20] times higher 
than that of LCs. 
 
5.2.3.4 Ex vivo Maturation of Emigrated Skin DCs 
The ability to change their functional and phenotypical characteristics in 
response to adequate stimuli is a fundamental characteristic of all DCs. The 
development from an relatively immobile sentinel with low stimulatory capacity to an 
Ag presenting, highly stimulatory and mobile cell emigrating to the lymph node is 
referred to as maturation. The process of maturation can be induced by various 
activation signals like microbial products or inflammatory cytokines.7 In response to 
these danger signals DCs enhance the surface expression of co-stimulatory 
molecules, slow down the Ag uptake, and emigrate to the lymphatic vessels. 
The surface expression of co-stimulatory molecules and activation markers, i.e., 
MHC II (HLA-DR), CD40, CD80, CD83 and CD86 was measured on emigrated LCs 
and DDCs. To explore if the emigrated cells already had obtained a fully activated 
phenotype or if the expression of the markers could be further increased a maturation 
cocktail was added to the emigration culture. Surface expression of MHC II (HLA-
Donor S:R Ratio 1:10  
 LC DDC Factor 
1 492 32292 65,6 
2 1140 2215 1,9 
3 1118 3086 2,8 
4 1216 4809 4,0 
5 8995 11324 1,3 
    
Median 1140 4809 2,8 
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DR), CD40, CD80, CD83 and CD86 was compared between cells of the same donor 
either treated or untreated with maturation cocktail. Experiments were performed with 
skin samples from three different donors and a representative result is shown in 
Figure 5-21. Interestingly a MHC IIhigh and a MHC IIlow subset of DDCs could be 
identified, whereas LCs showed a relative homogeneous expression of the marker. 
As already described MHC II was used as a prerequisite for the identification of LCs 
and DDCs. However, this marker was found to be up-regulated on LCs but not on 
DDCs as a result of treatment with the maturation cocktail.  
CD40, a member of the tumor necrosis factor receptor super family, is able to 
mediate activation by binding to its ligand (CD40-L) expressed on primed T cells.209 
Both, LCs and DDCs showed no expression of CD40 after their isolation by the 
emigration assay. However, treatment with the maturation cocktail profoundly 
induced CD40 expression on the surface of both cell types. 
Figure 5-21: Change in the 
expression of different surface 
markers after treatment with 
maturation cocktail ex vivo: 
Shown are changes in surface 
expression of MHC II (HLA-DR), 
CD40 , CD80, CD83 and CD86 
due to treatment with a 
maturation cocktail consisting of 
IL-1β, IL-6, TNFα and PGE2. 
Both, LCs (left column) and 
DDCs (right column) were treated 
with the maturation cocktail 
during the last two days of the 
emigration assay and compared 
to untreated cells of the same 
donor. One representative 
experiment out of three is shown. 
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CD80 expression was only found on a distinct population of untreated LCs but 
on all DDCs. Treatment with the maturation cocktail considerably increased the 
number of CD80+ LCs and only a minor population of LCs remained negative for the 
marker after the treatment. One part of DDCs the treatment enhanced the expression 
level of CD80. Therefore both cell types altered their CD80 expression in response to 
the maturation cocktail. 
CD83 was just weakly detectable on a small population of LCs. After treatment 
the number of CD83+ LCs slightly increased, but the expression level of the marker 
remained low. DDCs never expressed CD83, whether they were treated with 
cytokines or not. Therefore only part of LCs but not DDCs altered CD83 expression in 
response to the maturation cocktail. 
A minor part of LCs expressed low levels of CD86 after emigration. However, 
after cytokine treatment all LC showed CD86 expression and the majority of them 
showed a CD86high phenotype that was not detected before the cytokine treatment. 
Only a minor part of emigrated DDCs expressed low levels of CD86. Treatment with 
cytokines did not increase the portion of these positive DDCs nor did it increase the 
level of CD86 expression to a significant extent. Therefore the expression of CD86 
was not altered by the cytokine treatment, neither on DDCs. 
 In summary untreated LCs and DDCs exhibited a heterogeneous and semi-
mature phenotype after their emigration from the skin. Part of LCs expressed low 
levels of CD86 and CD80, whereas all DDCs expressed low levels of CD80 and 
portion of them was also positive for CD86. However, CD40 was complete absent 
from both LC and DDC after their emigration. The expression of CD40 as well as an 
enhanced expression of CD80 could be induced in both cell types by treatment with a 
cytokine cocktail. Furthermore, this treatment resulted in de novo expression of CD83 
at the surface of part of LC, whereas CD83 expression could not be induced on the 
surface of DDCs. In summary these experiments show that, in terms of their 
phenotype, emigrated LCs and DDCs are capable for a further maturation by 
cytokine treatment ex vivo. 
 Maturation predominantly affects the functionality of DCs. Therefore, cytokine 
cocktail treated and untreated LCs and DDCs were compared in terms of Ag uptake, 
migratory and stimulatory capacity. In comparison to untreated LCs the BSA-Uptake-
Ratio of matured LCs was significantly diminished after 10 min (P<0.05) of 
incubation. Contrary, matured DDCs were not diminished in their Ag uptake capacity 
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when treated with maturation cocktail [Figure 5-20A]. In all performed experiments 
BSA-FITC uptake minimally differed between treated and untreated DDCs and 
overall no significant influence of ex vivo maturation on DDCs Ag uptake was found. 
As shown in Figure 5-22B ex vivo maturation enhanced the trans-migratory 
capacity of LCs. Maturation significantly increased, i.e., doubled the proportion of LCs 
that trans-migrated in response to MIP-3β compared to untreated LCs (P<0.05). 
Contrary, ex vivo maturation of DDCs did not result in an altered trans-migratory 
capacity. The stimulatory capacity of LCs was clearly increased by the ex vivo 
maturation of these cells. As shown in Figure 5-22C maturation enabled LCs to 
stimulate the MLR in the quality of untreated DDCs. Contrary, ex vivo maturation did 
not further boost the stimulatory capacity of DDCs.  
 
Figure 5-22: Functional comparison 
of untreated and ex vivo matured 
LCs and DDCs 
 
A: Comparison of the capacity to take 
up BSA-FITC of untreated and ex vivo 
matured LCs or DDCs respectively. 
Samples of three different skin donors 
are indicated as paired samples.  
* P<0.05 
 
B: Comparison of the trans-migratory 
capacity of un-treated and ex vivo 
matured LCs or DDCs respectively. 
Samples of different skin donors are 
indicated as paired samples.  
* P<0.05 
 
C: Comparison of the stimulatory 
capacity of untreated and ex vivo 
matured LCs or DDCs respectively. 
One out of three representative 
experiment is shown. 
 
 
 
 
 
Taken together LCs can be matured ex vivo by cytokines. This maturation could 
be shown in terms of phenotypic activation and functional changes. Although DDCs 
showed a phenotypic activation in terms of CD40 and CD80 expression in response 
to the maturation cocktail, these cells did not alter their functional capacity in any 
significant way. 
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5.3 Results Part III - Implementation of Techniques in Clinical Trials 
To obtain skin samples from patients the upper skin layers were shaved off with 
a scalpel and the resulting biopsies closest resemble specimens of femoral split skin. 
If possible biopsies were obtained from the thigh or from anatomical sites that where 
inhabited by a comparable LC number.210 Due to these facts, only femoral skin 
samples were used as healthy controls in this part of the work. 
 
5.3.1 Skin Resident DC and T cells in Patients with Cutaneous GvHD 
This study focused on DC subsets and T cells within the skin of patients at the 
onset of aGvHD as these cells represent the most important cellular components in 
induction and progression of this serious complication following aHSCT. 
Simultaneous obtained, paired biopsies from GvHD affected and clinically unaffected 
skin were compared to each other and to healthy controls. Immuno-histochemistry 
and emigration assay were performed in parallel to compare DC and T cell patterns 
between the different sources. Biopsies from patients were obtained when first 
clinical signs of aGvHD appeared and before systemic treatment was initiated.  
 
5.3.1.1 The Epidermal Cell Compartment 
Within the skin of patients with aGvHD pathological changes including 
vacuolisation especially along the dermo-epidermal junction were noted by immuno-
histochemistrie. Furthermore, signs of spongiosis occurred. Because of these 
changes it was sometimes difficult to clearly identify the border between epidermis 
and dermis.  
 healthy control uninvolved skin lesional skin 
CD207 
 
 
  
 
 
 
Figure 5-23: Different distribution of LCs in Lesional Skin of aGvHD Patients: Shown is the 
staining of LC by CD207 in healthy femoral skin and in uninvolved and lesional aGvHD skin from a 
representative patient. Counterstaining was performed with Mayer’s hemalaun. Bars indicate a length 
of 50 µm (magnification 600x). Median number of epidermal CD207+ cells, range and number of 
individuals investigated are summarized in the table below. 
 
Median Range N Median Range N Median Range N 
CD207/mm 22 11-35 19 14 0-35 9 13 4-50 9 
Results Part III - Implementation of Techniques in Clinical Trials 
62 
 The epidermal alterations were detectable in both, lesional and clinically 
unaffected areas, but were more pronounced in lesional skin. Although the 
morphology of LCs in patients was undistinguishable from healthy controls their 
distribution within lesional epidermis appeared different. Compared to unaffected skin 
or control skin, in lesional skin CD207+ cells partially loosened their strict 
arrangement like beads on a string along the suprabasal layer and appeared 
randomly distributed [Figure 5-23]. 
 
Figure 5-24: More LCs and in some patients more epidermal T cells reside in lesional skin of 
patients with GvHD: Shown are numbers of CD207 + LCs (blue) and CD3+ epidermal T cells (green) 
detected in situ in healthy femoral skin (framed in grey) in uninvolved (framed in dark blue) or lesional 
skin (framed in red) of patients with aGvHD (paired samples). If groups differed significantly P values 
are indicated. 
 
Compared to 22 LCs/mm (range 11-35; n=19) in healthy femoral skin, patients’ 
uninvolved [14 (0-35; n=9) (P=0.01)] and lesional skin [13 (4-50; n=9) (P=n.s.)] was 
inhabited by a lower LC number. Paired comparison of the respective patient 
samples revealed that significantly more LCs reside in lesional skin than in 
uninvolved skin areas of each individual patient (P=0.008) [Figure 5-23]. As LC 
numbers varied considerably within the group of patients, the respective medians did 
not display this finding appropriately. But the presentation of results as paired 
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samples as shown in [Figure 5-24] indicating a clear trend toward higher LC numbers 
in lesional skin. 
 In addition the emigration assay was performed with samples of 19 patients and 
with samples of 18 healthy donors. 15.2x103/cm2 (2.1-58.5x103; n=18) MHC 
II+/CD207+ LCs emigrated out of the epidermis of healthy controls. From patients 
uninvolved skin significantly less LCs emigrated [1.7x103 (0.0-46.9x103; n=19) 
(P=0.0008)], whereas numbers of CD207+ cells emigrated from lesional skin [6.4x103 
(0.8-81.5x103; n=19) (P=n.s.)] were not statistically different from controls. 
 Paired comparison of emigrated CD207+ cells within patients’ uninvolved and 
lesional skin revealed that significantly more LCs emigrated from affected than from 
uninvolved skin (P=0.0008) [Figure 5-25A]. In general LC staining with CD1a 
confirmed the data obtained with CD207 [see Appendix Figure 7-4 and Figure 7-5]. 
 
Figure 5-25: More LCs and epidermal T cells emigrate from lesional than from uninvolved skin: 
Shown are numbers of emigrated CD207+/MHC II+ LC (blue symbols), and CD3+ T cells (green 
symbols) of healthy control donors (framed in grey) or as paired samples from uninvolved (framed in 
dark blue) or lesional skin (framed in red) of patients with aGvHD. P values are indicated. 
 
5.3.1.1.1 The Chimerism of LCs 
To investigate if LCs are of donor or recipients origin, the respective cell 
populations were sorted for donor chimerism analysis [Table 5-7]. Sorting was 
performed applying flow-cytometry in combination with the FACSVantage based cell 
Results Part III - Implementation of Techniques in Clinical Trials 
64 
sorting and resulted in a sorted cell purity of >95%. The DNA of sorted cell 
populations was extracted and used as template in a nested RT-PCR reaction to 
amplify informative short tandem repeat sequences (STR). The percentage of donor 
cells within the sorted population, referred to as donor chimerism, was calculated as 
described earlier.204  
 In patients with aGvHD a commonly mixed donor LC chimerism, that often 
differed between lesional and uninvolved sites was found. In two patients a higher 
number of emigrated LCs was clearly associated with an increased presence of 
donor cells. In two patients donor and recipient LCs were nearly equal frequent in 
lesional and uninvolved skin and in three patients a higher proportion of host LCs 
emigrated out of the skin affected by GvHD. 
Table 5-7: Donor Chimerism of emigrated LCs in patients with aGvHD: Shown is the relative 
donor cell proportion of LCs emigrated from lesional or uninvolved skin of patients with aGvHD. 
Patient number (Pat.No.), time point of biopsy post transplantation as well as degree of cutaneous 
aGvHD are indicated. If patients showed a higher donor cell proportion in lesional skin compared to 
uninvolved skin data is highlighted in light-grey. If patients showed an expanded donor cell proportion 
in uninvolved skin compared to lesional skin, data is highlighted in dark-grey. Chimerism analysis in 
patients No.: 2,11,13,14,16,18-21 failed to give any results. 
aGvHD Donor-Chimerism [%] 
of emigrated Langerhans Cells Pat.No: 
day degree lesional uninvolved 
1 65 1 21% n.a. 
3 15 2 59% n.a. 
4 16 3 71%   0% 
5 12 2   4% n.a. 
6 12 3 87% n.a. 
7 34 1 82% 69% 
8 17 3 19% 22% 
9 34 3 12% 32% 
10 56 3 95% 91% 
12 76 2 55% 69% 
15 19 3   3% 38% 
17 14 3 79% n.a. 
 
5.3.1.1.2 Epidermal T cells 
 Also the number of epidermal lymphocytes was observed by CD3 labelling 
[Figure 5-26]. Compared to the 0.3 (0.0-1.8; n=8) CD3+ cells/mm detected in healthy 
femoral skin patients’ epidermal T cell numbers were in the same range in lesional 
(0.8 (0.0-9.9; n=8) (P=n.s.)) and also in uninvolved epidermis [0.0 (0.0-5.0; n=8) 
(P=n.s.)]. 
By immuno-histochemistry 4 out of 8 patients showed a pronounced increase of 
epidermal T cell numbers in lesional compared to uninvolved skin. The 4 remaining 
patients did not show any epidermal T cells, neither in uninvolved nor in lesional skin. 
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In summary the number of epidermal T cells in lesional and uninvolved epidermis in 
situ did not differ significantly [Figure 5-24].  
As already shown CD3+ lymphocytes also actively leave the tissue during the 
emigration assay. Compared to 6.3x103/cm2 (1.2-23.1; n=9) CD3+ lymphocytes 
emigrated from healthy femoral epidermis, significantly reduced T cell numbers 
emigrated from patients’ uninvolved epidermis 2.0x103/cm2 (0.0-3.7; n=8 P=0.006), 
whereas equal T cell numbers emigrated from lesional epidermis 5.8x103/cm2 (0.0-
164.5; n=8). Paired comparison of emigrated T cell numbers in patients’ uninvolved 
and lesional skin revealed that significantly more CD3+ cells emigrated from lesional 
than from uninvolved epidermis (P=0.02) [Figure 5-25]. 
 healthy control uninvolved skin lesional skin 
CD3 
   
 
 
Figure 5-26: More dermal T cells as well as T cell clusters in lesional skin of aGvHD patients: 
CD3+ T cells in representative sections of a healthy donor and of uninvolved and lesional aGvHD skin 
of a representative patient. Counterstaining was performed with Mayer’s hemalaun. Bars indicate a 
length of 50µm (magnification 600x). Median number of epidermal (E), dermal (D) CD3+ cells, range 
and number of donors investigated are summarized in the table below. Furthermore the median 
number, range and N of clusters consisting of >3 interrelated CD3+ cells in the upper dermis is shown. 
 
5.3.1.2 The Dermal Cell Compartment  
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Figure 5-27:  CD206+ DDC in controls, uninvolved and lesional aGvHD skin: Shown is the 
immunohistochemical staining of CD206+ in a healthy donor and in uninvolved and lesional aGvHD 
skin of a representative patient. Counterstaining was performed with Mayer’s hemalaun. Bars indicate 
a length of 50µm (magnification 600x). Median numbers of dermal CD206+ DDCs, range and number 
of donors investigated are summarized in the table below. 
 
Median Range N Median Range N Median Range N 
E 0.3/mm 0.0-1.8 8 0.0/mm 0.0-5.0 8 0.8/mm 0.0-9.9 8 
D 111/mm2 46-211 8 93/mm2 0-264 8 250/mm2 78-637 8 
Cl 3.7/mm2 0.0-12.1 8 1.1/mm2 0.0-8.1 8 6.7/mm2 0.0-22.9 8 
Median Range N Median Range N Median Range N 
D 352/mm2 176-617 16 382/mm2 197-573 8 475/mm2 287-612 8 
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No remarkable differences in the morphologic appearance of DDCs was 
observed between healthy controls and patients. However in patients a larger 
proportion of CD206+ cells was located at the dermo-epidermal junction zone and 
some DDCs were detected within the epidermis of patients’ uninvolved and lesional 
skin [Figure 5-27]. 
Compared to the 352 (176-617; n=16) CD206+ DDCs/mm2 found within the 
upper dermis of healthy femoral skin, patients’ DDC numbers were in the same range 
in uninvolved [382 (197-573; n=8)] and higher in lesional skin [475 (287-612; n=8) 
P=0.09]. All but one patient showed substantially higher numbers of DDCs in lesional 
aGvHD skin compared to uninvolved skin. DDC numbers of lesional and uninvolved 
skin, however did not differ significantly (P=0.2) [Figure 5-28]. 
 
Figure 5-28: In situ number of DDC and dermal T cells in patients and controls: Shown are 
numbers of CD206 + DDCs (orange), the number of CD3+ dermal T cells (light green) as well as the 
number of dermal T cell clusters detected in situ in healthy femoral skin (grey border) in uninvolved 
(blue border) or lesional skin (red border) of patients with aGvHD (paired samples). P values are 
indicated. 
 
As already shown the absolute number of dermal cells that emigrate out of a 
biopsy may depend on the thickness of the dermis. As dermal thickness differed 
considerably between controls’ split skin samples and patients’ shave biopsies a 
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quantitative comparison of dermal cell numbers between controls and patients is of 
only limited validity. 
Double biopsies from patients were obtained simultaneously by the same 
physician and, their dermal thickness was alike, so the patients’ two samples could 
reasonably be compared. Significantly more MHC II+/CD206+ DDCs emigrated from 
lesional (5.2x103/cm2 (0.2-127.9x103; n=19 (P=0.0024)) compared to uninvolved skin 
(2.5x103/cm2 (0.0-21.4x103; n=19) [Figure 5-29]. 
 
Figure 5-29: More DDCs and dermal T cells emigrate from lesional than from uninvolved skin: 
Shown are emigrated numbers of CD206+/MHC II+ DDCs (orange) and CD3+ T cells (green) of healthy 
control donors (framed in grey) or as paired samples from uninvolved (framed in dark blue) or lesional 
skin (framed in red) of patients with aGvHD. P values are indicated. 
 
5.3.1.3 The Chimerism of DDCs 
Also DDCs were sorted to analyze if they were of donor or of recipients origin 
[Table 5-8]. Most patients showed a nearly complete donor cell chimerism within the 
DDC compartment, in lesional as well as in uninvolved skin. In 3 patients an 
increased number of DDCs that have been emigrated out of lesional skin was 
associated with a definitely higher donor cell proportion at this site. Only in one 
patient lesional skin contained slightly more recipient DDCs than uninvolved skin 
does. 
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Table 5-8: Donor Chimerism of emigrated DDCs in patients with aGvHD: Shown is the relative 
donor cell proportion of DDC emigrated from lesional and uninvolved skin of patients with aGvHD. 
Patient number (Pat.No.), onset and time point of biopsy as well as degree of cutaneous aGvHD are 
indicated. If patients showed a higher donor cell proportion in lesional skin compared to uninvolved 
skin data is highlighted in light-grey. If patients showed an expanded donor cell proportion in 
uninvolved skin compared to lesional skin data is highlighted in dark-grey. Chimerism analysis in 
patients No.: 2,11,13,14,16,18-21 failed to give any results. 
aGvHD Donor-Chimerism [%] 
of emigrated Dermal DCs Pat.No: 
day degree lesional uninvolved 
1 65 1 74% 38% 
3 15 2 66% n.a. 
4 16 3 91%   7% 
5 12 2 88% 91% 
6 12 3 97% 97% 
7 34 1 99% 94% 
8 17 3 62% 48% 
9 34 3 16% 23% 
10 56 3 91% 93% 
12 76 2 70% 70% 
15 19 3   4% n.a. 
17 14 3 89% n.a. 
 
5.3.1.4 Dermal T Cells 
As already shown dermal T cells were unevenly distributed in healthy skin. They 
occurred as single cells as well as in focal clusters of various interrelated cells. This 
clustering of dermal T cells was occasionally observed in healthy femoral skin (3.7 
clusters/mm2 (0.0-12.1; n=8)) and in uninvolved skin of patients (1.1 clusters/mm2 
(0.0-8.1; n=8)) but was common in lesional skin of patients (6.7 clusters/mm2 (0.0-
22.9; n=8)) [Figure 5-26]. 
Compared to 111/mm2 (46-211; n=8) CD3+ T cells located in the upper papillary 
dermis of healthy femoral skin T cells were similar frequent in patients’ uninvolved 
dermis [93/mm2 (0-264; n=8) (P=n.s.)]. But, more T cells were found in the dermis of 
patients lesional skin [250/mm2 (78-637; n=8) (P=0.06)]. Paired comparison of 
lesional and uninvolved dermis indicated a significant higher T cell number in lesional 
dermis (P=0.04) [Figure 5-26]. 
In the emigration assay a median of 36.0x103/cm2 (7.7-93.3; n=7) dermal CD3+ 
lymphocytes was obtained from healthy skin. Due to the described differences in 
dermal thickness normal dermis was not compared to the dermis of patients. As for 
the immuno-histochemistry, paired comparison of emigrated CD3+ cells from lesional 
(7.1x103/cm2 (0.0-378.4; n=7)) and uninvolved dermis (4.0x103/cm2 (0.1-66.9; n=9)) 
revealed a trend (P=0.07) towards higher T cell numbers in lesional dermis [Figure 
5-29]. 
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5.3.2 The Potential of Alemtuzumab in the Depletion of Skin DCs 
This study was conducted to investigate whether Alemtuzumab depletes skin 
DCs in addition to blood DCs. Skin and blood DCs were investigated before and after 
a four week course of Alemtuzumab in 10 patients. Patient characteristics are 
summarized in Table 4-2. Alemtuzumab was administered intravenously prior to 
aHSCT conditioning therapy until day -14 [Figure 5-30]. Briefly, the schedule consisted 
of a dose escalation within the first week followed by doses of 30 mg on three days 
during the second to fourth week. According to published guidelines211  treatment 
was discontinued if serious side effects occurred. 
Figure 5-30: Alemtuzumab treatment schedule and time of biopsies: First biopsy was obtained 
before start of the pre-conditioning therapy consisting of 3x30 mg Alemtuzumab weekly (day-35 to -14 
before aHSCT). Second biopsy was obtained before start of the conditioning therapy consisting of 30 
mg/m2 Fudarabine (day -6 to -2 before aHSCT) and 4 mg/kg Busulfan (day-3 to -2 before aHSCT).  
 
Skin biopsies and blood samples were collected before and after Alemtuzumab 
treatment. LCs and DDCs isolated from skin, as well as the major subsets of 
peripheral blood DCs (preDC1 and plasmocytoid DC) were characterized and 
counted. Biopsies were generally obtained from the right thigh. The second skin 
biopsy was usually obtained within 10 days after the last Alemtuzumab dose (median 
day 7.5 range 4-22). One patient (No. 6) refused a second biopsy. Emigration assay 
and skin DC characterization was performed as already described. 
Both blood DC subsets were found to distinctly express the target Ag CD52. In 
comparison to them, both types of emigrated skin DCs only weakly expressed CD52 
[Figure 5-31]. 
Bu
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The dosage schedule of the therapy was associated with measurable levels of 
unbound Alemtuzumab approximately two weeks after the last drug dose in the 
majority of patients. It resulted in an efficient depletion of absolute lymphocyte 
numbers in all patients (P=0.002). Furthermore a reduction to 29% (1-216%; 
P=0.010) of preDC1 and 53% (0-162% P=0.193) of plasmacytoid DCs in peripheral 
blood was observed after administration of Alemtuzumab [Table 4-2]. 
 
Figure 5-31: Influence of Alemtuzumab on DC numbers in skin and blood: The surface 
expression of CD52 is shown for LCs (blue), DDCs (orange) and peripheral blood DC subsets; 
preDC1 (turquoise) and plasmacytoid DC (green).  
Furthermore numbers of emigrated LCs (blue symbols), DDCs (orange symbols) as well as of 
peripheral blood preDC1 (turquoise symbols) plasmacytoid DC (green symbols) of healthy controls 
(open bar, median, percentiles and range are indicated) and of patients before and after Alemtuzumab 
treatment shown as paired samples are indicated. 
 
 Patients demonstrated significantly less emigrated LCs and DDCs (P<0.05) in 
comparison to healthy controls, even before Alemtuzumab therapy. Only in 4 patients 
less LCs (2-62% of pre) emigrated after the Alemtuzumab compared to the situation 
before the treatment, whereas 3 patients showed an increase in LC numbers after 
treatment (253-878%). 
DDC numbers were reduced in 3 patients (0-17% of pre), remained close to the 
detection limit in 3 patients, and substantially increased in 2 patients (829-1220%). 
LCs and DDCs both decreased after Alemtuzumab in only one patient, whereas in 
two patients both cell types significantly increased in number. 
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Therefore a thorough depletion of LCs or DDCs can not by achieve by the the 
selected administration schedule of Alemtuzumab in humans. Although Alemtuzumab 
was sufficient to reduce DC in the peripheral blood, it failed to deplete skin DCs 
reliably. 
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6 Discussion 
6.1 Immunohistochemistry as a tool for the quantification of specific cell types 
in the skin 
An essential prerequisite for the study of a given cell subset in situ is the ability 
to identify the desired cell type with certainty. DCs are difficult to study in situ for 
various reasons. It is interesting to note that although several past studies have 
investigated DCs in healthy and in diseased human skin, only a few studies have 
pointed this out.210;212-217 This study attempted to account for these difficulties by 
various means. 
First, to account for the fact that the morphology of DCs (and the resulting 
staining patterns in skin sections) make quantification of these cells difficult,218 this 
study adjusted the staining and quantification procedures to these special 
requirements. 
Second, this study counted DCs in skin taken from not only one, but from three 
different anatomical sites that are typically not sun exposed. This was done to assure 
that the epidermal morphology and UV exposure of the skin sample did not influence 
quantification results.218-221  
Third, because the thickness of the prepared vertical sections222 can influence 
quantification results, this study only used tissue sections whose thickness was within 
the range considered most suitable for DC quantification by de Jong and colleagues, 
who investigated this parameter in detail.222  
Lastly, antibodies traditionally used for skin DC visualization (CD1a, MHC II) 
were tested in a side-by-side approach against recently developed DC specific 
antibodies (CD207, CD206). Thus, it was possible to make direct comparisons of the 
staining patterns and cell counts produced by these different antibodies and to reveal 
their feaseability to study specific DC subsets. Additional double-staining experiments 
were performed to give final evidence for the co-expression of two specific markers, 
CD1a and CD207. 
 
6.1.1 MHC Class II Staining is Insufficient to Study Skin DC In Situ 
The distribution of MHC II+ cells within the stratum basale and stratum spinosum 
of the epidermis, as well as in the papillary and reticular dermis, of healthy human 
skin appeared equal at all investigated body sites. However, the number of these 
Discussion 
73 
cells differed between anatomical site. In femoral skin significantly fewer epidermal 
MHC II+ cells compared to breast- or foreskin were found in this study. This finding is 
consistent with previous studies in mice6 and in humans,221 which also found that 
there are differences in the number of epidermal MHC II+ cells at different anatomical 
sites.  
Because LCs are the only MHC II+ cells in healthy epidermis,223 these results 
suggest that a lower number of LCs reside in femoral skin compared to other body 
sites. But, using other markers than MHC II for LC detection, like ATPase, 
CD1a210;212 or CD207 in this study, showed that LC numbers in skin of the extremities 
(upper and lower), chest, back, buttock and genitalia are equal. Decreased numbers 
of LC have been only described in the skin from palms and soles.210;212 
For that reasons, it can be concluded that the lower number of MHC II+ cells in 
femoral skin does not reflect a lower overall LC number at this site, but instead 
indicates a variation in MHC II expression by LCs. Side-by-side comparisons of the 
number of MHC II+ and CD207+ cells revealed that only 10 % of CD207+ LCs were 
detected by staining for MHC II in femoral skin. MHC II expression on LCs in situ is 
poorly understood but may be influenced by the skin’s structure and 
microenvironment, and other factors such as fatty tissue compounds. This was 
suggested by Knight and colleagues who could show that certain fatty acids are able 
to decrease MHC II expression on DCs in vitro.224 However, female breast and male 
foreskin, are obviously different in the amount of underlying fatty tissue, but showed 
matching numbers of CD207+ LCs and of MHC II+ cells in the present study. This 
observation is in line with recently published data that provides direct evidence for a 
complete overlapping CD207 and MHC II labelling in mice and human breast 
skin.225;226  
However, the present study could clearly show that LC numbers in situ would be 
considerably underestimated by MHC II single staining in femoral skin. Thus MHC II 
is not sufficient to study skin DC numbers concisely in situ. 
 
6.1.2 Methods and Markers Used to Analyze LCs In Situ 
6.1.2.1 Historical summary 
In the past, several other markers than MHC class II have been applied to 
investigate LCs of healthy human skin in a quantitative manner, i.e., anti-ATPase,210 
anti-S-100,217 Okt6,212 T6222 and Leu6.227 Today, it is known that ATPase significantly 
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underestimates LC numbers,228 whereas S-100 has been found to be expressed also 
on a large dermal cell population.229 Okt6, T6, Leu6, and other antibodies were found 
to belong to a conjoint cluster of differentiation (CD) named CD1a.230 CD1a was 
considered the most specific LC marker for a long time and was applied in several 
studies to enumerate LCs in healthy and diseased skin.213-216 However, other 
authors,74 as well as our group,167 have shown that CD1a expression is not limited to 
LCs and could also be found at low levels on DDCs. 
 
6.1.2.2 LC Staining by CD1a is Burdened by Methodical Problems  
CD1a staining exceedingly visualizes the dendritic morphology of LCs, as in 
particular dendritic extensions exhibit an increased CD1a reactivity. Therefore, 
depending on the section plane, two-dimensional images of labelled LCs differ from 
each other and a proper identification of definite CD1a+ cell bodies is difficult.  
De Jong et al. concisely outlined the methodical problem arising from the 
special LC morphology as visualized by CD1a staining of vertical skin sections.222 As 
confirmed in the present work, CD1a staining produces three types of staining 
patterns. The first type comprises densely stained “definite” cell bodies presented as 
polygonal or circular profiles, with usually one or more dendritic extensions of varying 
length. The second type – the so-called doubtful cell body population (according to 
de Jong et al.) - consists of either oblique-sectioned parts of true cell bodies or 
crossing dendritic fragments of neighboring LCs. However, the authors indicated that 
both, type I and type II profiles should be counted when determining the LC number. 
The present work followed this instruction and did not discriminate between type I 
and type II profiles. In contrast, type 3 profiles consisting of “free floating” CD1a+ dots 
and intercellular lines of varying length, representing cross-, oblique-, or longitudinally 
sectioned LC dendrites, were not counted (according to de Jong et al.). The 
discrimination between type II profiles, that should be counted, and type III profiles, 
that should not be counted is difficult and somehow subjective. This constitutes a 
potential methodological problem for the quantification of LCs. This work tried to 
minimize the subjective component by averaging the counting results of three 
independent investigators working in the same laboratory.  
To date there is no “gold standard” of LC quantification in sectioned skin and 
published approaches vary. In previous studies LC quantification in vertical sections 
was either based on microscopic fields or, more precise and applied here, to the 
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length of the epidermis (mm). The majority of authors published LC numbers as a 
number of cells per epidermal area (mm2). Often the method for reaching this number 
was not outlined in the Methods section of the published paper, but if it was, the 
method was described simply as squaring the LC numbers counted per epidermal 
lenght. However, it was not described whether single or mean values were squared, 
a fact which would be important to know from a statistical point of view. Nevertheless, 
in any case the underlying measuring fault is also squared by this approach. All these 
facts limit the comparability of published LC numbers in situ and may account for the 
huge variation of CD1a+ LCs/mm2 found, ranging from 350 to 800.210;212;217;219;231  
In this work the number of LCs/mm epidermis was counted in vertical sections 
without further mathematical standardization. However, to relate the findings to the 
published data, numbers of LCs per mm² were calculated by squaring the median 
values of LC per mm. Using this approach 793 CD1a+ LCs/mm2 were calculated for 
femoral skin, a value that is in the range of published LC numbers, although at its 
upper end. 
 
6.1.2.3 CD207 is the Most Eligible Marker to Analyze LC In Situ 
Recently, a new antibody was designed that is directed against a protein named 
Langerin/CD207 which is involved in the Bierbeck granule formation. In the current 
study this new antibody was applied for LC quantification, because CD207 is now 
considered the most specific LC marker. To the knowledge of the author, there has 
not been any quantitative investigation of CD207+ LC numbers in vertical sections of 
healthy human skin published to date. Only LC numbers visualized by CD207 in 
epidermal sheets using confocal laser scanning microscopy have been reported.165 
However, it has been shown that cell numbers obtained by different methods 
(epidermal sheets vs. vertical sections) are not comparable.225 This might explain 
why the number of CD207+ LCs/mm2 found here in femoral skin (494), is lower than 
that reported in epidermal sheets of similar anatomical origin (754).165  
Surprisingly, CD207+ LC numbers did not match CD1a+ LC numbers but were 
almost always lower. Thus, a side-by-side comparison of CD1a and CD207 staining 
was performed. From a methodical point of view, staining for CD207 has major 
advantages compared to staining for CD1a. That is because, in contrast to CD1a, 
CD207 showed no extensive reactivity with LC dendrites, but densely stained the cell 
body, and consequently, the resulting images were much easier to analyse. In this 
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way, the staining pattern of CD207 was similar to that of MHC II. De Jong et al. 
already noted that MHC II did not produce different types of staining patterns and 
therefore was much easier to analyse.222 In summary, staining of CD207 is the 
preferred approach to study LC in sectioned skin, because it provides both a highly 
specific LC detection, as well as an uncomplicated analysis of staining results. 
 
6.1.2.4 Methodical Issues Account for Differences in CD1a+ and CD207+ LC 
Numbers 
The comparison of CD1a+ and CD207+ cell numbers indicates that, in all 
observed skin sources, CD1a+ cells are significantly more abundant. Using multi-step 
enzymatic, as well as more sensitive multi-step fluorescence staining of 5 µm-skin 
sections, a minor population of CD1a+/CD207- staining events was detected in 
healthy human skin. This study preliminary quantificatfied this population to 10-20% 
of all CD1a+ cells. This is in line with results of other authors, who suggested that LCs 
may be heterogeneous in terms of CD1a and CD207 expression, and that a minor 
but distinct subpopulation of CD1a+/CD207- LCs exists in human oral mucosa.232 In 
addition there is evidence that CD207 may be down-regulated during LC maturation 
while CD1a persists.233 Based on this observation, it was suggested by Dziegiel et al. 
that under inflammatory conditions mature LCs may be retained in the tissue and 
therefore a full co-expression of CD207 and CD1a cannot always be observed.232;234 
However, this explanation, as applied to the current study, is somewhat 
unsatisfactory for several reasons. First, the present observations were performed in 
skin of healthy individuals without signs of any inflammation. Second, in Langerhans 
cell histiocytosis (LCH), a disease with inflammatory aspects, no CD1a+/CD207- have 
been found, also in lesional tissue.234;235 Third, CD1a has also been shown to be 
down-regulated during LC maturation.69;236;237 Thus, there are justified doubts 
regarding the existence of a CD1a+/CD207- LC subset in human skin. 
To investigate if a population of CD1a+/CD207- LCs exists, epidermal sheets 
were fluorescence double labelled and analyzed by confocal microscopy in the 
present study. This technique allowed the possibility to observe whole LC cell bodies 
within a nearly untouched epidermal layer in a three dimensional fashion. These 
experiments spotlighted the different expression of CD1a and CD207 on the cell 
body of LCs. CD1a was found to be strongly expressed on cell bodies, as well as on 
dendrites, whereas CD207 was mainly located close to the cell body. Notably, this 
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method revealed that all LCs co-express CD1a and CD207 and, as a consequence, 
CD1a+/CD207- cells are unverifiable. Thus, differences in CD1a+ and CD207+ cell 
numbers are not due to a subpopulation of CD1a+/CD207- cells but may be due to 
variations in methodology. 
There are some difficulties that necessarily arise from the use of tissue sections 
to quantify LCs. This is because in order to identify the number of a given cell within a 
given mass of tissue, the mean apparent number of these cells within the volume of a 
vertical section has to be extrapolated. Because within a section not all of the objects 
are whole cells and because a number of staining events resemble fragments of cells 
only lying partly within the section examined, this approach is fraught with error. The 
error factor increases with an increasing cell dimension in relation to the section 
thickness, which in other words increases the number of cell fragments in a section.  
As shown here, CD1a+ LCs appeared approximately one third larger than 
CD207+ LCs. This result, as well as the double-staining results, show impressively 
that peripheral LC regions were preferentially detected by CD1a rather than by 
CD207. Recently a report applying two photon-high resolution 3D imaging confirmed 
the observation that CD207 Ags are rather sparsely distributed within distal dendritic 
processes.225 Therefore, it is conceivable that large LC fragments that had been 
emerged from the manufacture of sections, form CD1a type II staining patterns that 
were counted as whole LCs in the present study. But, these LC fragments were not 
stained to the same extent by CD207. This resulted in CD1a+/CD207- staining events 
which could clearly be demonstrated by double staining. These large LC fragments 
visualized by CD1a but not by CD207 may account for the inequality of CD1a+ and 
CD207+ LC numbers found in the present study.  
However, the true number of a given cell in a section is best regarded as the 
number of cell center points within this section. To date, there is no marker providing 
that kind of staining pattern for LCs. Nevertheless, a marker located more closely to 
the cell body, like CD207 will give more precise results than one that is highly 
expressed all over the surface of a large cell, such as CD1a. 
 
6.1.3 In Situ Analysis of Dermal APCs  
There is only limited knowledge regarding the identification, classification, and 
function of MHC class II-expressing cells in human dermis. It is known though that 
the cell population that constitutively expresses MHC II is heterogeneous and that 
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other cell types like T, B and endothelial cells are able to induce MHC II expression 
after activation.238-241 In the healthy dermis, MHC II+ cells appeared mostly distributed 
at random, with a low prevalence around small vessels and hair follicles in the 
papillary dermis. It has been previously suggested, and has been proven true in the 
present work, that the number of MHC II+ APCs decreases with increasing dermal 
depth.242;243 Based on this finding, a method to quantify the APC population within the 
upper dermis, the area of their greatest density, was developed. A small inter-sample 
variation of counting results from independent investigators indicates that the used 
quantification method is a robust technique delivering reproducible results. It can be 
argued that the used approach is more precise than the enumeration of cells per 
microscopic field, as the latter is not based on a defined dermal area.  
 
6.1.3.1 The Upper Dermis Exhibit the Highest Density of Dermal APCs 
Applying this technique, specific dermal cell subsets could be quantified and 
compared between different anatomical sites, or between patients and healthy 
controls, for example. In the present study the number of MHC II+ APCs was found to 
be different at diverse anatomical sites. Foreskin was inhabited by significant more 
MHC II+ cells compared to femoral or breast skin. Whether this difference is due to an 
increased APC density in femoral skin, or to a divergence in the expression of MHC II 
(like shown for femoral LCs), is not entirely clear. However, the detection of DDCs 
(as stained by CD206) revealed that equal numbers of this cell type reside in all 
investigated sources. Comparison of MHC II and CD206 cell numbers revealed that 
in femoral and breast skin, both numbers matched very well and that both of them 
decrease comparably with increasing dermal depth. However, in the foreskin, MHC 
II+ cells significantly outnumbered CD206+ DDCs. This argues for the existence of a 
huge non-DDC MHC II+ population (possibly Mφ) in the foreskin. However, for final 
clarification of co-expression, a double staining of MHC II and CD206 is needed, but 
was out of the scope of the present work. 
 
6.1.3.2 DDCs and Mφs Can Barely be Differentiated by Phenotype 
As expected, in healthy dermis only very few LCs were detected and it is 
believed that the LCs that were found represent epidermal LCs on their journey to the 
lymphatic system.6;70;70 Besides the negligible number of LCs, a population of 
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mononuclear phagocytes, known to consist of Mφs and DDCs stained brightly for 
MHC class II in normal dermis.242  
The following paragraph will list a bunch of partly conflicting theories trying to 
distinguish human DDCs from Mφs by their phenotype. In analogy to the situation in 
mice, dermal phagocytes had been differentiated into Mφs and DDCs by many 
authors. In mice, DDCs and Mφs could be easily distinguished by expression of the 
pan-DC marker CD11c.244 Unfortunately, this approach is not feasible in humans, 
because human Mφs also express CD11c.245 Initially it was suggested that human 
Mφs express the LPS receptor (CD14) and lack CD1a, whereas DDCs vice versa 
lack CD14 and express CD1a at a low level.245 However, it had been shown that in 
dermal suspensions, as well as in emigrated cells from dermal cultures beside the 
populations that are in accordance with this theory (CD1alow/CD14- DDCs and CD1a-
/CD14+ Mφs) also a significant population of unforeseen CD1a+/CD14+ APCs is 
detectable.66 What’s more, other markers such as CD36, CD205, CD206, CD209, 
Factor XIIIa and MHC class II have been suggested to separate both cell types but 
were shown to be expressed by the respective other cell type under certain 
circumstances.66;68;70;72;246 The situation is complicated by the fact that both Mφs and 
DDCs are heterogeneous cell populations in themselves.67;245;247;248    
To date none of the published attempts to establish a conclusive DDC 
phenotype have been able to plausibly exclude Mφs. As a result of these difficulties in 
providing a consistent phenotypic characterization of DDCs there is discordance 
within the scientific community regarding the origin and lineage affiliation of these 
cells. Some authors conclude by phenotypic and ultra-structural studies that DDCs 
are more closely related to the monocyte/Mφ lineage than to the DC lineage242  while 
the majority of other authors believe that DDCs resemble a distinct differentiation 
pathway of DCs. This second view is more reasonable because there is a lot of 
functional evidence that DDCs are professional APCs and as such are as potent as 
LCs in the activation of immune responses.249;250 Contrary to this, Mφs were referred 
to as “non-professional” APCs by most authors. But also this view was recently 
challenged by Pozzy and colleagues, who showed that murine Mφs can stimulate 
nave CD8 T cells to proliferate, to develop effector functions, and to differentiate into 
memory cells in vivo.244 This feature is traditionally restricted to professional APCs.  
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Some evidence has been provided that Mφs could give rise to LCs or DDCs and 
may in fact be true precursors of these populations.45;251-253 Also, a shift from mature 
skin DCs back to Mφ-like CD14+ cells under immuno-suppressing conditions in vitro 
has been reported.254 Taken together, these conflicting results indicate that the 
relationship between DDCs and Mφs is only insufficiently understood to date. 
Therefore, several authors bypass the problem by referring to dermal phagocytes or 
dendritic macrophages.243;255 Indeed, several studies point to the existence of a 
heterogeneous pool of Mφ/DC like cells, from which subpopulations of dermal Mφs 
and DCs may arise.256 
 
6.1.3.3 CD206 – A Marker to Analyze DDCs In Situ 
Given the lack of a marker that is able to conclusively separate DDCs from Mφs, 
the present work used the macrophage mannose receptor (MMR or CD206) to 
investigate the whole population of dermal phagocytes. The main focus of this work 
was to distinguish dermal APCs from LCs and it was found that indeed, DDCs and 
Mφs, but not LCs were found to express CD206.75;257;258 The detailed phenotypic 
analysis of the emigrated dermal APC subset (see below) showed that CD206+ APCs 
dimly expresses CD1a and that only a very small population was positive for the Mφ 
marker CD14. Thus, to the view of the author, it is justified to refer to this CD206+ cell 
population as DDCs.  
To the knowledge of the author, no publications regarding the absolute number 
of dermal APCs in general or of CD206+ DDCs in particular in the human dermis 
exists. In mice, DDCs constitute about 60% of all cells in the dermis.6 As the dermal 
tissue is composed of large extra-cellular matrix compounds, dermal cells (nuclei 
visualized by Mayers Hemalaun counterstaining) are rare and widespread comared 
to the epidermis. Indeed, only a small population of these widespread dermal nuclei 
did not stain for CD206+ in the current study. This implies that also in the human 
dermis, DDCs constitute the major dermal cell type. However, free nuclei were not 
quantified and no definite conclusion regarding this point could be drawn from the 
data available. 
 
6.1.4 Number and Distribution of T cells Varies at Different Anatomical Sites  
The number and distribution of T lymphocytes was investigated by staining for 
CD3, which is a protein complex associated with the TCR. This approach does not 
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distinguish between αβ TCR+ and γδ TCR+ T cells, as both of them express CD3. 
According to the literature, only very few isolated CD3+ cells are present in the 
healthy epidermis of femoral and breast skin.259 In the current study, CD3+ 
lymphocytes were more numerous in in the foreskin. The majority of skin resident 
CD3+ cells was found within the dermis. Like in the epidermis, the dermis of foreskin 
was inhabited by an increased number of lymphocytes compared to femoral and 
breast skin.  
To date, the T cell infiltration of healthy or diseased human skin is mostly 
described in a semi-quantitative manner. This might be due to the fact that in the 
dermis, but not in the epidermis, CD3+ cells occasionally form clusters.259 At first 
glance it appears difficult to identify how many single cells form a cluster and this 
complicates the enumeration. However, this study found that the mean diameter of a 
single lymphocytes visualized by CD3 staining in vertical sections was very constant. 
Consequently the number of CD3+ lymphocytes within a cluster could easily be 
calculated based on the area of a cluster. Interestingly, the incidence of clusters was, 
despite the higher T cell number in foreskin, equal in all skin sources. It has been 
reported that clusters may point to an intimate contact of T lymphocytes with 
DCs.241;260 Indeed, as shown in this work, T cell clusters were often intermixed with 
DDCs. Preliminary observations of other authors suggest that the ability to form 
clusters varies between different types of skin DCs and that T cells within these 
clusters acquire an activated phenotype during cluster formation.260 Furthermore, it 
has been shown that only mature DCs efficiently form conjugates with T cells, 
whereas immature DCs did not.261 This suggests that communication between T cells 
and skin DCs, thought to exclusively taking place in the lymph nodes, partly occurs 
directly in the skin very early in the immune response. The number of clusters may 
therefore be an additional source of information with potential diagnostic relevance.  
 
6.1.5 Immuno-Histochemistry Summary 
In summary, immuno-histochemistry was found to be efficient in the detection of 
skin resident DC and T cell types. The development of a stable analytical method for 
cell enumeration and its application to a substantial number of healthy skin donors 
was necessary before analyzing patient tissue samples.  
Several phenotypic and functional aspects of the observed cell types, especially 
those of DDCs, are poorly understood today. More detailed phenotypic observations 
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can be done by flow-cytometry but, like most functional in vitro assays, require a 
single-cell suspension of the tissue. Classically, enzymatic techniques using trypsin, 
collagenase or pepsin were used to generate fresh tissue suspensions.262;263 
However, these techniques were shown to digest sensitive markers from the cell 
surface226;264 and in addition may negatively influence cells’ vitality and functionality. 
As the number of DCs in skin is low compared to other cell types, these techniques 
naturally produce suspensions with only a low DC contingent. Therefore, the 
investigation of the functional capabilities of DCs, like chemotactic response or 
stimulatory potential, has been technically impaired for long time due to the difficulties 
in obtaining a large enough number of viable cells for in vitro studies. 
 
6.2 Development of the Emigration-Assay 
6.2.1 Historical Summary 
The emigration assay, also known as the “skin explant culture”, is an 
established method used to isolate cell populations able to migrate out of the tissue 
they reside in.67;265 This approach circumvents enzymatic and/or mechanical tissue 
suspension techniques and selectively enriches vital cells holding a fundamental DC 
function, namely migratory capacity. Several authors have applied the emigration 
assay to isolate and study skin resident DCs and/or T cells.67;205;253;265-268 
Microscopically both cell types are well distinguishable as DCs appear as granular 
cells with many thin projections or a few veils (DCs), whereas T cells have clear 
cytoplasm, a huge nucleus and are plain and round.269  
As most authors applyed the emigration assay to focus on LCs, it is difficult to 
extrapolate the information from these previous studies to other emigrating cell types. 
However, DDCs, Mφs, NK and T cells have also been detected in the emigration 
culture by other authors.205 As shown here and according to the literature, emigrated 
cells of hematopoietic origin can be divided into high granular, MHC II+ APCs and into 
low granular, lymphocyte-like cells of which the vast majority are CD3+ T cells.241   
As shown here and elsewhere the population of emigrating APCs is 
heterogeneous.16;66;253 It consists of LCs and DDCs, as well as of some CD14+ Mφs. 
As shown here the majority of emigrating lymphocytes consisted of CD3+ T cells and 
a minor population of NK cells, but no B cells. CD3+ T cells consisting of CD4+ 
TH cells, CD8+ CTL and CD4-/CD8- γδ T cells.  
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It has been reported that during skin culture at 37 °C, LCs retract their dendrites, 
round up, up-regulate their MHC II expression and emigrate from the tissue into the 
incubation medium.270 Thus, emigration is an active process and, as shown here, is 
temperature dependent. The lack of emigration of DCs and T cells at a lower 
incubation temperature of 4 °C verifies that these cells did not simply fall out of the 
tissue. Thus, viable cells are consistently enriched in the emigration medium and are 
available as single cell suspension for functional assays. 
 
6.2.2 Limited Practicability of the Emigration Assay Using Whole Skin Samples 
The kinetics of skin DC emigration have been reported by some authors.70;205 All 
of them conclude that the majority of skin DCs leave the tissue during the first 3 days 
of culture. However, a conclusive investigation regarding the absolute emigrating cell 
number per cm2 of incubated skin has not been published so far. The present work 
addresses this issue and found that the number of emigrating APCs differed 
considerably between skin samples from different anatomical origin. Significantly less 
APCs emigrated from the foreskin and breast skin samples compared to femoral skin 
samples. But, as shown here by the immuno-histochemistry, LC and DDC numbers 
are equal at these anatomical sites. Thus, the observed differences are due to an 
inability of the cells to emigrate from fore- and breast skin. It is possible, but not very 
likely, that cells at these sites are inherently less potent to emigrate. A more plausible 
explanation is the different thicknesses of the skin samples. Most cells were found to 
emigrate from thinnest femoral biopsies obtained as split-skin samples that have an 
approximate thickness of 0.3 mm.226 Contrary, full-skin samples obtained from fore- 
and breast skin consisted of a much thicker dermis. This thicker dermal layer may 
represent a barrier impeding the emigration of LCs. As DDCs predominantly reside in 
the upper part of the dermis, their emigration may also be impeded by a thicker 
dermis. All three skin sources had commonly been used in the literature but, as 
shown here, are not comparable with respect to the number of emigrating cells. 
Variations of the dermal thickness may also have an impact on the huge intra- and 
inter-individual variations that were observed in cell numbers of whole-skin 
incubations. Due to the poor reproducibility of the emigration assay in this particular 
design, it may not be suitable to compare emigrated cell numbers from different 
sources in a conclusive way.  
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An additional limitation of the whole skin emigration assay was that dermal and 
epidermal cell types are mixed together in the harvested culture. The fraction of LCs 
within the APC subset was small and the absolute number of LCs that could be 
isolated by this approach was mostly not suitable to perform functional assays in 
vitro. In addition, functional testing of the emigrated whole skin APC population in the 
mixed leukocyte reaction (MLR) did not result in definite conclusions regarding the 
stimulatory capacity of a certain APC subset. This is because the explored overall 
stimulatory capacity is only the summarized stimulatory capacities of all present APC 
subsets. In the past, the presence of DDCs within the whole skin emigration culture 
has often been overlooked. Thus, it is not known how much DDCs contribute to the 
stimulatory effect that has been observed in these studies and that has been 
assigned only to LCs.7 By now, there is more and more evidence that DDCs play an 
essential role in the skin immune surveillance that may be different from that of 
LCs.48;70 However, to date there is only limited information derived from a functional 
side-by-side comparison of LCs and DDCs. To perform this kind of comparison, an 
efficient technique for the separation of both cell types that itself did not negatively 
influence cells vitality and functionality, is required.  
 
6.2.3 Improvement of the Emigration Assay Toward a Diagnostic Tool 
The separation of the epidermis and the dermis prior to the emigration assay 
using the neutral protease dispase I is an elegant way achieve the separation of 
epidermal and dermal cell subsets. The enzyme which is derived from bacillus 
polymyxa, had long been known for its ability to detach the epidermis from the 
dermis.201 As shown here, a fractional amount of the published dose201 is effective to 
detach the epidermis from the basement membrane. The treatment with dispase I did 
not result in a decreased cell vitality, neither in the low dose applied here, nor in the 
published dose, that was 500 to 1000 fold higher.201 However, specific cell surface 
molecules may be sensitive to dispase I treatment and could limit the field of its 
application. It has been reported elsewhere that dispase I digests surface molecules 
like DEC-205,226 CD4 and CD8271 and this work confirmed this observation for the 
latter two markers. However, the majority of markers applied in this study, like CD1a, 
CD3, CD206, CD207, MHC II (HLA-DR) are not sensitive to the enzyme. In addition, 
dispase I treatment seems not to negatively influence the vitality or functionality of 
DCs. This conclusion was drawn from a couple of experiments comparing Ag uptake, 
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as well as migratory- and stimulatory capacity between DCs emigrated from dispase I 
treated and untreated full-skin incubations. Therefore, dispase treatment can be 
safely applied in the context of the emigration assay, which has been done in the 
recent past by a number of authors.67;226;269;272-274  
In general, emigration of LCs from the epidermis occurs irrespective of the 
presence of the dermis274 and DDCs can also be obtained from dermal 
incubations.205;269;275 In accordance with the literature, more cells were found to 
emigrate from epidermal than from dermal sheets of the same biopsy.269 Compared 
to full-skin incubations, significantly more LCs and equal numbers of DDCs could be 
obtained from epidermal or dermal culture, respectively. Although a substantial 
barrier for the emigration of LCs was removed by detaching the dermis in addition to 
the basement membrane from the epidermis, LCs’ emigration remained an active, 
temperature-dependent process. It was clearly shown in the present study that, at an 
incubation temperature of 4 °C, neither LCs nor DDCs were able to leave their 
respective layers. Thus, the assay furtheron selectively enriches vital DCs capable of 
migration.  
The higher yield of LCs, as well as their complete separation from DDCs, 
facilitated a side-by-side comparison of phenotypic and functional properties of both 
cell types in vitro. An additional important finding was that the intra-variability of 
emigrated cell numbers, as measured in parallel incubations of samples from the 
same donor, was much lower than that observed in full-skin incubations. This 
improved reproducibility made the assay applicable for the quantitative investigation 
of skin DCs in a clinical setting. 
 
6.3 The Phenotype of Cells Obtained Via the Emigration Assay 
6.3.1 Phenotype of Emigrated LCs and DDCs 
Because phenotype and function are correlated to some extent, a detailed 
discussion of markers known to be functionally related is outlined under the 
respective function. FACS is a highly sensitive technique able to also visualize a very 
weak surface expression of a given marker. The technique is superior to immuno-
histochemistry but also has its limitations. First, as mentioned above, the generation 
of a single cell suspension, which is needed to perform FACS, could interfere with the 
phenotype and may lead to false negative results. Second, mechanical and chemical 
steps during the cell separation may change the phenotype by inducing the up- or 
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down-regulation of specific (stress-related) markers. Third, tissue-derived cells often 
expose high levels of background fluorescence (non-specific staining and auto-
fluorescence), a fact that complicates the analysis of results.  
The phenotypic characterization of emigrated LCs and DDCs in this study 
largely confirmed results of other authors. The characterization of LCs by combined 
MHC II and CD207 expression is highly specific and distinguishes this cell type 
unequivocally from any other cell type including DDCs.69;276 A weak but distinct CD4 
expression was found on LCs, and has also been described by several other 
authors.7;277;278 Also, the lack of CD8, CD14, CD206, FactorXIIIa and linage markers 
(including CD3, CD16, CD19, CD20, CD56) is consistent with the literature.7;279-281 
The characterization of DDCs by a combined MHC II and CD206 expression 
clearly separates this cell type from LCs, but, as already discussed, may include part 
of activated Mφs as well. As described by Larregina et al.,253 a small population of 
MHC II+/CD14+ is occasionally detectable in the emigration culture, whereas most 
emigrated CD14+ Mφs are MHC II negative. Also within the MHC II+/CD206+ 
subpopulation of DDCs, a small population of CD14+ cells was found. Like LCs, 
DDCs exhibited a low CD4 but lacked CD8 expression, an observation also 
described by other authors.7 Also in accordance to the literature, DDCs were found to 
express the coagulation Faktor XIIIa which is the catalytic subunit of a beta-globulin 
mainly expressed in the cell plasma.66 Despite this intra-cellular expression, Faktor 
XIIIa was weakly detectable by conventional FACS on DDCs but not on LCs. 
 
6.3.2 Phenotype of Emigrated T Cells 
Immuno-histochemistry revealed that only very few CD3+ T cells reside in 
healthy skin. Accordingly, only low numbers of CD3+ T lymphocytes were found to 
have emigrated from healthy skin. As known from whole skin incubations this small 
population is heterogeneous and consists of CD4+ TH and CD8+ CTL expressing 
αβ TCR, as well as of γδ TCR+ T cells lacking CD4 and CD8 expression.282 In the 
emigration culture of whole skin samples CD4+ TH cells were most frequent, whereas 
only small subsets of CD8+ CTL and γδ T cells were present. As already mentioned, 
CD4 and CD8 molecules are dispase I sensitive.271 Indeed, dispase I treatment 
removes both markers completely from T cells’ surface. However, during a culture 
period of three days both markers were reconstituted. Thus, CD4+ and CD8+ T cells 
could be detected in dispase I treated, epidermal and dermal skin cultures and a 
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comparison of the T cell subset composition in both skin layers became feasible. 
According to the literature and to the results of immuno-histochemistry in this study, 
the fast majority of T cells was located in and emigrated from the dermis.282 
Therefore, the composition of T cell subsets observed in dermal cultures closely 
resembled that of whole skin incubations, with a majority of TH cells and equal 
amounts of CTL and γδ T cells. However, the low numbers of T cells residing in and 
emigrating from the epidermis differed considerably in their subset composition. Most 
T cells emigrating from the epidermis were γδ T cells. It is known, and could be 
confirmed here using the emigration assay, that more than 40% of tissue-resident, 
intra-epithelial T-cells are γδ TCR+ cells.83 Only minor contingents of TH cells and 
CTLs emigrated from epidermis.  
The low absolute number of emigrated cells made the determination of T cell 
subsets along with DCs impracticable in patients. Therefore, only emigrated CD3+ 
cell numbers were counted. However, the emigration assay is feasible to observe 
T cell subsets in a qualitative manner and the results that have been described here 
may be a good starting point to investigate the pattern of T cell subsets in a clinical 
setting. 
 
6.3.3 Maturation Status of DCs After Emigration 
It has to be mentioned that the described phenotype refers to cells that had 
been emigrated from their respective layer in vitro. DC emigration from the tissue to 
the lymph node is a naturally occurring process and is associated with maturation. 
Maturation of DCs is regulated by exogenous signals and probably does not occur 
spontaneously.283 The invasive obtainment of skin samples or the skin culture itself 
may provide activating signals that stimulate the so called “spontaneous” emigration 
of DCs. As a consequence, this way of isolation inherently impacts the maturation 
state of DCs. 
 
6.3.3.1 Emigrated Skin DCs are Phenotypically Not Fully Mature  
To date it is not entirely clear if DCs that have been emigrated from skin culture 
are fully mature. Most authors noted that most of them appear to be phenotypically 
mature.16;29;67;226;265;270;284-286 However, a recent publication concluded that emigrating 
DCs consist of sub-populations at different maturation stages.16 Based on the 
heterogeneity of DCs, it is likely that different DC subsets show a varying 
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responsiveness to equal maturation signals.16;287 Maturity in terms of a phenotypic 
description denote DCs expressing high levels of MHC molecules, CD40, CD80, 
CD83 and CD86 as this phenotype often correlates with T cell priming ability.52;288;289 
In the present study a side-by-side comparison of emigrated LCs and DDCs to 
investigate the expression of these maturation markers was performed.  
Both cell types expressed HLA-DR, a variant of MHC II, but LCs were found to 
express significantly more MHC II compared to DDCs after their emigration. The 
expression of CD80 and CD86 is crucial to deliver co-stimulatory signals that 
promote survival, metabolic competence and cell-cycle progression of T cells.290 Only 
a sub-population of LCs but all DDCs expressed low levels of CD80. Also a dim 
surface expression of CD86 was found on a minor sub-populations of LCs and 
DDCs. Overmore, very small sub-population of LCs, showed a weak CD83 
expression, whereas DDCs completely lacked this marker. The neo-expression of 
CD83 is also associated with DC maturation236;260 but, to date, neither a function nor 
a ligand of CD83 has been discovered. No CD40 expression was detected, neither 
on LCs nor on DDCs. CD40 is able to mediate T cell activation by binding to its ligand 
(CD40-L) expressed on primed T cells.209  
Taken together, this work shows that skin DCs obtained by emigration from 
epidermal cultures were not as fully mature (as measured by phenotypic criteria) as 
reported elsewhere.29 Instead, they appeared non-uniform in their phenotypic 
maturation status.16 
 
6.3.3.2 Cytokines Cause Emigrated Skin DCs to Mature Further 
Treatment of LCs and DDCs with the cytokine cocktail described by Jonuleit et 
al.291 revealed that both cell types can be transformed into a more mature phenotype. 
Jonuleit’s cocktail consists of IL-1β, IL-6, TNFα and PGE2 and has been effectively 
used for the maturation of DCs generated in vitro.291  The effect of this cocktail on 
emigrated skin DCs was initially discovered by a former team member, Falk 
Heidenreich (unpublished data).  
If Jonuleit’s cocktail was added during the last two days of emigration culture 
both, LCs and DDCs were found to respond by de novo expression of CD40. The 
treatment also increased the portion of LCs expressing CD80, CD83, CD86. 
Furthermore, the level of MHC II, CD80 and CD86 surface expression on LCs and of 
CD80 on DDCs was considerably increased by the cytokine treatment. These results 
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support the view of some authors that emigrated skin DCs are semi- or intermediately 
mature292-294 and contradict the view that the emigration assay mirrors a strong 
cutaneous inflammation resulting in full maturated DCs.270;285 However, the observed 
state of intermediate maturity is due to the way of cell isolation and may be artificial. It 
is not known if DCs’ characteristics observed after emigration ex vivo truly mirror the 
capacities of these cells in vivo. This is a general limitation of all in vitro approaches 
and has to be accepted if there is a technical inability to observe the respective 
processes in vivo. Testing of DCs’ functional capacities in vitro facilitates the control 
of several relevant parameters and allows the comparability of different experiments 
performed under identical conditions. Therefore, a functional comparison of LCs and 
DDCs in vitro is able to characterize the capacities of both cell types in relation to 
each other. Because LCs have been extensively investigated during the last several 
decades and their functional capabilities are thus well understood, this cell type is an 
ideal benchmark for studying DDCs. 
 
6.4 Aspects of DC Function 
It is believed that all DC subsets are able to take up Ags, migrate in response to 
certain chemokines and stimulate T cells. However, functional capacities and the role 
in immunity may vary considerably between different DC subsets and also within on 
specific DC subset dependend on presence or absence of inflammatory stimuli. A 
thorough functional side-by-side comparison of LCs and DDCs has not been 
published so far, but is awaited by authorities in the DC field.29 The present work 
addressed this issue by comparing functional capacities of LCs and DDCs isolated by 
the emigration assay. As emigrated DCs were found to be intermediate mature and 
could still be turned into a more mature state by the application of the Jonuleit 
cocktail, the influence of such an ex vivo maturation upon all tested functions was 
investigated in addition. 
 
6.4.1 Antigen Uptake 
6.4.1.1 LCs and DDCs Express Different Receptors for Ag Uptake  
Skin DCs efficiently take up exogenous Ags including apoptotic bodies,295 
viruses,296 bacteria,56 and intracellular parasites297 via receptor-mediated 
endocytosis.298 In this process, DCs express subset-specific membrane lectins to 
mediate the uptake and delivery of Ag to MHC II compartment for optimal 
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presentation.299 As already explained, the phenotypic distinction of LCs and DDCs, 
as carried out in this work, was based on the surface expression of different 
endocytotic receptors. On of theses receptors, CD207 (Langerin), is a type II 
membrane-associated C-type lectin that recognizes mannose residues via a single 
carbohydrate recognition domain. It functions as an endocytic receptor for targeted 
transport of mannose-containing ligands to the Birbeck granules.276;300 The exclusive 
expression of CD207 by LCs confirmed here is already discussed above. Vice versa, 
DDCs can be clearly separated from LCs by the expression of CD206. CD206 is a 
type I membrane-associated C-type lectin involved in endocytosis of mannosylated 
glycoproteins, phagocytosis of mannose-coated particles and receptor-mediated Ag 
presentation.301  As shown here and elsewhere, LCs never express CD206,75;279-281 
neither in situ nor after emigration or ex vivo maturation, whereas DDCs never 
express CD207,69 likewise neither in situ, nor after emigration or ex vivo maturation. 
Other surface markers that are potentially involved in Ag uptake are CD11 and 
CD71. CD11 belongs to the family of 2 integrins which are composed of one of 
three different α-chains (CD11a, CD11b and CD11c) linked to a constant β-chain. 
The expression of the α-chain variant varies between different cell types. CD11 is 
mainly involved in cell-to-cell or cell-to-matrix adhesion, but also interacts with 
obsonizing components of the complement system, thereby linking it to Ag 
uptake.72;302 Contrary to the limited published information, no surface expression of 
CD11a nor CD11c was found on LCs in this study.72;302;303 Also the detection of 
moderate levels of CD11a on DDCs is not in agreement with the literature whereas, 
this study confirmed the high expression of CD11c on these cells.303 The 
inconsistency of these findings with the literature may be due to the fact that, unlike 
the experiments performed in this study, other authors performed their observations 
on resting DCs in situ and consequently, the expression of CD11 during emigration 
has not been explored. However, it is reasonable to assume that CD11 will be down-
regulated during LCs’ emigration considering that CD11 is involved in adhesion of 
generated DCs to the tissue.304 
Another marker involved in endocytotic processes is CD71. Its function is the 
uptake of iron through binding and endocytosis of transferrin, which is the major iron-
carrying protein. Iron is essential for many metabolic pathways and plays a critical 
role in cell proliferation. This study confirmed the expression of CD71 on LCs305 and 
in addition found low CD71 expression on a subpopulation of DDCs. To the 
Discussion 
91 
knowledge of the author this is the first time that data has been gathered regarding 
CD71 expression in this particular cell type. 
  
6.4.1.2 LCs Show Higher Ag-Uptake Capacity than DDCs Until Maturation 
The uptake of protein Ag as carried out in this study is related to processes like 
pinocytosis and phagocytosis that are not necessarily receptor mediated. Thus, there 
is no direct relation between protein Ag uptake capacity and the expression pattern of 
the receptors mentioned above. In this study, the ability to take up protein Ag was 
exclusively demonstrated for the MHC II+ population of emigrated cells. After 
application of FITC-labelled BSA on top of skin samples and the subsequent 
performance of the emigration assay, only MHC II+ cells showed a FITC signal, 
whereas other cells, including lymphocytes, did not [see Appendix Figure 7-2].  
It has been reported that LCs loose their capacity to phagocyte during 
emigration.56 This finding was not corroborated by our study, which found that after 
emigration, both LCs and DDCs were capable of protein Ag uptake. Moreover, 
compared to DDCs, LCs showed an increased capacity for fast protein Ag uptake 
and also took up significantly more protein Ag during a longer period of time. This 
increased uptake capacity of LCs may be a general quality of LCs, or it may be due 
to a more immature state of these cells after emigration compared to DDCs. The 
second view is supported by maturation experiments in the present study. 
Specifically, ex vivo maturation significantly decreased LCs capacity for Ag uptake, to 
levels observed for DDCs. For DDCs, on the other hand, Ag uptake capacity was low 
whether they were exposed to maturation cocktail or not. It is also interesting to note 
that after exposure to the maturation cocktail, both cell types did not completely lose 
their capacity to phagocyte protein Ags. However, it is not clear from these 
observations whether or not DDCs would be more efficient in the uptake of Ag if they 
could be isolated in a more immature state and cannot be answered with the 
methods used in this study. What is clear though is that under the given conditions 
(DC isolation by emigration assay), LCs show an increased Ag uptake capacity 
compared to DDCs, which capacity is lost after their maturation ex vivo. 
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6.4.2 Chemotactic Migration Toward MIP-3β 
6.4.2.1 LCs and DDCs Express CCR7 and Lack E-Cadherin 
Chemotaxis is defined as the directional locomotion of cells sensing a gradient 
of a chemical stimulus. This type of directed migration from the tissue they reside in, 
to the lymph nodes or spleen is pivotal to accomplish the function of professional 
APCs.9;10 In the case of DCs, this migration occurs in response to a number of low 
molecular weight proteins named chemokines.306;307 MIP-3β, a chemokine 
constitutively produced in lymphoid tissues,308 is a chemo-attractant for DCs207 and 
acts through CCR7.206 Surface expression of CCR7 is up-regulated during DC 
maturation and is necessary for DCs to home to lymph nodes. As shown here, both 
emigrated LCs and DDCs express CCR7 (with LCs expressing slightly higher 
amounts) and are thus able to detect MIP-3β. 
In addition to the expression of chemokine receptors, DCs have to alter the 
expression of adhesion molecules in order to leave the tissue. One of these adhesion 
molecules is E-cadherin, which has been shown to retain DCs within the tissue matrix 
and to be down-regulated prior to DC migration.309;310  It has been published that E-
cadherin expression is limited to non-migrating LCs and that it is not expressed on 
DDCs.69 Consistent with these findings, in this study E-cadherin was nearly 
undetectable on LCs and DDCs that have emigrated.   
 
6.4.2.2 The Migratory Capacities of LCs Changed After Maturation 
To test and compare the migratory capacity of LCs and DDCs, a standardized 
trans-well assay was used. In vivo migratory properties of LCs and DDCs may be 
different. Although both cell types have been shown to be responsive to MIP-3β, 
DDCs migrate preferentially to the paracortex adjacent to the B cell follicles, whereas 
LCs migrate to the deeper T cell areas of lymph nodes.48 In addition, DDCs’ 
migration clearly precede that of LCs in an experimental model.48 Consistent with 
these observations, this study found that a higher number of DDCs transmigrated in 
response to MIP-3β compared to LCs, suggesting that DDCs may inhabit a higher 
MIP-3β responsiveness and motility. But, other authors have shown that the 
responsiveness to chemotactic factors like MIP-3β is increased during the maturation 
of DCs.308  As shown in the present study, emigrated DDCs appear to be more 
mature than LCs in terms of their Ag uptake capacity and to have an increased 
migratory capacity in response to MIP-3β. Exposure to the maturation cocktail failed 
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to enhance the migratory capacity of DDCs, which remained nearly unchanged after 
the treatment, but significantly increased the migratory capacity of LCs. After ex vivo 
maturation LCs transmigrated as efficiently as DDCs in response to MIP-3β. Thus, 
these data further strengthen the view that DDCs emigrate in a more mature state 
than LCs from the skin samples.  
 
6.4.3 Stimulation of Allogeneic T Cells 
6.4.3.1 Different Expression of MHC II and CD1 Variants on LCs and DDCs 
The presentation of internalized Ags on specific surface molecules in 
combination with co-stimulatory signals facilitates the strong T cell stimulatory 
capacity of DCs.11;32-36 Presentation of exogenously acquired protein Ags to CD4+ 
T cells is mediated by MHC II. In humans, HLA-DR, -DQ und -DP are different 
variants of MHC II. This work confirmed that emigrated LCs and DDCs express HLA-
DR, but to different levels. Compared to DDCs, LCs express a significantly higher 
density of HLA-DR on their surface. After treatment with the maturation cocktail, 
DDCs kept their low HLA-DR expression nearly constant, whereas LCs further 
increased their already high expression. Thus, LCs showed phenotypic maturation in 
terms of MHC II expression, whereas DDCs did not. However, other maturation 
markers like CD80 as well as decreased Ag uptake and increased migratory 
capacity, suggest that DDCs are more mature than LCs after their emigration. 
Therefore, the reduced HLA-DR expression by DDCs (compared to LCs) may not 
necessarily be a sign of immaturity.  
Recently, an MHC-independent pathway for lipid Ag presentation that is 
mediated by molecules of the CD1 family has been identified in skin-derived DCs.311-
313
 Thus, skin DC-mediated immunity may involve T cell recognition of both peptide 
and lipid Ags. CD1 isoforms have been found to be expressed at different levels on 
LCs and DDCs. According to the literature, LCs are strongly CD1a+, whereas DDCs 
only weakly express this marker.32;167 Although some authors reported that CD1a is 
down-regulated during emigration/maturation of LCs,69;236;237 this study clearly 
demonstrated that the levels of CD1a remained constant on the surface of LCs after 
their emigration/maturation and thus confirmed the view of other authors.268;314-316 
Consistent with the high surface expression of CD1a on LCs, these cells have been 
shown to efficiently activate lipid specific T cells via this marker. On the other hand, 
DDCs with low CD1a surface expression inefficiently present lipid Ags to specific T 
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cells.32 However, there are other isoforms of CD1 that are also involved in lipid Ag 
presentation that are differentially expressed on both cell types. As confirmed here, 
LCs demonstrate only low levels of CD1b77 whereas this marker is distinctly 
expressed on DDCs.317 However, it is not known if CD1b also contributs to the MHC 
independent Ag presentation pathway. Moreover, there is some evidence that, in 
addition to Ag presentation, γδ T cells could be directly activated by CD1 molecules 
without any Ag involvement.311;318 
 
6.4.3.2 Only Mature LCs Show a Stimulatory Capacity Comparable Dermal APCs  
In this study, LCs and DDCs were found to be well equipped with molecules that 
mediate the presentation of Ags and with others that provide co-stimulatory functions. 
The T cell stimulatory capacity of both cell types was tested in an allogeneic MLR. 
Since virtually all MHC II+ cells from epidermal culture were found to express CD207, 
it is justified to assign the stimulatory capacity of the epidermal emigration culture to 
LCs. Although DDCs make up the majority of APCs in a dermal culture, a substantial 
number of MHC II+/CD206- cells was also detected. Because all MHC II expressing 
cells can potentially stimulate the MLR, the term “dermal APCs” rather than DDCs 
were used. This assured that the measured effect was not due to the MHCII+/CD206+ 
cell type alone. However, it has been shown elsewhere that the stimulatory capacity 
of dermal cell suspensions is mainly due to a CD1alow/CD1b+ cell subset.303 As 
shown above, this phenotype is consistent with the definition of DDCs in this study. 
Furthermore, emigrated human CD14+ cells have been shown to be very poor 
stimulators of allogeneic T cells.16 
Also LCs from fresh tissue suspensions are poor stimulators of the MLR. 
However, after a 2 day in vitro culture, LCs become exceedingly potent in this 
function.52 As the emigration assay inheres a comparable culture period, it could be 
expected that emigrated LCs might be potent stimulators. But, their capacity to 
stimulate the proliferation of allogeneic T cells, although detectable, was found to be 
very low.  
Compared to LCs, emigrated dermal APCs were much more potent stimulators 
of the MLR. These results are in discordance with a report showing that both cell 
types are similar in their stimulatory capacity.260 In analogy to HLA-DR expression, 
LCs were found to increase their stimulatory capacity after treatment with the 
Discussion 
95 
maturation cocktail, whereas maturation had no significant influence on dermal APCs’ 
strong ability to stimulate allogeneic T cells.  
 
6.4.4 Overall Functional Conclusion 
In summary, the ability of emigrated LCs and DDCs to take up protein Ags, as 
well as their migratory and stimulatory capacity, showed that both cell types have all 
relevant APC functions. After their emigration from the epidermis, LCs are not fully 
mature in a phenotypic as well as in a functional view. This becomes evident by 
treatment with inflammatory cytokines, which shifted phenotype and function of LCs 
toward a more mature state. These observations are not in line with the general 
concept of DC maturation by Steinman et al.,8 who proposed that DCs may appear in 
only two discrete functional states, i.e., immature and mature. The present results 
suggest that maturation may be a more continuous process rather than an on/off 
decision. Also, results of other studies indicate that there is a need to refine 
Steinman’s maturation paradigm, but currently there is no coherent and universal 
theory that does full justice to the richness and diversity of DC biology.283;287 
As in LCs, Jonuleit’s cocktail induced the phenotypic maturation of DDCs. 
However, in contrast to LCs, the functional capacities of DDCs were not altered by 
the treatment. Therefore, these cells appear to behave according to the maturation 
paradigm and ex vivo emigration resulted in a (final) functional maturation.  
Emigrated LCs demontrated a higher Ag uptake capacity and therefore 
appeared immature compared to DDCs, which had a stronger migratory and 
stimulatory capacity. Treatment with the maturation cocktail skewed LC functions 
toward functional capacities observed for DDCs, i.e., it decreased the Ag uptake and 
increased the migratory and stimulatory capacity. Therefore, terminally mature skin 
DC types were found to have equal functional capacities in vitro. The fact that LCs 
emigrate in a rather immature state suggests that DDCs may be more sensitive to 
maturation stimuli or may acquire full functional maturation more rapidly. This may 
contribute to their faster emigration from the skin to the lymph nodes in vivo.48 
As described in sections 6.1 and 6.2, immuno-histochemistry, as well as the 
emigration assay, were extensively studied, upgraded and developed toward stable 
methods to investigate skin DCs and T cell subsets. Afterwards these techniques 
were implemented in clinical trials to observe the number, distribution and migratory 
capacity of these cells in patients undergoing aHSCT. 
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6.5 Skin DCs and T cells in Patients with Acute Graft-versus-Host Disease 
Although the skin is the most extensively studied organ involved in aGvHD, 
there is no clear picture of the cellular network that initiates and maintains this 
inflammatory state. Skin biopsies serve as histological confirmation of the diagnosis 
of aGvHD, but do not bear prognostic relevance or have any influence on treatment 
selection.319 To date there is only limited knowledge regarding the number, the origin 
and the interaction of different immuno-competent cell subsets within the skin during 
aGvHD. Therefore, this study was undertaken to compare the pattern of DCs and T 
cells in skin of patients following an aHSCT.  
The important role that DCs are hypothesized to play in aGvHD has already 
been described in section 3.4. Recently, the fate of skin DCs during the course of 
human aHSCT has been investigated by several groups, including ours. It has been 
shown that LC numbers in patients undergoing an aHSCT are decreased and remain 
low during the first year after therapy when compared to healthy controls.37;167;277 
Also, DDC numbers appeared to be diminished in aHSCT patients.167;282;320 The 
reduction of skin DCs was mainly a consequence of the conditioning regimen even 
when irradiation was not a part of it.37;277;321 However, an own preceding study167 and 
also the Alemtuzumab study322 presented here, revealed that these patients 
consistently had low DC numbers prior to the start of any conditioning therapy. These 
studies demonstrated a decrease not only in skin DCs, but also in peripheral blood 
DC subsets. Thus, patients with malignant diseases may be systemically deficient of 
DCs, and this may contribute to the immune insufficiency that is often observed in 
these individuals. 
Some studies have investigated the number of LCs during 
aGvHD,37;133;165;277;321;323-328 whereas very little data is available addressing DDCs.320 
The vast majority of these studies concluded that skin DCs are diminished in patients 
during the course of aGvHD. Moreover, these studies showed that patients with 
GvHD have a stronger reduction in LC numbers than patients without this 
complication.37;133;323-326 A few others studies did not find a numerical differences 
between patients with and without GvHD, but found that LCs slower repopulate in 
patients with GvHD.277;327;328  
In contrast to all these studies, the present work found evidence for the increase 
of both LCs and DDCs in lesional aGvHD skin compared to unaffected areas at the 
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onset of the disease. Compared to the skin of healthy controls, lesional skin 
contained more DDCs and dermal T cells, while maintaining the same number of 
LCs. Consistent with the literature, a clear reduction of patients’ LC numbers (in 
comparison to healthy controls) was found in non-lesional skin areas. These 
diminished numbers of LC at unaffected sites may be due to the LC deficiency shown 
in patients before and after aHSCT.167;322 An additional explanation may be that this 
low number reflects a prior emigration of LCs into the draining lymph nodes. It was 
recently reported that LCs changed their morphology on the day of GvHD onset in a 
mouse model.329 The LCs underwent phenotypical activation and became larger and 
round in shape and vanished from epidermal layers. The authors suggested that LC 
activation takes place at the early GvHD onset to amplify the GvHD reaction in the 
lymph nodes. Therefore, the decrease of LCs in uninvolved skin may reflect the 
initiation of skin inflammation. However, this is not very likely because uninvolved 
areas were not diminished in DDCs numbers, which were found to be 
indistinguishable from healthy controls’ skin. A beginning skin inflammation should 
also mobilize these cells, which have been shown to emigrate quicker than LCs in 
response to inflammatory stimuli.48 In contrast, the presence of higher LC and DDC 
numbers in lesional sites of aGvHD skin samples suggests that both cell types, 
despite their capacity to leave the tissue (proven in the emigration assay), do not 
preferentially migrate into the draining lymph nodes. However, DC numbers in the 
draining lymph were not investigated in this study and therefore can neither support 
nor contradict this hypothesis. 
In summary, this study demonstrated for the first time that at the onset of 
aGvHD, different DC types accumulate in lesional skin of GvHD patients. These 
results, which are apparently contradictory to the literature, may be explained by the 
sophisticated study design that directly focused on the effects of aGvHD.  
First, the present study considered the topical nature of skin aGvHD and 
compared lesional and uninvolved skin within every single patient. In contrast, most 
of the former studies compared DC numbers between different individuals with and 
without aGvHD or with healthy controls’ skin. The major advantage of comparing 
lesional and uninvolved skin in parallel is that a maximum of physiological and clinical 
parameters, like age, underlying disease, clinical history, conditioning regimen and 
aGvHD prophylaxis, is kept constant for the paired specimens. A consequence of this 
approach is that compared biopsies were taken from slightly different anatomical 
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sites, which may theoretically vary in their DC number. However, chosen biopsy sites 
such as the upper and lower extremities, chest, back and buttocks have been shown 
here and elsewhere210;212  to be inhabited by comparable LC numbers. Differences in 
DDC numbers according to body site have not been published so far, but the present 
work revealed that DDC numbers are equally in the lower extremities and the chest. 
Second, the biopsies were taken very early, when the first clinical signs of 
aGvHD appeared and before systemic treatment was initiated. Both the paired 
comparison of lesional and uninvolved skin, and the very early time point at onset of 
aGvHD may be particularly suitable to separate the effects of aGvHD itself from 
those arising from an aGvHD treatment. Thus, this study provides a close view of the 
patho-mechanism of the initial phase of aGvHD. However, because of this very early 
time point (median day 17 (range 8-76) post transplantation), it is likely that some of 
the full-blown aGvHD-related pathological changes were not fully established at the 
time of biopsy. This may explain why the incipient recruitment of T cells to lesional 
skin, a hallmark of aGvHD,330 was found to be less pronounced than expected in 
some patients. 
To confirm histological findings, the emigration assay was applied as a second 
technique. In full analogy to immuno-histochemistry, the emigration assay revealed 
increased numbers of LCs and DDCs residing in and migrating from lesional areas. 
Since DCs and also T cell numbers isolated by the emigration assay were found to 
be proportional to the respective cell counts in immuno-histochemistry, the assay can 
be considered to reflect the actual number of DCs and T cells in situ.  
Different roles for DCs of different origin have been discussed in pathogenesis 
and induction of GvHD. Whereas host DCs are required for the induction of aGvHD in 
mice, donor DCs intensify the severity of aGvHD.172 By using the emigration assay 
skin DC types became accessible to investigate if they are of donor or of recipient 
origin. This chimerism analysis has also been applied in a previous study, in which 
we discovered that even very early after an aHSCT, the majority of emigrating LCs 
and DDCs are of donor origin.167 However, several other authors found evidence that 
a large proportion of recipient LCs and DDCs remained in patients' skin after HSCT, 
despite complete donor BM chimerism.37;188;331 An explanation for these controversial 
data might be the difference in methodology. Other authors performed chimerism 
analyses using immuno-histochemistry and FISH in skin biopsies of sex-mismatched 
BM transplanted patients, whereas this work analyzed the chimerism of cells isolated 
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by the emigration assay. Therefore, only vital and functional cells able to emigrate 
from the tissue, but not non-migrating, resident cells, were analyzed. It was shown 
here (see supplementary data) and elsewhere205 that a portion of skin DCs also 
remained after tissue culture in healthy skin. If the inability to emigrate ex vivo 
resembles the in vivo situation of this portion of LCs and DDCs seems possible but 
needs to be proven. Also, in patients, a number of recipient DCs (potentially amplified 
by the effects of chemotherapy) that survived the conditioning regimen may have 
loosened their migratory function. This will lead to the fixation of these cells in the 
tissue, which in turn may contribute to an incomplete in situ donor chimerism. 
However, impairment in or loss of migratory capacity will bar DCs from playing their 
role in secondary lymphoid tissues. Whether cells which do not emigrate ex vivo 
perform comparable DC functions or whether they contribute at all to the immune 
response in vivo has not actually been determined, however it appears unlikely. 
Therefore, the emigration assay selects cells that are particularly interesting for their 
immunologic potency. In this context, the finding that even very early after an aHSCT, 
the majority of emigrating LCs and DDCs are of donor origin was in line with data 
from Ikeda et al. who showed a complete donor LC chimerism in lymph nodes early 
after aHSCT.332  
Contrary to the rapid replacement of host DCs by donor derived progenitors 
after an aHSCT,164;167 a commonly mixed donor LC chimerism was found in patients 
affected by aGvHD. Interestingly LC chimerism regularly differed between lesional 
and uninvolved sites of the same patient. A higher compound of donor LCs in 
lesional compared to uninvolved skin was detected in two patients. Thus in these 
patients the increase of LCs was most likely due to the recruitment of donor LCs to 
GvHD skin areas. Conversely, in three patients a higher proportion of host cells was 
found in lesional skin compared to uninvolved skin. With respect to the preceding 
conditioning therapy and the establishment of the donor hematopoietic system, host 
derived LC progenitors are probably absent at the time of an aGvHD. Thus a 
recruitment of host LCs to the lesional skin is not likely. Differences in the migratory 
capacity of residing host LCs and recruited donor LCs is also not very likely, but 
could not be ruled out. Another explanation is that the high proportion of host LCs 
may result from proliferation of these cells in situ at sites of GvHD. This capacity of 
LCs had been demonstrated for murine LCs.46 Unfortunately in nearly half of the 
patients (9 out of 21) the low LC number that could be obtained from uninvolved and 
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lesional skin was insufficient to perform the chimerism analysis. In an additional three 
patients, chimerism analysis of LCs from uninvolved skin failed to give results, 
whereas LCs chimerism could be analyzed in lesional skin. Due to these difficulties, a 
general conclusion regarding a possible prevalence of host or donor derived LCs in 
lesional skin could not be drawn. However, the data suggest that both scenarios may 
be possible.  
Contrary to the mixed chimerism of LCs, but in analogy to the complete donor 
skin DC chimerism found in patients without aGvHD in a previous study,167 DDCs 
were commonly of donor origin, irrespective of whether they emigrate from lesional or 
uninvolved skin of patients with aGvHD. Their higher number in lesional skin could be 
caused by DDC precursor recruitment from the periphery or by in situ proliferation of 
already recruited donor DDCs. The capacity to proliferate locally has recently been 
shown for DDCs.70 
The accumulation of skin DCs in inflammatory lesions has been also observed 
in other lymphocyte-mediated diseases of the skin. Increased epidermal and dermal 
DCs have been reported in patients suffering from contact dermatitis, spongiotic 
dermatitis, psoriasis and lichen planus.333-338 Interestingly, these diseases share 
some clinical features with aGvHD, including a responsiveness to steroid treatment. 
This increase of DC numbers at lesional sites combined with the absence of DC 
accumulation in unaffected areas in aGvHD (as well as in other inflammatory 
diseases) strongly suggests that DCs may contribute to the inflammatory process in 
situ. However, this hypothesis is not in line with the classical model of DC role and 
functions. According to the prevailing understanding, DCs take up Ag at sites of 
inflammation and subsequently leave the tisssue to present the Ag to lymphocytes in 
the draining lymph node.10 A direct interaction between DCs and T cells within sites 
of inflammation is not foreseen in this model, but some evidence for a local 
interaction has recently been published. A study by Santoro et al. describes co-
localization of recruited DCs and T cell infiltrates in oral lichen planus.337 In response 
to contact sensitizers applied to the skin, DCs accumulated there and close contacts 
between DCs and lymphocytes could be observed.339 As shown here, the number of 
T cell clusters, consisting of intermixed T cells and DDCs, increased in GvHD lesions. 
Thus, these results strongly suggest a role of skin DCs in the inflammatory process of 
cutaneous aGvHD in situ. It is of great scientific and therapeutic interest if the 
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observed increase of modulating DCs in lesional skin is caused by the process of 
aGvHD or may itself cause an inflammatory skin response. 
 
6.6 Alemtuzumab Did Not Efficiently Deplete Skin DCs 
The general concept of host DC depletion for the prevention of aGvHD is 
attractive since it is known that these cells are necessary for the induction of the 
disease in a mouse model.172 Depletion of residual skin DCs might be achieved by 
approaches such as phototherapy (ECP),46;162;340 electron beam therapy,341;342 topical 
steroids60 or by the administration of monoclonal antibodies targeting cutaneous DC 
surface markers.190 Furthermore, it is likely that drugs that are effectively used in 
GvHD prevention or treatment, may partly act by an unknown DC-depleting potential. 
Against this background a second study investigated if Alemtuzumab (Campath-1H), 
a drug approved for the treatment of patients with advanced CLL191;192 and effective 
in vivo and in vitro for GvHD prevention193;194, may also work by targeting host DCs in 
the skin. 
Alemtuzumab, a humanized IgG1 monoclonal antibody directed against CD52, 
mediates cell death by antibody-dependent cytotoxicity and apoptosis.198;199 CD52 is 
expressed on the surface of lymphocytes, certain subtypes of DCs, monocytes, Mφs, 
and eosinophils.190;195-197 Alemtuzumab is generally believed to act by depleting 
donor T-cells before or during stem cell infusion.194 However, considering that anti-
CD52 antibodies have been found to eradicate blood DCs,190 depletion of DCs in a 
transplantation recipient could be an alternative mechanism of Alemtuzumab’s 
GvHD-preventive effect. 
Collin et al.189 have shown that CD52 is readily detectable on LCs by FACS, 
however several other authors were unable to detect this marker by immuno-
histochemistry.343;344 This work confirmed the data of Collin et al. and additionally 
showed that CD52 is also weakly expressed on DDCs. Since the applied 
flowcytometric method can detect even weak amounts of cell surface Ag, it is more 
sensitive than immunohistology. Even with the low intensity of CD52 expression on 
LCs and DDCs, these cells represent a potential target for Alemtuzumab. 
As already discussed above (see section 6.5), this study found that most 
patients had significantly less LCs and DDCs in comparison to healthy controls, even 
before the start of therapy. Alemtuzumab therapy was sufficient to deplete blood 
lymphocytes and even rare cell populations like blood DCs. The administered dose 
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was associated with measurable levels of unbound Alemtuzumab approximately two 
weeks after the last drug dose in the majority of patients. This suggests that available 
CD52 binding sites within the patients were fully saturated with antibody. Of course 
serum levels do not strictly allow extrapolation regarding tissue concentrations. As 
yet, only indirect evidence is available regarding the tissue penetration of 
Alemtuzumab. Several studies have found that skin lesions of patients with 
cutaneous T cell lymphoma improved in response to Alemtuzumab.345;346 It therefore 
seems unlikely that insufficient tissue penetration is the underlying cause for the lack 
of skin DC depletion in the study. It is more likely that this is related to the weak 
target Ag expression on these cells and/or their insufficient killing. To date it is not 
clear which target Ag density is needed for an efficient induction of antibody-
dependent cytotoxicity. 
The fact that emigrating LCs were not depleted by Alemtuzumab in vivo is 
consistent with the results of Collin et al., who demonstrated ineffective LC depletion 
in vitro.189 Considering that the target Ag CD52 is expressed to the same dim extent 
on DDCs as on LCs, the similar effects observed for DDCs in the study were not 
unexpected. However, the general concept of host DC depletion for GvHD prevention 
remains attractive, and might be achieved by other therapeutic approaches such as 
phototherapy (ECP), or by administration of monoclonal antibodies targeting DC 
surface markers other than CD52. Further studies are required to explore the 
possibilities of DC immunodepletion in skin and other tissues of aHSCT recipients. 
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7 Appendix 
 
7.1 Supplementary Data 
 
Figure 7-1: Separated Fluorescence Channels of CD1a/CD207 Double Staining 
Fluorescence double staining of LCs in sectioned femoral skin using CD1a, CD207 and DAPI. 
Separated green (FITC) fluorescence channel of CD1a (A), red (Cy3) fluorescence channel of CD207 
(B), blue (DAPI) fluorescence channel of cell nuclei (C) and their merge (D). Original magnification 
200x; bars indicate a length of 20µm. 
 
 
 
 
CD1a CD207 
DAPI Merge 
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Figure 7-2: Uptake of BSA-FITC applied directly to the epidermis before emigration assay 
BSA-FITC was applied to the epidermis on one of two samples of the same donor and both were 
separately incubated to allow emigration of cells (emigration assay). After 3 days at 37°C emigrated 
cells were harvested, stained with HLA-DR (MHC class II). Only cells that expressed MHC II (brown) 
but not others (red) showed a FITC signal, indicating the uptake of the BSA-FITC which was applied to 
the epidermis. MHC II+ cells of the sample that was not labelled with BSA-FITC (grey) did not show a 
FITC signal. Therefore only MHC II+ cells acquired the BSA-FITC applied to the epidermis and than 
emigrated to the medium. 
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untreated
treated with Dispase I
treated with Dispase I 
and cultured for 3 days
lymphocytes
 
Figure 7-3: CD4 and CD8 but not CD3 are dispase I sensitive. After observing equal effects in skin 
derived T cells the disase I sensitivity of T cell markers was investigated in peripheral blood cells, due 
to the accessibility of higher cell numbers. Lymphocytes were gated with respect to their SSC/FSC 
pattern (low granularity/large size) (A) and their expression of CD3 (B), CD4 (C) and CD8 (D) was 
investigated before treatment (black line), after treatment with 1U/ml dispase I for 1h at 37°C which 
was comparable to the amount used for splitting epidermis from dermis (grey line). Due to the 
treatment CD4 was completely removed from the surface, CD8 was almost completely removed, 
whereas CD3 surface expression was not changed. During the culture of lymphocytes for 3 days in 
AIM-V medium at 37°C (doted black line) CD4 and CD8 were restored at the surface. Experiments 
performed with skin derived T cells showed equal results but, due to the lower cell number are less 
demonstrative. No changes in the surface expression of MHC II, CD1a, CD206 and CD207 due to 
dispase I treatment could be found. 
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 healthy control uninvolved skin lesional skin 
CD1a 
   
 
 
 
Figure 7-4: Shown is the staining of LC by CD1a in healthy femoral skin and in uninvolved and 
lesional aGvHD skin from a representative patient. Counterstaining was performed with Mayer’s 
hemalaun. Bars indicate a length of 50 µm (magnification 600x). Median number of epidermal CD207+ 
cells, range and number of individuals investigated are summarized in the table below. 
 
 
Figure 7-5: Shown are numbers of CD1a + LCs (blue) detected in situ (A) or emigrated from skin (B). 
Each symbol indicates the cell number in healthy femoral skin (open diamonds) in uninvolved (grey 
diamons) or lesional skin (black diamonds) of patients with aGvHD as paired samples. If groups 
differed significantly P values are indicated.  
 
 
Median Range N Median Range N Median Range N 
CD1a/mm 27 16-37 18 12 0-30 8 13 5-36 8 
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7.4 Abbreviations 
Ag   antigen 
AEC   3-amino-9-ethylcarbazole 
aGvHD  acute graft-versus-host disease 
aHSCT  allogeneic hematopoietic cell transplantation 
APCs   antigen presenting cells 
cGvHD   chronic graft-versus-host disease 
CTL   CD8+ cytotoxic T lymphocyte 
DCs   dendritic cells 
DDCs   dermal dendritic cells 
FACS   fluorescence associated cell sorting 
FITC   Fluorescein isothiocyanate 
GvHD   graft-versus-host disease 
GvL   graft-versus-leukemia effect 
h   hour 
HLA   histo-compatibility leucocyte antigen 
HRP   horseradish peroxidase 
IFNγ   Interferon gamma 
LC   Langerhans cells 
LPS   lipopolysaccaride 
Mφs   macrophages 
MFI   main fluorescence intensity 
MHC    major histo-compatibility complex 
MHC I   major histo-compatibility complex class I 
MHC II   major histo-compatibility complex II 
MLR   mixed leukocyte reaction 
min   minute 
PE   Phycoerythrin 
Pc5   Cychrome 
RT   room temperature 
sec   second  
TCR   T cell receptor 
TH   CD4+ T helper cell 
TH1   inflammatory immune response mediated by TH cells of type 1 
TH2    humoral immune response mediated by TH cells of type 2 
TNFα   tumor necrosis factor alpha 
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